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Abstract 
Viruses are highly efficient at infecting cells. They overcome the cellular barrier and transfer 
their genetic material into the host cell nucleus, and efficiently use the cellular machinery for 
the replication and production of new virions (Gale et al, 2000; Brave et al, 2006). Viruses 
have been widely studied as naturally existing vehicles, and for utilization for the delivery of 
heterologous antigens to the immune system (Souza et al, 2005; Brave et al, 2006; Ura et al, 
2014). 
 
The development of reverse genetics for negative-strand RNA viruses made it possible to 
manipulate the influenza virus genome (Stukova et al, 2006). The influenza virus offers 
several advantages as an antigen delivery vector,‎ including‎ safety‎profiles‎and‎ the‎ virus’s‎
ability to induce strong cellular and humoral immune responses (Stukova et al, 2006; 
Martinez-Sobrido & Garcia-Sastre, 2007). 
 
There are two main reverse genetics systems that can be used for recombinant influenza 
virus generation, and for this study the helper virus-based method was used. Development 
of an effective selection system to isolate the generated recombinant influenza virus from the 
background of helper influenza virus is essential as the first step to continue the 
development of influenza viral vector vaccines. The widely used isolation technique utilising 
insertion of affinity tags within the desired protein is one very powerful method (Bornhorst & 
Falke, 2000). Theoretically, inserting an affinity tag within a selected influenza protein could 
be an applicable approach for the purification of the generated recombinant virus. 
 
This study investigates the possibility of generating His tagged influenza virus, which can be 
positively selected using the Immobilized-metal affinity chromatography (IMAC) technique. 
 XXI 
The successful production of tagged influenza virus will help to overcome the issue of 
selection for the desired recombinant virus (i.e., expressing immunogenic antigen) using the 
helper virus-based system. 
 
The first objective of this study was to design a gene structure for tagged influenza 
hemagglutinin (HA) gene. The His tag sequence was placed within the HA1 subunit, 
specifically within the Ca2 antigenic region gene between amino acid 158 and 159. The HA 
gene used for this study was from H1N1 influenza virus. Mapping of the HA sequence 
features suggested that the selected insertion site was unlikely to interfere with any vital 
regions. Also, building a structural model for the recombinant HA predicted that the His tag 
was placed within an exposed HA domain. Finally, the HA-His6 pol I construct was 
successfully designed, and synthesis and cloning of the recombinant HA gene-construct into 
DNA plasmid was completed.  
 
The second objective of this study was to generate a recombinant influenza virus using 
helper virus-based reverse genetics. Influenza virus (A/Puerto Rico/8/34, H1N1) propagation 
was achieved using MDCK cells, and a reasonably high virus titer was obtained. MDCK cells 
were also used for the generation of recombinant influenza virus. Around 40% of the cells 
were successfully transfected with the plasmid containing the HA-His6 pol I construct (canine 
RNA polymerase I), which was assessed by using EGFP plasmid as an indicator of 
transfection efficiency. Co-infecting the cells with the helper virus (wild-type PR8) at MOI 0.1 
resulted in the generation of His tagged influenza virus. The presence of the recombinant 
virus was confirmed using the PCR detection technique, which was performed afterward 
when immunodetection by anti-His antibody failed to detect the His tagged protein.  
 
 XXII 
The third objective of this study was to further investigate the availability and stability of the 
His tagged influenza virus. As the first anti-His antibody failed to recognise the generated His 
tagged virus, another anti-His with high affinity and specificity was used. However, 
immunorecognition failed using this other antibody as well. Moreover, using the highly 
sensitive enhanced chemiluminescent assays (ECL) assay for developing the Western blot 
membrane also resulted in unsuccessful detection. A recent tertiary model structure (2014) 
showed a different His tag folding than what was predicted in the earliest model (2011) 
within the HA protein. The latest model prediction resulted in a partially hidden His epitope, 
and this was in agreement with the solvent accessibility value predicted by the I-TASSER 
server. After performing molecular dynamics simulation, the results obtained suggested that 
there was no significant difference between the recombinant HA and the wild-type HA 
proteins in terms of stability. Availability of the recombinant virus was confirmed after 
passaging the virus mixture (recombinant and wild-type viruses) for up to three rounds. The 
final investigation in this study was performed to enhance the production of the recombinant 
virus amongst the wild-type one. Again, this trial did not improve on antibody detection.  
 
Taken together, these results indicate that recombinant influenza virus incorporating a His 
tag could be generated using the helper virus-based system. Also, the recombinant virus can 
replicate among the wild-type viruses, and it can be stable for several passages. As there 
were many factors that might lead to unsuccessful immunodetection, it is still possible to 
generate a tagged influenza virus that can be successfully detected by antibody, because 
there are other alternatives to investigate in the future. Studying the HA sequence features 
and the possible sites to insert the affinity tag, as well as the structural prediction in this 
study, provided useful information for the future incorporation and expression of pathogenic 
or disease proteins within the HA protein. The investigations that were undertaken in this 
study have resulted in new knowledge in the field of recombinant influenza virus. 
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1.1 Introduction  
More than two centuries have passed since Edward Jenner’s‎discovery‎of‎vaccination‎in‎the‎
1790s.‎ The‎ word‎ “vaccine”‎ originated‎ from‎Variolae vaccinae, which is smallpox in cows 
(Stern & Markel, 2005; Azegami et al, 2014, Doolan et al, 2014). Since then, vaccines have 
played a vital role in controlling and preventing infectious diseases (Oyston & Robinson, 
2012). Immunization has successfully eradicated smallpox from two million cases worldwide 
per year in 1959 to zero in 1978 (Oyston & Robinson, 2012). Moreover, vaccination has led 
to protection from infectious diseases including diphtheria, tetanus, whooping cough and 
measles, and prevented around two to three million deaths every year (WHO, 2015). Illness 
and disability from diseases such as hepatitis B, cervical cancer, rotavirus diarrhea, rubella 
and tetanus has been reduced by immunization (WHO, 2015). To date, vaccines have 
prevented 28 infectious diseases. The most universally used vaccines against these 
diseases and their introduction dates are shown in Table 1.1.  
 
Despite the remarkable vaccine achievements in global health, the demand for new vaccine 
approaches is paramount. Vaccines‎ still‎ don’t‎ exist‎ for some of the most devastating 
infectious‎pathogens‎(Table‎1.2)‎(O’Hagan‎et al, 2001; Koff et al, 2013). 
 
1.2 Challenges in vaccine development  
1.2.1 Conventional vaccine approaches 
The first vaccines that were introduced consisted of partially purified live attenuated vaccines 
or inactivated vaccines (Josefsberg & Buckland, 2012). Also, many of the currently available 
vaccines have been developed empirically, following the principle established by Louis 
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Table 1.1: Vaccine-preventable diseases, year of vaccine development and vaccine type. 
Table obtained from Pharma.organization with some modifications, accessed in 2015 
http://www.phrma.org/sites/default/files/pdf/PhRMA_Vaccine_FactBook_2013.pdf 
Vaccine-preventable 
disease 
Type of 
disease 
Year developed Type of vaccine 
Smallpox Viral 1798 Live attenuated 
Rabies Viral 1885 Inactivated 
Cholera Bacterial 1869 Inactivated 
Typhoid 
 
 
 
Bacterial 1886 
1983 
1994 
2008 
Inactivated 
Live attenuated 
Polysaccharide 
Protein conjugate 
Plague Bacterial 1897 Inactivated 
Pertussis 
 
Bacterial 1914 
1981 
Inactivated 
Purified protein 
Tuberculosis Bacterial 1921 Live attenuated 
Diphtheria Bacterial 1923 Toxoid 
Tetanus Bacterial 1926 Toxoid 
Yellow fever Viral 1932 Live attenuated 
Japanese encephalitis Viral 1935 
1988 
Inactivated 
Live attenuated 
Influenza Viral 1936 
2003 
Inactivated 
Live attenuated 
Tick-borne encephalitis Viral 1937 Inactivated 
Mumps Viral 1948 
1967 
Inactivated 
Live attenuated 
Anthrax Bacterial 1954 Protein 
Polio Viral 1955 
1962 
Inactivated 
Live attenuated 
Measles Viral 1963 Live attenuated 
Rubella Viral 1969 Live attenuated 
Meningococcal Bacterial 1971 
1999 
Polysaccharide 
Protein conjugate 
Varicella (chickenpox) Viral 1974 Live attenuated 
Hepatitis B Viral 1981 
1986 
Plasma derived 
Recombinant protein  
Pneumococcal Bacterial 1983 
2000 
2010 
23-valent polysaccharide 
Protein conjugate 7 valent 
Protein conjugate 13 valent 
Haemophilus influenza b Bacterial 1985 
1987 
Polysaccharide 
Protein conjugate 
Hepatitis A Viral 1995 Inactivated 
Herpes Zoster Viral 2005 Live attenuated 
Rotavirus Viral 2006 Recombinant protein 
Human Papillomavirus Viral 2006 Recombinant protein 
Adenovirus types 4 & 7 Viral 2011 Live attenuated 
  
Table 1.1 
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Table 1.2: Major worldwide diseases for which vaccines or effective vaccines do not 
currently exist. 
(1)
 Adapted from Koff et al (2013).  
(2)
 Adapted from Pallett and Hand (2010). 
 
 
 
 
Disease
(1)
 Type of disease 
Campylobacter Bacterial 
Chlamydia Bacterial 
Cytomegalovirus Viral 
Dengue Viral 
Epstein-Barr (mononucleosis) Viral 
Helicobacter pylori: Gastrointestinal ulcers Bacterial 
Hepatitis C Viral 
Herpes Simplex Viral 
HIV Viral 
Influenza (universal flu vaccine to replace need 
for annual flu vaccine) 
Viral 
Leishmaniasis Parasitic 
Malaria Parasitic 
Respiratory syncytial virus Viral 
Rhinovirus Viral 
Schistosomiasis Parasitic 
Shigella Bacterial 
Streptococcus groups A and B Bacterial 
Tuberculosis Bacterial 
Urinary tract infections Majority are bacterial
(2) 
Other: Allergies, Autoimmune diseases, Cancers - 
 
 
 
Table 1.2 
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Pasteur‎to‎“isolate,‎inactivate,‎and‎inject”‎the‎microorganism causing the disease (Barbosa & 
Barral-Netto, 2013; Kaufmaan et al, 2013).  
 
Pasteur’s‎ paradigm‎ helped in the eradication of many important infectious diseases, 
including smallpox, measles and poliomyelitis (Serruto & Rappuoli, 2006; Barbosa & Barral-
Netto, 2013). However, numerous infectious diseases have failed or were not easy to control 
or prevent using‎ Pasteur’s‎ strategy‎ (Barbosa‎ &‎Barral-Netto, 2013). There are two major 
drawbacks‎ in‎ Pasteur’s‎ strategy. First, some disease-causing organisms are difficult to 
cultivate in vitro, such as Mycobacterium leprae (which causes leprosy [Hansen disease]), 
Hepatitis C virus (HCV) (which causes liver disease) and Plasmodium falciparum, the 
causative agent of malaria (Arnon & Ben-Yedidia, 2003; Barker, 2006; Barbosa & Barral-
Netto, 2013; Bei et al, 2014). The second primary concern is the safety of attenuated 
vaccines. Some live attenuated vaccines have a risk of causing disease, primarily in 
immunosuppressed and immunocompromised individuals. They also may have the potential 
to revert from the attenuated to the virulent‎form‎(O’Hagan‎et al, 2001; Nascimento & Leite, 
2012; Barbosa & Barral-Netto, 2013).  
 
Traditional vaccines rely on their ability to successfully induce neutralizing antibodies, which 
can reduce or clear the infection against pathogens that have low antigenic variability 
(Nascimento & Leite, 2012; Koff et al, 2013; Kaufmaan et al, 2014). However, protection 
from the most challenging pathogens cannot be mediated by antibody stimulation alone 
(Kaufmaan et al, 2014). Many of the most challenging pathogens exhibit extensive antigenic 
variability, or have evolved complex and efficient mechanisms to obstruct the immune 
system (Koff et al, 2013). For example, after infection by influenza virus, immunological 
memory can be stimulated and provide protection only by the re-infection of the homologous 
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serotype, but not the heterologous subtypes (Koff et al, 2013). Therefore, annual 
immunization against circulating strains of influenza virus is essential (Koff et al, 2013). In 
the case of HIV, its unique ability to integrate into the host genome, mutate rapidly and also 
attack the immune defence mechanism not only allows it to escape neutralizing antibodies, 
but also inducing cell-mediated immunity (McElrath & Haynes, 2010).  
Although considered safer than attenuated pathogens, inactivated vaccines or killed 
pathogens often lack the ability to elicit adequate innate immune responses, which is an 
important step for the induction of immune memory (O’Hagan‎et al, 2001; Barbosa & Barral-
Netto, 2013). 
 
Referring to Pasteur’s strategy, if a vaccine candidate was successfully isolated, and it was 
assumed to be unable to cause disease or harmful side effects, it would still have to undergo 
many tests to be declared safe before direct human testing (Barbosa & Barral-Netto, 2013). 
Animal models have been used for evaluating vaccine safety, immunogenicity and 
efficiency, since early vaccine development (Zepp, 2010). However, the immune responses 
observed from the animal models to the pathogens may not be similar to humans (Oyston & 
Robinson, 2012). Additionally, there are many factors that may influence vaccine responses 
by the human immune system (Moore et al, 2004; Poland et al, 2008; Bruyn, 2010). These 
include low birth weight, polymorphism of genes associated with immune response, other 
infections and exposure to environmental factors.  These factors can be controlled during 
animal testing and may not be apparent (Moore et al, 2004; Poland et al, 2008; Bruyn, 
2010). 
 
1.2.2 Understanding the fundamentals of immune responses for better vaccine 
design 
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Understanding vaccine immunology will improve vaccine development against both previous 
and new infectious diseases. Also, considering the interaction between the host and the 
pathogen may assist in designing appropriate vaccines type will lead to the induction of 
adequate, appropriate immune responses. 
 
There are two major linked compartments in the human immune system: the innate and the 
adaptive immune systems (Figure 1.1) (Leo et al, 2011). The innate immune system is the 
frontline defence during infection or vaccine introduction. It performs a significant role in the 
early recognition of‎ pathogen’s‎molecular‎ pattern‎ and structure and activation of immune 
responses‎ (O’Hagan‎ et al, 2001; Mogensen, 2009). Initiation of immune responses is 
primarily mediated by the activation of antigen-presenting cells (APCs) such as dendritic 
cells (DCs) and macrophages, as well as natural killer cells (Mogensen, 2009; Harizi, 2013). 
The rapid recognition and response of the innate immune system depends on a limited 
number of germ line-encoded pattern recognition receptors (PRRs), which include Toll-like 
receptors (TLRs) (Mogensen, 2009; Woodrow et al, 2012). These receptors have the ability 
to directly recognize conserved structures on the infectious microbes called pathogen-
associated molecular patterns (PAMPs), such as bacterial cell wall components and 
uncommon forms of nucleic acids (Mogensen, 2009; Woodrow et al, 2012).  
 
The activation of innate immune cells not only promotes phagocytosis and killing of the 
bound pathogen, it coordinates the adaptive immune response by secreting cytokines and 
inflammatory‎mediators‎(O’Hagan‎et al, 2001; Mogensen, 2009). 
Unlike the innate immune system, which lacks specificity, the adaptive immune system 
promotes highly specific immune responses, and it develops by clonal selection
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Figure 1.1: Cells of the innate and adaptive immune systems. 
Figure adapted from Leo et al (2011). 
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from a broad range of antigen-specific receptors on lymphocytes (Mogensen, 2009; Zepp, 
2010). The adaptive immune system is characterized by a large set of lymphocytes, which 
can be divided into two main subsets: T cells and B cells (Leo et al, 2011).  
 
The link between innate and adaptive immunity is the activation of APCs. DCs are the most 
highly effective antigen-presenting cells in terms of capturing and presenting antigens 
(Santambrogio et al, 1999). In addition to antigen presentation and T cell activation by DCs, 
they also promote the initial differentiation of T helper cells (CD4+ cells) into Th1 or Th2 
subsets by cytokine signals received early during infection (Leo et al, 2011). Moreover, 
cytotoxic T cells (CD8+ cells) will also receive antigenic and cytokine signals from APCs to 
be stimulated (Leo et al, 2011). Activation of B cells into antibody-secreting plasma cells is 
promoted by CD4+ cell interaction (Leo et al, 2011). The cycle of the immune responses that 
result from vaccination or infection is summarized in Figure 1.2. 
 
Most of the vaccines that have been developed rely on their ability to produce an antibody 
response (Leo et al, 2011). However, as mentioned before, this is insufficient for vaccine 
development against several complex pathogens (Kaufmaan et al, 2014). Therefore, 
triggering immune responses such as CD8+ T cells, or successfully targeting DCs is the aim 
of designing future vaccines (Leo et al, 2011; Koup & Douek, 2011). It is also important to 
acknowledge that the dominant immune response by a pathogen or a vaccine may not be 
the ideal response for protection (Leo et al, 2011). More importantly, an effective vaccine 
has to develop immune memory in order to protect from the threat of reinfection (Pulendran 
& Ahmed, 2006). 
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Figure 1.2: A brief summary of immune responses to vaccination or infection. 1) After the 
antigen or pathogen is taken up by APCs and macrophages, it is presented to naïve T cells 
in the lymph node. 2) Adapted effector cells such as CD4+, CD8+ and antibody-secreting B 
cells are produced. 3) Then, the effector T cells and the antibody migrate via the 
bloodstream and back to the site of vaccination or infection. 
Figure adapted from Leo et al (2011). 
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1.2.3 Novel technology revolution and antigen discovery 
Vaccine development strategy has changed since the sequencing of the first bacterial 
genome, Haemophilus influenza, in 1995 (Seib et al, 2012). Advances in bioinformatics and 
genome sequencing together have accelerated the development of new vaccine 
candidatures.‎The‎term‎“reverse‎vaccinology”‎is‎used‎for‎genomic sequencing and analysing 
it in silico (by computer), by screening the entire genome to predict antigenic proteins 
(Rappuoli, 2000). In contrast to conventional vaccine development, which is time consuming, 
identifying antigens using reverse vaccinology can take two years instead of decades 
(Figure 1.3) (Rappuoli, 2000). The first successful application of reverse vaccinology was the 
development of a group B meningococcus vaccine, which is the leading cause of septicemia 
and meningitis (Seib et al, 2012). The antigens that were discovered using genomic 
technology in less than two years were greater in number than what had been identified in 
40 years by conventional methodologies (Doolan et al, 2014). Also, new vaccine candidates 
for many other pathogens, such as group A and B Streptococcus, Streptococcus 
pneumonia, Staphylococcus aureus and Chlamydia, have been identified by applying 
reverse vaccinology (Koff et al, 2013). 
 
Another‎ novel‎ approach‎ is‎ termed‎ “antigenomic”‎ technology,‎ which‎ uses‎ genomic-based 
strategies. This approach combined the identified serological antigens during infection with a 
comprehensive genomic library to select for a vaccine candidate (Meinke et al, 2005; Koff et 
al, 2013).  
 
Another advanced technology is the generation of broadly neutralizing antibodies (bnABs) 
against highly hypervariable pathogens such as HIV, influenza virus and HCV (Burton et al, 
2012). 
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Figure 1.3: Illustrative representation of the fundamental steps for the development of 
conventional vaccines and reverse vaccinology.  
Figure adapted from Rappuoli (2000). 
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Efforts were made in sequencing and bioinformatics analysis for the identification of bnABs 
from serum cross-neutralizing activity against antigenically diverse viruses (Burton et al, 
2012; Navis et al, 2014). Also, structural identification and cloning of the epitope binding 
sites of bnABs on a vector was undertaken to produce such bnABs in animal models (Burton 
et al, 2012; Koff et al, 2013; Navis et al, 2014). The first example that used reverse 
engineering for vaccine design was respiratory syncytial virus (RSV) (Koff et al, 2013).  
 
1.2.4 Remaining challenges in modern techniques 
New advanced vaccine technologies have ushered in a new era of vaccine development. 
However, most of the vaccines licensed were built based on conventional approaches to the 
improvement of vaccine purity and safety (McCullers et al, 2008). Ideal immunization 
strategies in humans that drive the maturation process for antibody from the germ line to 
broadly neutralizing antibody are not well understood (Koff et al, 2013). Also, our knowledge 
about human immunology has largely come from studying the blood, while the lymph node is 
mostly the site for the fight between the immune system and the invaders (Koff et al, 2013).  
 
There are some limitations in computational antigenic analysis, such as the inability to 
identify non-protein antigens (e.g. polysaccharides), (Table 1.3) (Rappuoli, 2001). Also, a 
combination between in silico analysis and in vitro or in vivo studies is needed in the case of 
vaccine safety and efficacy (Kaufmann et al, 2014). There is a significant challenge with 
computational vaccinology approaches due to the broad set of high-throughput data and 
diversity of analysis strategies (Kaufmann et al, 2014). Despite the big advantages from 
antigen selection technology, developing an effective universal vaccine for pathogens 
exhibiting high antigen variation remains very challenging (Kaufmann et al, 2014).  
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Table 1.3: Comparison between conventional vaccines and reverse vaccinology. 
Table obtained from Rappuoli (2000).    
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More research is needed for developing vaccines beyond infectious diseases, which include 
therapeutic vaccines mainly for cancer, chronic diseases that are related to aging and 
autoimmune diseases (Rappuoli et al, 2011). 
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1.3 Overview of vaccine delivery strategies 
Different vaccine designs for delivering antigens can be divided into two types with respect 
to‎ Pasteur’s‎ principles‎ and‎ the‎ pre-genomic era: traditional vaccines and novel vaccines. 
Traditional vaccines are based mainly in producing protective antibodies through vaccines 
formulated with the whole microbe, thus presenting a complex range of antigens (Moingeon 
et al, 2002). Meanwhile, modern vaccines construct specific pathogenic peptides, which can 
induce neutralizing antibodies or specific T cell responses (Zepp, 2010). 
 
1.3.1 Traditional vaccines 
1.3.1.1 Inactivated vaccines 
The two main advantages of the inactivated vaccines (IV) and killed whole cell vaccines 
(WCV) are the presentation of multiple antigens, including unidentified but protective 
antigens, and the fact that they are stable and generally safe (Pace et al, 1998; Walker 
2005). WCVs can be administered orally in order to mimic the natural uptake of the antigens 
and provide better immunization (Walker, 2005). Production of WCVs and IVs is relatively 
fast and not expensive, and the commonly used inactivation/killing process is by formalin or 
heat (Pace et al, 1998). The term “inactivated” refers to viral vaccines, while “killed” indicates 
bacterial vaccines (Baxter, 2007). The first killed vaccine produced was the typhoid vaccine 
at the end of the 19th century (Baxter, 2007). Current inactivated vaccines used in many 
countries are hepatitis A and polio vaccines (Baxter, 2007). However, the major drawback to 
the killed vaccines is that they generally require a series of doses due to weak protective 
immunity (Kumaru et al, 2014). 
 
CHAPTER 1 
 
 
 17 
1.3.1.2 Live attenuated vaccines 
Live attenuated vaccines (LAV) are more efficient (with regard to protective immunity) than 
the killed vaccines because they are able to infect and replicate in the host, but they are 
unable to cause disease (Dudek & Knipe, 2006). LAVs are capable of inducing CD4+ and 
CD8+ T cell responses, as well as humoral immune responses (Dudek & Knipe, 2006). 
Generally, there are two main approaches for attenuating the infectious microbe. The first is 
growing the pathogen in a foreign host for multiple passages (an example of this is 
cultivating the measles virus in chicken eggs), which results in a several mutations leading to 
virulence reduction (Baxter, 2007). The second approach is growing the pathogen with 
several passages at a temperature lower than the one found in its natural host, which then 
leads to a pathogen that is sensitive to small increases in temperature (Baxter, 2007; White 
et al, 2011; He et al, 2013). An example of this is the cold-adapted live attenuated influenza 
vaccine (He et al, 2013). 
 
1.3.1.3 Toxoid vaccines 
Toxoid production was started in 1924, when Gaston Ramon transformed the tetanus toxin 
using formaldehyde and heat into a non-toxic product and referred to‎ it‎ as‎ “anatoxin”‎
(Bonanni & Santos, 2011). The toxoid is antigenically similar to the native toxin, but the 
chemical treatment induces some molecular conformational changes that change it to a non-
toxigenic form (Baxter, 2007).  
 
1.3.1.4 Subunit vaccines 
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Instead of vaccinating with a whole pathogen that carries a set of diverse antigens, selecting 
and purifying a single or a couple of proteins or antigens can be used as an effective form of 
immunization (Baxter, 2007). Safety concerns and a loss of public confidence about cell-
culture technology have driven the development of subunit vaccines (Bonanni & Santos, 
2011; Rappuoli et al, 2011). The first subunit vaccine introduced was the influenza vaccine 
in the 1970s (Bonanni & Santos, 2011). The subunit vaccine antigen can be a protein or a 
capsular polysaccharide (Baxter, 2007). The subunit vaccine based on an antigenic protein 
generates T-dependent immune response (B cell activation with the help of T cells), while 
polysaccharides produce a T-independent response (activation of B cells without T cell help) 
(Jeurissen & Bossuyt, 2004; Baxter, 2007). An example of subunit vaccine that uses one 
antigen is hepatitis B, and a subunit vaccine with two antigens is the influenza vaccine  (HA 
and NA) (Baxter, 2007). 
 
The main disadvantage of the subunit vaccines is their low immunogenicity, especially with 
children, as well as their short-term protection due to an inability to produce immunological 
memory (Rappuoli et al, 2011).  
 
1.3.1.5 Conjugated vaccines 
The efficiency of subunit vaccines has been dramatically improved by covalently binding 
them to protein molecules (Goldblatt, 2000; Baxter, 2007). The first licensed subunit-
conjugated vaccine was the Hib (Goldblatt, 2000). The conjugated vaccine has converted 
the T-independent responses (not sufficient with young children’s immunity) that are 
mediated by polysaccharides into a T-dependent response when they are conjugated to a 
protein carrier (Goldblatt, 2000; Baxter, 2007). Many immunogenic proteins have been 
proposed as protein carriers, but the most widely used proteins are diphtheria toxoid, 
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tetanus toxoid and the Neisseria meningitidis outer membrane protein (Ada & Isaacs, 2003). 
In addition to the significant improvement in immunogenicity with children, conjugate 
vaccines were also able to elicit immunogenic memory responses (Goldblatt, 2000). An 
example of conjugated vaccines and also their advantages and disadvantages, as well as 
the other conventional vaccine designs are presented in Table 1.4. 
 
1.3.2 Adjuvants 
Adjuvants were first demonstrated by Ramon between 1925 and 1926, and described as 
“substances‎used‎in‎combination‎with‎a‎specific‎antigen‎that‎produce‎more‎robust‎ immune‎
responses‎ than‎the‎antigen‎alone”‎ (O’Hagan‎et al, 2001; Sivakumar et al, 2011). The first 
approved adjuvant by the Food and Drug Administration was called alum, and aluminium-
based‎ mineral‎ salts‎ (O’Hagan‎ et al, 2001). Other adjuvants licensed and currently used 
include mineral oil emulsion, the immune stimulating complex that is composed of saponin, 
cholesterol, phospholipid and immunogen, virosomes, TL4 agonists (such as bacterially 
derived monophosphoryl lipid A [MPL]) and liposomes (Sivakumar et al, 2011; Koff et al, 
2013).  
 
Adjuvants can be used with a vaccine for many reasons: 1) to enhance immunogenicity to a 
weak antigen; 2) to induce cell-mediated immunity (CMI); 3) to reduce multiple immunization 
doses; 4) to speed the induction of immune response; 5) to enhance the duration of immune 
protection; 6) to reduce the antigen dose and cost effect; 7) and to improve the immune 
responses in immunocompromised individuals, children and the elderly‎ (O’Hagan‎ et al, 
2001; Sivakumar et al, 2011; Mohan et al, 2013). 
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MMMRV=measles, rubella and varicella combination. Hib= Haemophilus influenza type b. PnC=pneumococcal conjugate for groups A, C, W-135, and Y. 
Table 1.4: Traditional vaccine designs in the pre-genomic‎era‎through‎Pasteur’s‎paradigm.‎ 
Table adapted from Rappuoli et al (2011), with some modification.  
 Advantages Drawbacks Examples 
Killed microorganisms Efficacious Some pathogens are difficult or almost 
impossible to cultivate in a scalable 
setting; regularly authorities require high 
safety and quality standards for all new 
vaccine might be difficult 
Polio; influenza vaccine; rabies 
vaccine; oral cholera vaccine  
 
Live attenuated 
microorganisms 
The causative agent is live, 
but it has lost the ability to 
cause the disease  
Some pathogens are difficult or almost 
impossible to cultivate in a scalable 
setting; regulatory authorities require high 
safety and quality standards for all new 
vaccine formulations, so obtaining 
approval might be difficult  
Polio vaccine; intranasal influenza 
vaccine (cold adapted); MMRV 
vaccine  
 
Subunit Vaccines contain purified 
portions of the causative 
agents  
 
Identification of the few protective 
components from the pool of molecules in 
the pathogen is usually complex and 
time-consuming  
 
Diphtheria, tetanus, and pertussis 
toxoids; hepatitis B vaccine; 
acellular pertussis vaccine  
 
Conjugated A polysaccharide component 
of the causative agent is 
chemically linked to a protein 
carrier  
Need to grow the pathogen in vitro to 
obtain the capsular polysaccharide; 
capsule not always immunogenic; too 
many capsule types 
Hib vaccine; PnC vaccine; Men 
ACWY vaccine  
 
Table 1.4: Traditional
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Moreover, adjuvants can improve antigen delivery by increasing the infiltration of the cellular 
responses into the injection site, and thus more cells are available to engulf the antigen 
(O’Hagan‎et al, 2001).  
 
Generally, live attenuated vaccines do not need the addition of adjuvants because they are 
efficiently immunogenic (Reed et al, 2008). On the other hand, inactivated or killed vaccines 
and vaccines based on purified antigens stimulate weaker immune responses, and the 
formulation of vaccines with potent adjuvants is required to enhance the vaccine 
immunogenicity (Vogal, 2000; Reed et al, 2008). Currently, vaccine researchers are aiming 
to develop adjuvants that can boost CD4+ and CD8+ T cell responses, which could have a 
critical role in preventing or/and controlling infectious diseases, and this is required for the 
improvement of the next generation vaccines, mainly against malaria, HIV and tuberculosis 
(Reed et al, 2008; Coffman et al, 2010 koff et al, 2013). 
 
1.3.3 Novel vaccines 
The evolution of modern vaccine delivery and the recombinant vaccine has been initiated 
with the emergence of genomic technology and bioinformatics advances (Nascimento & 
Leite, 2012). Selected antigen delivery systems are described below. 
 
1.3.3.1 DNA vaccines 
Development of DNA vaccines started the early 1990s when it was stated that delivering 
naked DNA plasmid into the skin could induce both cellular and humoral immune responses 
to viral and tumour antigens (Kutzler & Weiner, 2008; Ferraro et al, 2011). Theoretically, 
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DNA vaccines are considered safe, similar to live-attenuated vaccines with regard to eliciting 
broad immune responses, highly stable and flexible (Ferraro et al, 2011; Saade & Petrovsky, 
2012). When comparing DNA preparation with recombinant protein, plasmid DNA is rapid 
and does not have problems such as protein folding (Saade & Petrovsky, 2012). The only 
potential concern with DNA vaccines is the possible risk of partial or complete integration 
into the host genome (Saade & Petrovsky, 2012). 
 
The plasmid DNA is delivered into the skin or muscle by injection or any other delivering 
technique (Kutzler & Weiner, 2008). Once it enters, it is taken up by the local cells, including 
the APCs. Then, the plasmid-encoded genes are expressed, and the generated foreign 
antigens are loaded into MHC class I, or both MHC class I and MHC class II (Saade & 
Petrovsky, 2012). Then, the antigen-loaded APCs present the antigenic peptide to naïve T 
cells, which will initiate the activation and expandability of T cell and B cell responses 
(Kutzler & Weiner, 2008). 
 
Studies on DNA vaccines targeting HIV, malaria, influenza, herpes simplex virus and cancer 
antigens have shown them to be effective in animal models (Kutzler & Weiner, 2008; Ferraro 
et al, 2011; Saade & Petrovsky, 2012). Current licensed DNA vaccines for animal use 
including West Nile virus in horses, melanoma cancer in dogs and infectious hematopoietic 
necrosis virus in salmon (Saade & Petrovsky, 2012).  
 
However, DNA vaccines have been proved to be poorly immunogenic when tested in 
individuals infected with HIV-1, influenza and malaria (Kutzler & Weiner, 2008). Efforts are 
ongoing to improve the immunogenicity of the second-generation DNA vaccines (Ferraro et 
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al, 2011). These enhancement strategies include optimisation of the encoded antigen 
expression levels and improved formulation by the inclusion of molecular adjuvants, such as 
cytokines (Kutzler & Weiner, 2008). 
 
1.3.3.2 RNA vaccines  
Another recent approach with the nucleic acid-based vaccine is the use of RNA in 
vaccination. It has been shown that induction of immune responses by the inoculation of 
similar doses of mRNA and plasmid DNA on a mass basis was equivalent, and the 
expression level of the encoded gene was similar (Ulmer et al, 2012; Geall et al, 2013). 
Many studies have demonstrated immune responses elicited by RNA vaccines for several 
gene targets, such as viral antigens, tumour antigens and allergens in animal models (Ulmer 
et al, 2012). Two major forms of RNA were used as vaccines: mRNA and RNA replicons 
(Geall et al, 2013). mRNA’s primary advantage is the construct simplicity, and the fact that it 
only encodes the gene of interest, without any additional encoded proteins (Geall et al, 
2013). On the other hand, RNA replicons are self-amplifying RNA, which encode for viral 
enzymes that promote amplification. These RNA vaccines enable more production of 
antigens, which make them considerably more effective that mRNA vaccines (Liu, 2010; 
Geall et al, 2013). The main two advantages of RNA vaccines over DNA vaccines are: 1) 
RNA only needs to be delivered into the cytoplasm in order to be translated into protein, 
whereas DNA has to enter the host cell nucleus to be transcribed into mRNA, and that 
means they have to pass through two membrane barriers (Ulmer et al, 2012; Geall et al, 
2013); and 2) the potential of DNA to integrate into the genome of immunised hosts raises a 
safety concern, but with the RNA there is no possibility for integration (Ulmer et al, 2012; 
Geall et al, 2013).  
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1.3.3.3 Live vector vaccines 
Due to the enormous improvements in the fields of genetic engineering and molecular 
biology, generating live recombinant vectors that are able to deliver heterologous antigens is 
currently achievable (Nascimento & Leite, 2012). The basic idea behind the development of 
live vectors is to use their natural ability to infect the host cells. These live attenuated 
vaccines have been successfully used to elicit immune responses against their own 
antigens, and immune responses will be induced against the presented heterologous 
antigen (Nascimento & Leite, 2012).  
 
1.3.3.3.1 Bacterial vectors 
The use of intracellular bacteria for the direct delivery of DNA vaccines into APCs or via 
mucosal surfaces is a promising technique (Guido et al, 2001). Both gram-negative and 
gram-positive attenuated or mutant strains were used as plasmid DNA carriers (Moingeon et 
al, 2002). Bacterial vectors have several advantages for presenting antigenic proteins. They 
are suitable for large-scale immunization programs due to their low-cost of preparation 
(Shata et al, 2000; Medina & Guzman, 2000). They can be easily administered orally and 
are therefore able to induce mucosal immunity (Nascimento & Leite, 2012). Moreover, most 
of the bacteria that are used as DNA plasmid carriers are antibiotic-sensitive strains, and this 
allows for treatment with antibiotics if any side effects occur (Shata et al, 2000; Nascimento 
& Leite, 2012).  
 
Besides using the bacteria as a DNA vaccine carrier and delivering it to the host cells, the 
foreign antigen can also be made as a recombinant bacterial protein to be expressed by a 
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bacterial promoter, which can then be presented to‎ the‎ immune‎ system‎ (Chin’ombe‎ &‎
Ruhanya, 2013).  
After bacteria are taken up by the host APCs, some of the bacterial vectors can escape from 
the phagolysosomal compartment to the host cytoplasm, and upon bacterial disintegration 
the plasmid DNA vaccine is then released into the cytoplasm (Dietrich et al, 1999; Schoen et 
al, 2004). Other bacteria lyse inside the phagosome, which results in the release of plasmid 
molecules within this compartment, and from there they can enter the cytoplasm via 
phagosomal leakage (Figure 1.4) (Dietrich et al, 2001; Schoen et al, 2004). Then, the 
plasmid DNA can enter the nucleus for transcription and expression. The expressed 
antigens are processed and presented by the APC with MHC class I, resulting in the 
activation of CD8+ T cells (da Silva et al, 2015). 
 
Many attenuated strains of pathogenic bacteria have been utilized successfully as vaccine 
vectors in animal experiments against pathogens and tumour antigens, and also as a 
protection from pathogen infection and tumour challenge (Dietrich et al, 2001; Carleton, 
2010). Examples include Mycobacterium bovis BCG, Salmonella spp, Listeria 
monocytogens, Vibrio coholera, Shigella spp. and Bacillus anthracis (Medina & Guzman, 
2001; Carleton, 2010). Current live attenuated bacterial vectors that have reached Phase I 
clinical trials include Salmonella typhi, Bordetella pertussis and Listeria monocytogens (Lin 
et al, 2015). 
 
1.3.3.3.2 Viral vectors 
Viruses are highly efficient at infecting cells. They overcome the cellular barriers and transfer 
their genetic material into the host cell nucleus (Gale et al, 2000; Brave et al, 2006). They 
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Figure 1.4: Bacterial vector vaccine for the delivery of plasmid DNA.  
(1) Bacteria carrying the DNA vaccine adhere to APC. (2) Then, they are phagocytosed by 
the APC. (3a) Bacteria such as Salmonella spp. lyse, and the plasmid DNA is released into 
the phagosomal compartment. (3b) Bacteria such as Listeria monocytogenes and Shigella 
spp. lyse the phagosomal membrane, escape into the cytoplasm, (3c) and upon the bacterial 
disintegration the plasmid is released into the cytoplasm (3d). (4) The DNA plasmid enters 
the host cell nucleus. (5) The plasmid-encoded antigens are expressed, processed (6) and 
presented by MHC class I, and possibly MHC class II. 
APC= antigen-presenting cell; MHC= major histocompatibility complex 
Figure adapted from Dietrich et al (1999). 
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efficiently use the cellular machinery for the replication of their genomes and assembly of the 
viral structural proteins, which result in the production of new viral particles (Gale et al, 2000; 
Brave et al, 2006. Moreover, attenuated viral vaccines are effective at eliciting CD8+ and 
CD4+ T cell responses and humoral immune responses, and provide protection from future 
infection by the same pathogen (Dudeck & Knipe, 2006). Based on that, viruses have been 
extensively studied as naturally existing vehicles that can be utilized for the delivery of 
heterologous antigen and facilitate its presentation to the immune system (Brave et al, 2006; 
Reyes-Sandoval et al, 2007). The cDNA encoding for foreign antigen is cloned into the viral 
vector by incorporating it into a selected viral protein gene, which can then be efficiently 
expressed directly in the host cells along with the virus’s own proteins (Moingeon et al, 
2002).  
 
Viral vectors provide many advantages as a vaccine delivery system. First, viruses are 
naturally the most professional microorganisms at infecting cells, and for some viruses 
around 95% of the initial load successfully enter the intracellular location within 10 minutes 
(Rocha et al, 2004). Second, viral proteins have a potential adjuvant effect of boosting 
immune responses (Rocha et al, 2004; Souza et al, 2005). Also, viruses can induce CD8+ T 
cells (cytotoxic T cells), which are critical to protect against intracellular pathogens (Rollier et 
al, 2011). Finally, many viruses can directly infect APCs, which are essential for the 
stimulation of innate and adaptive immune responses (Joss & Chirmule, 2003; Rocha et al, 
2004). Illustration of the immune responses elicited by viral vector vaccines is shown in 
Figure 1.5. 
 
In order to use a virus as a delivery vector, there are some desirable criteria for selecting a 
particular viral vector. These include an ability to propagate in a cell culture that is accepted 
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Figure 1.5: Induction of immune responses by recombinant viral vectors.  
A viral vector encoding a foreign antigen has the potential to induce both CD8+ and CD4+ 
cellular immune responses. 1) Effective cell invasion by the virus. 2) Successful release of 
the viral genomic material, as well as the one encoding for the recombinant protein. 3) 
Expression of the recombinant protein within the host cell cytoplasm, and fragments of the 
recombinant product may be loaded on MHC molecules (class I and class II) and be 
presented on the host cell surface to T cells. 
Figure adapted from Rocha et al (2004). 
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by regulatory authorities and the ability to grow to high titres and allow easy purification 
(Moingeon et al, 2002; Nascimeto & Leite, 2012; Ura et al, 2014). Also, it should be 
genetically stable in the presence of heterologous antigens, as well as in the attenuated form 
(Moingeon et al, 2002; Nascimeto & Leite, 2012). More importantly, viral vectors must not 
cause disease or toxicity, nor result in in integration into the host genome (Moingeon et al, 
2002, Ura et al, 2014). It is also crucial to consider how well the inserted gene will be 
expressed in terms of availability of the encoded protein for immune responses (Liu, 2010).  
 
Many different viruses have been studied and evaluated as recombinant vaccine vectors, 
and they can be classified according to their genomic type (DNA or RNA), foreign gene 
insert capacity and host or tissue tropism (Nascimeto & Leite, 2012). Immunogenicity and 
protection have been demonstrated in animal models immunized with viral vectors encoding 
genes for critical pathogens such as HIV, malaria and tuberculosis (Limbach & Richie, 2009; 
Nascimeto & Leite, 2012).  
 
The most extensively tested viral vectors are adenovirus and vaccinia virus, because they 
are highly stable and safe, have a large insert capacity and induce strong humoral and 
cellular immune responses (Souza et al, 2005; Ura et al, 2014). Advantages and concerns of 
these two viruses and other studied viral vectors are summarized in Table 1.5. 
 
Adenovirus serotype 5 has been considered the most promising vaccine against HIV-1. 
However, phase II clinical trials in humans did not obtain the same results that were 
achieved in monkeys immunized with adenovirus expressing HIV antigens (Nascimeto & 
Leite, 2012). A recent approach using a “prime-boost”‎ includes‎ vaccination‎ with‎ different‎
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Virus Advantages Disadvantages 
Retrovirus 
Long-term gene 
expression 
Generation of replication-
competent virus 
Potential for tumorigenesis 
Infects dividing cells only 
Lentivirus 
Long-term gene 
expression 
Infect non-dividing and 
dividing cells 
Generation of replication-
competent virus 
Potential for tumorigenesis 
 
Vaccinia virus 
High immunogenicity 
Safety: used in many clinic 
trials 
High titer production 
Pre-exciting immunity 
Adenovirus 
High immunogenicity 
Safety: used in many clinic 
trials 
High titer production 
Pre-exciting immunity 
Adeno-associated 
virus 
Long-term gene 
expression 
Non-pathogenic virus 
Low titer production 
Cytomegalovirus 
Induces a unique CTL 
response 
Protects against SIV 
infection in an animal 
model 
Pre-exciting immunity 
Risk of pathogenesis in 
specific individuals 
Sendai virus High immunogenicity Pre-exciting immunity 
 
Table 1.5: Major advantages and disadvantages of several viral vectors.  
Table obtained from Ura et al (2014). 
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vaccine types, in which an antigen is administered by one method and subsequently boosted 
by a different method to deliver the same antigen (McConnell et al, 2007). The combination 
includes initial prime with a DNA vaccine, followed by a viral vector vaccine. Or prime-boost 
using two different viral vectors (McConnell et al, 2007). Animal studies showed that the 
combination of DNA/ modified vaccinia Ankara (MVA) and DNA/ adenovirus serotype 5 
(Adh5) or MVA/ Adh5 can control HIV infection (Souza et al, 2005; Reyes-Sandoval et al, 
2010). Also, in another study, MVA/Adh5 prime-boost immunization has been showed to 
enhance protection against malaria (Souza et al, 2005; Reyes-Sandoval et al, 2010).  
 
The development of reverse genetics methods have led to RNA vaccine vector evolution. 
RNA viruses were engineered to express vaccine antigens against a broad range of 
pathogens and cancers. RNA viruses have studied such as Venezuelan Equine Encephalitis 
Virus (VEEV), yellow fever virus, replication-defective flavivirus, vesicular stomatitis virus 
(VSV) and influenza A virus (IAV) (Moglar & Kamurud, 2014; Stobart & Moore, 2014). 
Development of a tetravalent dengue vaccine has showed efficiency and safety in animal 
studies, and it has been progressed to human trials and is awaiting regulatory approval 
(Moglar & Kamurud, 2014). Also, VEEV vaccine expressing the influenza HA gene is a fully 
licensed veterinary vaccine against H3N2 swine influenza virus (Moglar & Kamurud, 2014). 
Moreover, influenza virus has been demonstrated as a potential vaccine vector, particularly 
with the development of the live attenuated influenza vaccine that is used for seasonal 
influenza vaccination (Pena et al, 2013; Moglar & Kamurud, 2014). Examples of influenza 
virus as a vaccine vector are described in Section 1.4.  
 
Using a replicating viral vector has advantages for mimicking the live attenuated vaccine, 
which is known to effectively induce robust immune responses. This is a big benefit to 
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developing vaccines against the most important pathogens, such as HIV and malaria (Koff et 
al, 2013; Parks et al, 2013). However, it is still challenging in terms of developing a stable 
viral vector (Koff et al, 2013). Another major challenge is the possible presence of pre-
existing immunity against the viral vector that can affect antigen delivery and expression in 
the immunized host (Koff et al, 2013). With all the promising results obtained by using viral 
vector-based vaccines, there is still no viral vector licensed for humans. More studies and 
trials are needed to overcome the present obstacles, and to develop an ideal viral vector 
vaccine to be used for humans (WHO, 2014). 
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1.4 Influenza A virus 
Influenza A virus is a member of the Orthimyxoviridae family (Iwasaki & Pillai, 2014). It is an 
enveloped virus, and contains a genome composed of eight negative single-stranded RNA 
segments (ssRNA) (Iwasaki & Pillai, 2014). Hemagglutinin (HA) and neuraminidase (NA) are 
the major viral glycoproteins that are targeted and detected by antibodies (Iwasaki & Pillai, 
2014). Influenza A viruses are classified into subtypes according to HA and NA surface 
proteins. Currently, there are 18 different subtypes of HA (HA1 to HA18) and 11 subtypes of 
NA (NA1 to NA11) (CDC, 2014). 
 
1.4.1. Influenza virus infection  
Influenza virus is one of most common causes of viral respiratory infection (van de Sandt et 
al, 2012). It causes annual winter outbreaks (epidemics) and occasional pandemics (van de 
Sandt et al, 2012). Influenza results in an estimated 3 to 5 million severe clinical infections 
and between 250,000 and 500,000 fatal cases yearly (van de Sandt et al, 2012). Influenza 
infection is characterized by sudden onset of high fever, rhinitis, headache, malaise and 
inflammation of the upper respiratory tract (Taubenberger & Morens, 2008). These 
symptoms can persist for up to 10 days (Taubenberger & Morens, 2008). Type A and type B 
of influenza viruses are the most common causes of influenza-like symptoms (Taubenberger 
& Morens, 2008). The current influenza A viruses found in people are the H1N1 and H3N2 
subtypes (CDC, 2014).  
 
1.4.2 Outline immune responses to influenza virus infection 
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Influenza viruses can infect different host species, such as humans, birds and pigs (Iwasaki 
& Pillai, 2014). Influenza virus enters the host via the nasal or oral cavity, and its primary 
targets are the epithelial cells lining the respiratory tract (van de Sandt et al, 2012; Iwasaki & 
Pillai, 2014). In addition to non-immune cells, the virus can also spread to immune cells 
including macrophages and dendritic cells (Iwasaki & Pillai, 2014). The innate immune 
system forms the first defence line, which is composed of the physical barriers (e.g., 
mucous) and the innate cellular response (van de Sandt et al, 2012). Once the virus 
successfully invades host cells, the virus RNA within the infected cell is recognized as 
PAMPs by the pattern recognition receptors (PRRs), which initiates the antiviral signalling 
cascade (van de Sandt et al, 2012; Iwasaki & Pillai, 2014). This results in the secretion of 
type I interferons (IFNs), pro-inflammatory cytokines and chemokines, which leads to the 
induction of an antiviral state and the recruitment of neutrophils and natural killers (NK), as 
well as activating macrophages and maturation of DCs (van de Sandt et al, 2012; Iwasaki & 
Pillai, 2014). The three main PPR classes that are engaged in virus recognition and the 
activation of the signal transduction pathway are Toll-like receptors (TLRs), retinoic acid 
inducible gene-I (RIG-I) and nucleotide oligomerization domain-like receptors (NODs) 
(Mogensen & Paludan, 2001; van de Sandt et al, 2012). The NK mediate viral clearance by 
targeting the infected epithelial cells, and the phagocytic cells (macrophages and 
neutrophils) help to clear the dead infected cells (Iwasaki & Pillai, 2014).  
 
If the innate defence system was not successful in clearing the viral infection, adaptive 
immune responses are then required (Figure 1.6). Dendritic cells form an essential link 
between the innate and adaptive immune responses. They migrate from the infection site to 
the draining lymph node and present the viral antigens to naïve T and B cells (Braciale et al, 
2012). DCs can obtain the viral antigens by two mechanisms: 1) influenza virus direct 
infection to DCs or 2) phagocytosis of virus particles or apoptotic epithelial cells 
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Figure 1.6: Activation of cellular and humoral immune responses. The solid arrows indicate 
immune response activation after a primary infection with influenza virus. The dotted arrows 
indicate the rapid induction of virus-specific memory cell responses with a secondary 
influenza virus infection. 
Figure obtained from van de Sandt et al (2012). 
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the HA globular head (see below). Of interest, humoral immunity elicited after an influenza virus 
infection does provide long-lasting antibody mediated protection against the strains that resemble the 
infected strain. This was exemplified during the pandemic of 2009 caused by an influenza virus of the 
H1N1 subtype. Elderly people that were exposed to influenza A/H1N1 virus in the 1950s had 
antibodies which cross-reacted with the pandemic strain and were relatively spared from contracting 
infections and developing disease [109–112]. Recently, broadly reacting antibodies directed against the 
conserved stem region of HA have been identified [113–120].  
Figure 4. Induction of humoral and cellular immunity. Induction of immune responses 
after a primary influenza A virus infection is indicated by solid arrows. The more rapid 
activation of virus-specific memory cell populations upon secondary encounter with an 
influenza A virus are indicated by dotted arrows. 
 
 
Antibodies to the other major glycoprotein, the viral NA, interfere with the last phase of the viral 
replication cycle and also exert protective immunity. NA is a sialydase and removes sialic acids from 
infected cells and budded virions, thereby facilitating efficient release and sprea  of newly formed 
viral particles [1]. Unlike HA-specific antibodies, NA-specific antibodies do not neutralize the virus. 
However, by inhibiting the enzymatic activity of NA, these antibodies limit the viral spread and thus 
shorten severity and duration of illness [121–125]. Furthermore, NA-specific antibodies may also 
contribute to clearance of virus-infected cells by facilitating ADCC [85]. 
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(van de Sandt et al, 2012).The first mechanism leads to the presentation of the viral peptides 
via MHC class I molecule, which is then recognized by CD8+ cytotoxic T cells (CTLs) (van 
de Sandt et al, 2012). The second mechanism results in loading of the viral peptide in MHC 
class II, which can be recognized by CD4+ T helper cells (van de Sandt et al, 2012). 
 
The virus-specific CD4+ and CD8+ T cells play a major rule in regulating the immune 
response and clearing the virus infection (van de Sandt et al, 2012). After the activation of 
CD4+ cells, they differentiate into T helper 1 (Th1) and T helper 2 (Th2) cells (van de Sandt 
et al, 2012; Braciale et al, 2012). Th1 promote CTL responses and produce IFN-γ‎and‎IL-2 
(van de Sandt et al, 2012; Braciale et al, 2012). Th2 secrete IL-4, IL5 and IL13 and stimulate 
the activation of B cells, resulting in antibody production (van de Sandt et al, 2012; Braciale 
et al, 2012). Viral-specific IgG antibodies mediate a long-lasting protection, but are only 
strain-specific (van de Sandt et al, 2012). CTLs travel to the infection site and remove the 
cells infected with influenza virus. Therefore, they prevent virus propagation and spreading 
(van de Sandt et al, 2012. Moreover, after primary infection, memory CD4+ T cells are 
produced and provide rapid response and protection against secondary infection with the 
same virus subtype (van de Sandt et al, 2012).   
 
1.4.3 Influenza vaccine 
Seasonal influenza vaccines include two types of influenza A virus (H1N1 and H3N2) and 
one type of influenza B virus (Isakova-Sivak et al, 2011). The vaccine is designed 
specifically for each upcoming season against the most common circulating flu viruses 
(CDC, 2015). The 2015–2016 trivalent vaccine formulation is made to protect from the 
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A/California/7/2009 (H1N1), A/Switzerland/9715293/2013 (H3N2) and B/Phuket/3073/2013 
viruses (CDC, 2015). 
 
The two main types of influenza vaccines that are licensed for human use are the inactivated 
influenza vaccine (IIV) and the live attenuated influenza vaccine (LAIV) (Isakova-Sivak et al, 
2011). The IIV includes split virus, subunit or recombinant HA-based vaccines, and 
protection is mediated by the production of specific IgG antibodies to the HA (Isakova-Sivak 
et al, 2011; Sridhar et al, 2015). On the other hand, the LAIV provides a much broader 
immune response with local and systemic T cell and antibody responses (Sridhar et al, 
2015). Although LAIV also has an excellent safety profile, its usage has some restrictions in 
certain age groups. It is recommended for children from six months, the elderly and 
asthmatics due to its high safety profile (Sridhar et al, 2015). In the US and Canada, the 
LAIV is recommended for children from 2 years, and up to 49 and 59 in healthy adults 
(Sridhar et al, 2015). However, in Europe it is only recommended for children between 2 and 
18 years old (Sridhar et al, 2015). 
 
The LAIV is generated using reverse genetics techniques, and it contains HA and NA 
proteins from circulating viruses and the remaining proteins from the attenuated, 
temperature-sensitive and cold-adapted virus, which is referred as the master donor virus 
(MDV) (Isakova-Sivak et al, 2011; Sridhar et al, 2015). There are two critical requirements 
for the MDV to be used as a virus backbone: first, the mutation leading to attenuation should 
be present within one or more of the six RNA segments (other than the HA and NA 
segments) (Isakova-Sivak et al, 2011). Second, the new epidemic virus generated by using 
the MDV should maintain the attenuating capacity (Isakova-Sivak et al, 2011). The LAIV 
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cannot replicate at temperatures above 33°C. Therefore, the replication is restricted to the 
upper respiratory tract, and not the lower respiratory tract (Sridhar et al, 2015). 
 
1.4.3 Structure and composition of influenza virus particles 
1.4.3.1 Virus morphology 
Influenza viruses in the environment are relatively unstable, and they are susceptible to 
physical factors including heat, extreme pH, dryness, organic solvents and detergents 
(Kapoor & Dhama, 2014). 
 
Virus particles are enclosed by a lipid bilayer membrane, which is obtained from the host cell
during the viral budding process (Samji, 2009; Noda, 2012). Mostly, the viruses are in 
spherical or oval shapes and reach around 80 nm in diameter (Noda, 2012). However, 
sometimes viruses can be found in filamentous and irregular shapes (Figure 1.7) (Noda, 
2012). The surface of the virus particle contains three transmembrane proteins: HA, NA and 
M2 (Noda, 2012). HA and NA form a spike-like structure on the virus surface coat. 
Approximately 80% of the viral spikes are HA, and the remaining spikes are NA (Samji, 
2009; Moules et al, 2011). M2 protein is less present in the viral envelope, with only 16–20 
molecules per viral particle (Samji, 2009).  
 
The spherical or oval shapes are usually found with the influenza virus A laboratory-adapted 
strains, whereas the filamentous shape is primarily seen with clinical isolates (Noda, 2012). 
A study has observed the influenza virus in the filamentous‎shape,‎and‎it‎was‎up‎to‎30‎μm‎in‎
length. They have suggested that this morphology could be critical for virus survival in nature  
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Figure 1.7: Images of influenza virions under the electron microscope. The viruses were 
purified using ultracentrifugation and examined using negative-staining EM. 
A) Spherical viral particles for A/WSN/33 (H1N1). B) Filamentous viral particles for 
A/Udorn/307/72 (H3N2). C) Irregular-shaped viral particles for A/Puerto Rico/8.34 (H1N1). 
Images obtained from Noda (2012). 
 
200 nm 
200 nm 200 nm 
CHAPTER 1 
 
 
 40 
(Roberts & Compans, 1998). Moreover, it has been demonstrated that ultracentrifugation 
can affect the virion morphology and result in irregularities (Sugita et al, 2011). 
 
1.4.3.2 Virus internal structure 
The influenza A virus genome contains eight different RNA segments (Hutchinson & Fodor, 
2013). Each segment is encapsidated by multiple copies of the viral-encoded nucleoprotein 
(NP), which binds to the whole RNA sequence (with the exception of the terminal sequence) 
(Lamb & Choppin, 1983; Zheng & Tao, 2013). The RNA terminal sequences (3` and 5` ends) 
bound to the trimeric RNA-dependent RNA polymerase proteins  (PB1, PB2 and PA) (Lamb 
& Choppin, 1983; Zheng & Tao, 2013). The vRNA, NP and polymerase proteins form a 
double helical rod-shaped structure called the ribonucleoprotein (RNP) complex (Bae et al, 
2001; Zheng & Tao, 2013). The eight viral RNPs have uniform diameter, but can be divided 
into three groups by length, depending on the size of the vRNA that is associated with the 
RNP: 90–110 nm, 60–90 nm and 30–50 nm (Zheng & Tao, 2013). Each vRNA 5` and 3` end 
comprise a 12- to 13-nucleotide sequence  (in length) that are partially complementary, and 
thus able to base pair with one another (Samji, 2009; Zheng & Tao, 2013). They are highly 
conserved between the eight vRNA segments, and they serve as a binding site for the viral 
heterotrimeric polymerase complex (Neumann et al, 2004; Zheng & Tao, 2013). 
 
The viral NP’s main role is to coat the vRNA and facilitate it folding into a double-helical 
structure. Other demonstrated functions include interaction with several viral and host 
proteins (Zheng & Tao 201). The viral polymerase complex plays a vital role in virus life 
cycles. It is responsible for initiating viral genome replication and transcription (Lit et al, 
2009; Samji 2009). 
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1.4.3.3 Influenza A virus proteins 
The eight viral RNA (vRNA) segments encode for 11 proteins: polymerase basic protein 1 
(PB1), polymerase basic protein 1-F2 (PB1-F2), polymerase basic protein 2 (PB2), 
polymerase acidic protein (PA), hemagglutinin (HA), neuraminidase (NA), nucleocapsid 
protein (NP), matrix 1 (M1), matrix 2 (M2), non-structural protein 1 (NS1) and non-structural 
protein 2 (NS2) (Figure 1.8) (Samji, 2009; Kapoor & Dhama, 2014).  
 
Segments 1, 2 and 3 encode for the transcriptase-associated proteins PB2, PB1 and PA 
respectively (Lamb & Choppin, 1983; Kapoor & Dhama, 2014). PB1 and PB2 are similar in 
size (encoded by 2341 nucleotides), and biochemical and structural studies revealed that 
their activities are involved in the synthesis of mRNA (Lamb & Choppin, 1983). Specifically, 
PB2 is responsible for binding to the cap structures of the host cell mRNA, and PB1 is 
involved in initiating transcription (Lamb & Choppin, 1983; Wakai et al, 2011). On the other 
hand, PA proteins have been suggested to be responsible for vRNA and cRNA synthesis 
(Lamb & Choppin, 1983; Huarte et al, 2003). PB1-F2 is involved in regulating polymerase 
activity (Kapoor & Dhama, 2014). 
 
Segment 4 encodes the HA protein (Lamb & Choppin, 1983). The HA precursor (HA0) 
consists of two subunits: HA1, which contains the receptor binding region and the HA 
antigenic domains, and HA2, which includes the fusion peptide (Sriwilaijaroen & Suzuki, 
2012). These two subunits are linked together by disulfide bonds (Samji, 2009). HA is 
responsible for virus attachment to the cell and facilitates cell penetration by the virus into 
the cell (Lamb & Choppin, 1983; Sriwilaijaroen & Suzuki, 2012). It is the major viral antigen 
that stimulates host neutralizing antibody, and the HA antigenic variation plays a leading role
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Figure 1.8: Schematic structure of a typical influenza A virus. 
Figure obtained from VDU, accessed in 2015. 
http://www.virologydownunder.blogspot.com.au 
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in influenza epidemics (Lamb & Choppin, 1983; Sriwilaijaroen & Suzuki, 2012). The structure 
and function of HA is described in more detail in Section 1.5.5. 
 
Nucleoprotein (NP) is encoded by RNA segment five (Lamb & Choppin, 1983). NP is a type-
specific antigen, and is used to identify the classification of the isolated influenza virus as A, 
B or C (Lamb & Choppin, 1983. Moreover, NP is a multifunctional protein. It interacts with 
several viral proteins, such as PB1, PB2 and M1 (Portela & Digard, 2002), as well as cellular 
polypeptides such as actin, and factors of nuclear import and export machinery (Portela & 
Digard, 2002). 
 
Viral segment six encodes the NA membrane glycoprotein (Lamb & Choppin, 1983). The 
structure of the NA spikes is composed of a stalk and a head, and together they form a 
mushroom-like shape (Lamb & Choppin, 1983). NA activity promotes the release of newly 
formed viral particles from the host-cell membrane. Also, it assists in viral movement to the 
target cell by helping to free the virus from the neuraminic acid residues in the respiratory 
tract mucins (Shtyrya et al, 2009). 
 
The membrane protein M1 and the non-structural protein M2 are encoded by viral segment 
seven (Lamb & Choppin, 1983). M1 is the most abundant viral protein, and it forms an inner 
layer of the virus particle (Pielak & Chou, 2012). M2 forms an ion channel in the viral 
envelope. Its role involves equilibrating the pH level throughout the viral membrane during 
viral entry to host cell, and in viral maturation through the Trans-Golgi membrane within 
infected cells (Pielak & Chou, 2012). 
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The last viral segment is the smallest one in size, and it is encoded for non-structural 
proteins 1 and 2 (NS1, NS2) (Lamb & Choppin, 1983). It has been demonstrated that NS1 
contributes to influenza virus virulence by interfering with the immune defence system, and 
specifically with IFN (Lin et al, 2007). The NS2 or so-called nuclear export protein (NEP) is 
mediated through export of the vRNP from the host cell‎nucleus‎(O’Neill‎et al, 1998). 
 
1.4.3.4 vRNA structure 
The eight vRNA segments share a common structure: a large central coding region (in the 
antisense orientation) flanked by a noncoding region (NCR) (Hutchinson et al, 2010; Zhao et 
al, 2014). The NCR is composed of a non-conserved region followed by a highly conserved 
promoter region at the 3` and 5` termini (Hutchinson et al, 2010; Zhao et al, 2014).  
 
The promoter region is made of 12 nucleotides at the 3` end and 13 nucleotides at the 5` 
end (Robertson, 1979). The nucleotides of this region are partially complementary to each 
other and form the double-stranded panhandle structure (Flick et al, 1996; Leahy et al, 
2001). This structure serves as the binding site for the vRNA polymerase (Flick et al, 1996).  
 
The non-conserved region at the 3` and 5` ends is located between the promoter region and 
the start or stop codon (Zhao et al, 2014). This region varies in length and nucleotide 
composition between the different vRNA segments, but they are highly conserved for the 
same segment of different influenza A strains (segment-specific NCR) (Zhao et al, 2014).  
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Genomic RNAs are differentiated from non-genomic by the presence of the conserved 
promoter sequence located at the 5` and 3` ends during virion packaging (Hutchinson et al, 
2010). Also, the absence of a functional terminal panhandle structure will not allow 
packaging into viral particles (Hutchinson et al, 2010).   
 
1.4.4 Virus replication 
Influenza virus replication occurs in the infected cell nucleus, and the RNPs play a vital role 
in the virus life cycle (Zheng & Tao, 2013). The influenza life cycle is illustrated in Figure 1.9, 
and the major stages involved in the virus life cycle, from cell entry to viral release, are 
discussed below. 
 
1.4.4.1 Virus entry to host cell 
Influenza infection starts with the recognition of a specific host cell receptor by the HA 
receptor-binding site that is located on the top of the HA1 globular head (Chu & Whiiaker, 
2004; Hamilton et al,‎2012).‎The‎α-sialic acid is the target receptor molecule found on the 
surface of many cell types (Luo 2012). Human influenza viruses favourably bind to the 
α(2,6)-sialic‎acid‎ linkage,‎while‎avian‎influenza‎viruses‎bind‎to‎the‎α(2,3)-sialic acid linkage 
and swine viruses can bind to both (Samji, 2009; Hamilton et al, 2012).  
 
Once the virus is bound, the tight association between the virion and the host cell results in 
endocytosis induction (Luo, 2012). Therefore, the virus enters the cell in an endosome (Luo, 
2012). The endosome has a low pH environment (5 to 5.5), which triggers conformational 
changes in HA0 (Cho et al, 2004; Hamilton et al, 2012). The acidic pH leads to the cleavage
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Figure 1.9: The life cycle of influenza virus. 
The helical structure represents the RNP, and the polymerase subunits are indicated by red, 
green and brown circles. 
Figure obtained from Zheng and Tao (2013). 
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of HA0 into HA1 and HA2, and this is an essential step to initiate the viral-endosomal fusion 
(Luo, 2012, Hamilton et al, 2012). Exposure of the HA2 fusion peptide fuses the viral and 
endosomal membranes (Samji, 2009). Also, the acidic environment opens up the M2 ion 
channels and exposes the matrix protein (M1) to this low pH, which then releases all eight 
vRNPs into the cytosol (Samji, 2009; Luo, 2012). 
 
1.4.4.2 Viral RNP entry into nucleus 
Transcription and replication of influenza vRNA happens in the cell nucleus. Hence, after the 
release of vRNP, it must travel and enter the nucleus (Samji, 2009; Luo, 2012). In order to 
enter through the nucleus envelope, vRNP must have the nuclear localization signals (NLSs) 
(Hutchinson & Fodor, 2013). The three viral polymerase proteins and the NP contain the 
NLSs, which mediate the entry of the genome through the nuclear pore complex using the 
host transport machinery (NPC) (Cohen et al, 2010).  
 
1.4.4.3 Transcription and replication of the vRNA 
The eight vRNPs act as a self-regulating transcription and replication unit (Resa-Infante et 
al, 2011). Transcription and replication are two different modes of RNP function, which 
produce two types of positive-sense RNA (Figure 1.10) (Mikulasova et al, 2000; Hutchinson 
& Fodor, 2013). Transcription of the vRNA produces a messenger RNA (mRNA) molecule, 
which lacks 15–22 nucleotides at its 3` termini and contains a poly(A) tail, as well as a 7-
methylguanosine cap structure at its 5` termini generated from the host mRNA (Mikulasova 
et al, 2000; Bae et al, 2001; Hutchinson & Fodor, 2013). On the other hand, replication of the 
vRNA produces a full-length copy of complementary RNAs (cRNAs), which become 
encapsidated by NP and polymerase proteins (Bae et al, 2001; Resa-Infante et al, 2011; 
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Figure 1.10: Influenza transcription and replication processes, and structural differences 
between the three types of RNA molecules. 
The diagram represents the vRNA containing helical viral ribonucleoprotein (vRNP) 
(negative polarity), and the cRNA containing cRNP (positive polarity). The promoter is 
located within the panhandle structure, and the polyadenylation signal (oligo U) location is 
shown. The capped fragment in the mRNA is indicated with a green box, and the poly(A) tail 
is shown. 
Red line: vRNA; blue line: cRNA; orange circles: NP; green circle: PB2; purple circle: PB1; 
yellow circle: PA. 
Figure obtained from Resa-Infante et al (2011). 
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Hutchinson & Fodor, 2013). The methylated cap fragment is used as a primer by the viral 
RNA-dependent RNA polymerase (RdRp) to initiate mRNA transcription from the template, 
and then it is finally polyadenylated (Samji, 2009; Resa-Infante et al, 2011). mRNAs are only 
produced from vRNAs; cRNAs are not able to produce them due to their inability to perform 
the cap-snatching reaction from the host mRNA (Resa-Infante et al, 2011). The cRNAs 
containing RNP act as a replicative intermediate that generates numerous numbers of 
progeny vRNPs (Resa-Infante et al, 2011). Synthesis of mRNA can occur in cis. Hence, it 
functions by using the polymerase present in vRNA (Resa-Infante et al, 2011; Hutchinson & 
Fodor, 2013). However, replication demands free polymerase proteins that are assembled 
from translated and imported viral proteins (Resa-Infante et al, 2011; Hutchinson & Fodor, 
2013).  
 
The transcription process occurs early in infection (referred as primary transcription), while 
the replication process comes later (Resa-Infante et al, 2011; Hutchinson & Fodor, 2013). 
After cRNPs produce progeny vRNPs by using the parent templates, they can serve as 
templates for initiating the secondary transcription process (Resa-Infante et al, 2011; 
Hutchinson & Fodor, 2013). It has been demonstrated that only the vRNPs export from the 
nucleus to the cytoplasm, but the cRNPs do not export (Tchatalbachev et al, 2001). 
 
1.4.4.4 Viral particle assembly and release 
The final step of the influenza virus life cycle is virion assembly and release from the apical 
plasma membrane in polarized epithelial cells (Gorai et al, 2012; Hutchinson & Fodor, 2013). 
The viral envelope proteins, M1 and the vRNPs must transport to the assembly location 
(Nayak et al, 2004). The HA and NA transported from the trans-Golgi network (TGN) to a 
certain domain on the plasma membrane containing lipid rafts (Hui & Nayak, 2001). M1 is 
CHAPTER 1 
 
 
 50 
synthesised by non-membrane-bound polyribosomes (Nayak et al, 2004). The vRNPs are 
exported into the cytoplasm with the assistance of M1 and NEP (NS2) through the nuclear 
pores (Nayak et al, 2004). The lipid raft serves as a platform for viral particle budding, and 
also helps to accumulate the viral glycoproteins (HA and NA) and the ion channel M2 
(Nayak et al, 2004). The matrix protein M1, a non-raft-associated protein, interacts with the 
cytoplasmic tail of HA, NA and M2, and can also interact with the plasma membrane (Gorai 
et al, 2012; Hutchinson & Fodor, 2013). Both M1 and M2 interact with vRNPs (Hutchinson & 
Fodor, 2013). These interactions facilitate the concentration of viral components and the 
elimination of host cell proteins from the budding site (Nayak et al, 2004). Beside viral 
factors, virus budding also requires host factors, including G-protein signalling and kinase 
activity, as well as adenosine triphosphate (ATP) as an energy source (Hui & Nayak, 2001; 
Hui & Nayak, 2002; Nayak et al, 2004; Hutchinson & Fodor, 2013). M1 and M2 play a critical 
role in budding. However, the precise mechanism of virus budding remains unknown (Nayak 
et al, 2004; Gorai et al, 2012). The release of the virus requires closing of the bud, and also 
requires the NA to free the virus particle from the sialic acid residues on the surface of the 
host cell (Nayak et al, 2004; Samji, 2009). 
 
1.4.5 HA protein 
The HA surface protein is the primary target in vaccination (DuBois et al, 2011). It is 
composed of three identical monomers that form a cylindrical shape (Isin et al, 2002). It was 
estimated that each virion contains around 340-400 HA trimmers (Harris et al, 2006). Each 
HA monomer (mature HA) consists of HA1 and HA2 subunits. HA1 represents the globular 
head of HA, which is folded into a jelly-roll motif formed from eight‎ antiparallel‎ β-sheets 
(Wilson, 1990; Isin et al, 2002). HA2 forms the stem region of HA, and it is anchored in the 
viral lipid membrane by a helical structure near the C-terminus (Isin et al, 2002). The distal 
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tip of each HA globular head contains the receptor binding pockets, which are surrounded by 
the HA antigenic sites (Isin et al, 2002; Ellebedy & Ahmed, 2012).  
 
1.4.5.1 HA antigenic regions 
The antigenic domains are located within the globular head of the HA1 subunit (Caton & 
Browniee, 1982; Wilson, 1990). They have been categorized into five sites: Sa, Sb, Ca1, 
Ca2 and Cb for H1 subtype viruses, and A, B, C, D and E for H2 subtype viruses 
(Figure1.11) (Caton & Browniee, 1982; Wilson, 1990). These antigenic sites were defined 
according to monoclonal antibodies observed to bind to a single site (Caton & Browniee, 
1982; Magadan et al, 2013). To clarify that, binding by these specific antibodies to a 
particular site was not affected when modification occurred in the other antigenic sites 
(Caton & Browniee, 1982).  
 
Antigenic sites Sa and Sb are located in the upper part of the globular head, as are antigenic 
sites A and B (Caton & Browniee, 1982; Tsuchiya et al, 2001). Ca1 and Ca2 antigenic sites 
are located below the receptor-binding site and at the globular head interface, as well as site 
D (Tsuchiya et al, 2001; Xu et al, 2010). Site Cb and site C are situated near the globular 
head bottom (Caton & Browniee, 1982; Tsuchiya et al, 2001). Antigenic site E is located 
between sites A and C (Tsuchiya et al, 2001). 
 
These antigenic domains are antigenically variable, and mutations within these sites that 
accumulate over time result in the antigenic drift of influenza viruses (Soundararajan et al, 
2011; Ellebedy & Ahmed, 2012). 
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Figure 1.11: Antigenic sites in HA trimmers of A) H1N1 and B) H3N2.  
HA1 and HA2 subunits are in grey and brown respectively.  
Figure obtained from Iba et al (2014), with some modification. 
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1.4.5.2 HA folding and trimerization 
Synthesis of HA occurs in the endoplasmic reticulum (ER) of the host cells, which is then 
carried across the Golgi complex (GC) to the cell surface (Copeland et al, 1988; Magadan et 
al, 2013). N-linked glycosylation occurs co-translationally as the HA extrudes into the ER via 
the translocon, which is then trimmed and considerably modified while transporting HA to the 
plasma membrane (Magadan et al, 2013).  
 
HA folding begins co-translationally, and is immediately performed once the polypeptide 
enters the ER (Copeland et al, 1988; Braakman et al, 1991; Magadan et al, 2013). Early 
folding of HA monomers is completed within one or two minutes, and the two HA subunits 
are disulfide bonded (Copeland et al, 1988; Magadan et al, 2013). The location of HA 
trimerization seems to be a strain, or could be subtype-specific, with H2 and H3 subtypes 
trimerizing of HA happening in the ER, whereas with H1, and specifically A/PuertoRico/8/34, 
trimerization happens in the ER-Golgi intermediate compartment (Magadan et al, 2013). 
 
Trimerization causes subtle conformational effects that are required for HA to gain complete 
antigenicity, and these effects can mostly persist after partial or complete trimer dissociation 
(Magadan et al, 2013). Using specific monoclonal antibodies, it has been demonstrated that 
some epitopes in the Ca, Cb and Sa antigenic sites are generated or completed with HA 
trimerization (Magadan et al, 2013; Magadan et al, 2014).  
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1.5 Influenza virus reverse genetics 
The term “reverse genetics” is used to define the generation of infectious viral particles 
possessing genome(s) derived from cloned cDNA(s), which have been modified (Neumann 
et al, 2002; Muraki & Hongo, 2010). The reverse genetics technique was first applied to DNA 
viruses, and followed up by positive-sense RNA viruses (Minskaia & Luke, 2015). 
Transfection of full-length DNA or positive-sense RNA, for DNA and positive-sense RNA 
viruses respectively into a particular cell line, leads to viral replication (Neumann et al, 2002; 
Minskaia & Luke, 2015). In contrast, the genome of negative-sense RNA viruses alone is not 
able to initiate infection when transfected into an applicable cell line (Neumann et al, 2002; 
Minskaia & Luke, 2015). Positive-sense RNA viruses and their genomic RNA also serve as 
functional mRNA, whereas mRNA for negative-sense viruses are truncated in their 3` ends 
(Minskaia & Luke, 2015). Therefore, they are missing some of the viral specific information 
that is needed for new vRNA production, and cannot serve as a template for replication 
(Minskaia & Luke, 2015).  
 
For influenza viruses to initiate the virus replication and transcription cycle, functional RNP 
complexes are required (see Section 1.4.4) (Luytjes et al, 1989; Hoffmann et al, 2000; 
Neumann et al, 2002). Purification of the influenza virus polymerase proteins and NP 
proteins, and in vitro assembly of vRNPs in the late 1980s, were considered as primary 
steps in generating recombinant influenza viruses (Luytjes et al, 1989; Neumann & 
Kawoaka, 2001). Reverse genetics systems, helper virus-based methods and helper virus-
free methods for the generation of recombinant influenza viruses are described below. 
 
1.5.1 Helper virus-based methods 
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1.5.1.1 RNP transfection system 
Reconstitution of biologically active RNP complexes in vitro was successfully achieved by 
Parvin et al (1989) and Honda et al (1990). It was achieved by purifying the viral polymerase 
proteins (PB1, PB2 and PA) and NP through a CsCl-glycerol gradient centrifugation (Honda 
et al, 1990; Neumann & Kawoaka, 2001; Minskaia & Luke, 2015). This is followed by 
incubation with full-length naked vRNA that is either transcribed from plasmids in vitro or 
isolated from viral particles (Honda et al, 1990; Neumann & Kawoaka, 2001; Minskaia & 
Luke, 2015). Luytjes et al (1989) were the first to establish a system for modifying the 
influenza virus genome. The recombinant RNA for NS genes containing chloramphenicol 
acetyltransferase (CAT) was synthesised from plasmid DNA in vitro using T7 promoter, and 
was then reconstituted into the RNP complex (Luytjes et al, 1989). The RNPs were 
transfected into eukaryotic cells, which was followed by influenza virus infection to provide 
the other remaining viral RNPs (Luytjes et al, 1989). CAT activity was demonstrated in the 
cells after RNP transfection, as well as after re-infection with the recombinant virus (Figure 
1.13) (Luytjes et al, 1989). One year later, Enami et al (1990) successfully generated 
influenza virus containing a recombinant NA gene and using the T3 RNA polymerase.  
 
1.5.1.2 Pol I-based system  
An alternative system was established to reconstitute the virus RNP within cells rather than 
in vitro, and also to eliminate the need to purify both polymerase and NP proteins in addition 
in vitro RNA transcription (Palese et al, 1996; Neumann & Kawoaka, 2001). Neumann & 
Hobom (1995) established the use of RNA polymerase I (pol I) to generate vRNA 
intracellularly (in vivo). The RNA pol I is localized in the nucleus, and it transcribes rRNA, 
which resembles the influenza virus RNA in that it does not contain 5` cap and 3` poly(A) 
structures (Neumann & Kawoaka, 2001; Minskaia & Luke, 2015). Also, RNA pol I starts and 
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finishes transcription at specific promoter and terminator regions, thereby yielding transcripts 
with precise 5` and 3` ends (Neumann & Kawoaka, 2001; Minskaia & Luke, 2015). Neumann 
& Hobom (1995) cloned the viral cDNA encoding for CAT protein, and inserted it between 
mouse RNA pol I promoter and terminator sequences in antisense orientation. The cDNA 
plasmid was then transfected into a mouse cell line and co-infected with influenza helper 
virus, which resulted in the transcription of mRNA, expression of CAT protein and packaging 
of progeny infectious virus particles (Figure 1.12) (Neumann & Hobom, 1995; Neumann et 
al, 1999).  
 
1.5.1.3 Recombinant influenza virus selection systems 
The RNP transfection method and the pol I based method require the co-infection of helper 
influenza virus in order to deliver the remaining viral proteins (Palese et al, 1996; Neumann 
et al, 1999). With the Pol I system, it is also required to provide the polymerase proteins and 
the nucleoproteins to form the functional RNPs, thus initiating transcription and replication 
for the transfected recombinant vRNA (Palese et al, 1996; Neumann et al, 1999; Hoffmann 
et al, 2000). With both methods, a strong selection system is required to isolate the 
recombinant virus from the vast majority of helper virus (Neumann & Kawoaka, 2001). 
 
Most of the methods used for isolating the recombinant virus are based on the utilisation of a 
selective property presented by the recombinant viral genome (Garcia-Sastre, 2000). 
Several influenza A virus strains require a cell culture medium supplemented with a protease 
such as trypsin in order to efficiently replicate in a specific cell line (Garcia-Sastre, 2000). It 
has been demonstrated that influenza virus A/WSN/33 does not need this protease to grow 
in Madin-Darby bovine kidney (MDBK) cells and this phenotype 
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Figure 1.12: Schematic diagram of helper virus-dependent system for the generation of 
recombinant influenza virus possessing a gene derived from cloned cDNA. 
In the RNP transfection method, both purified polymerase and NP proteins are mixed with in 
vitro synthesised vRNA to assemble vRNP complex in vitro. Cells are then transfected with 
vRNP and followed by helper virus infection. In the RNA pol I method, a cDNA encoding one 
of the vRNAs is inserted between the RNA pol I promoter and terminator. This cDNA is then 
transfected into cells. Transcription by cellular RNA polymerase I produces synthetic vRNA 
that is packaged into progeny virus after helper virus infection. Both methods require a 
strong selection system to select for the recombinant virus from the background helper virus. 
Figure obtained from Neumann and Kawoaka (2001). 
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is conferred by the NA protein (Garcia-Sastre & Palese, 1993; Garcia-Sastre, 2000). On the 
other hand, the WSN-HK virus contains the NA gene from A/HK/8/68 virus, and all the 
remaining genes from the WSN virus (Garcia-Sastre & Palese, 1993; Garcia-Sastre, 2000). 
The WSN-HK virus cannot replicate in the MDBK cells in the absence of trypsin. Therefore, 
transfecting the cells with a recombinant WSN NA-derived RNP, or with a pol I system 
encoding for NA-derived RNA, followed by helper WSN-HK virus, results in the generation of 
recombinant virus capable of replicating in the absence of trypsin (Garcia-Sastre & Palese, 
1993; Garcia-Sastre, 2000). 
 
Selecting for a virus with a recombinant HA genome was achieved by using antibodies more 
specific to the helper virus HA. The virus-trapping system results in capturing and trapping 
the helper virus, and washing out the recombinant virus (Hormito & Kawaoka, 1994). Other 
selecting methods include host-range restriction (used with PB2 gene), temperature 
sensitivity (used with NP gene) and drug resistance (used with M2 gene) (Garcia-Sastre, 
2000; Neumann & Kawoaka, 2001). 
 
1.5.2 Plasmid-based reverse genetics 
1.5.2.1 17 and 12 plasmids transfection systems 
Plasmid-based systems were established in 1999 and allow for the generation of influenza 
virus entirely from cloned cDNAs, and without the need for helper virus infection (Neumann 
et al, 1999; Hoffmann & Webster, 2000). Influenza-cloned cDNAs encoded for the eight viral 
segments were inserted (antisense orientation) between the human RNA polymerase I 
promoter and the mouse RNA polymerase I terminator on eight different plasmids (Neumann 
et al, 1999). Plasmids encoding vRNA segments were transfected into 293T cells (human 
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embryonic kidney cells) (Neumann et al, 1999; Pekosz et al, 1999; Neumann & Kawoaka, 
2001), along with nine plasmids expressing viral structural proteins under the control of Pol II 
promoter (a total of 17 plasmids) (Neumann et al, 1999; Pekosz et al, 1999; Neumann & 
Kawoaka, 2001). This resulted in the generation of infectious viral particles (Figure 1.13) 
(Neumann et al, 1999; Pekosz et al, 1999; Neumann & Kawoaka, 2001; Engelhardt, 2013). 
The number of the plasmids was then reduced to 12 instead of 17 by using only four protein 
expression plasmids for the polymerase complex proteins and nucleoprotein (Figure 1.13) 
(Fodor et al, 1999; Pekosz et al, 1999; Neumann & Kawoaka, 2001; Engelhardt, 2013). 
 
1.5.2.2 Eight plasmids transfection system (the bidirectional system)  
An improvement has been made to the RNA pol I system by designing a pol I/pol II system 
(Hoffmann et al, 2000). The viral cDNA was cloned between RNA polymerase I promoter 
and terminator sequences in negative-sense orientation (Hoffmann et al, 2000; Hoffmann & 
Webster, 2000; Neumann & Kawoaka, 2001). This entire cassette was cloned in a positive-
sense orientation between an RNA polymerase II promoter (human cytomegalovirus early 
promoter) and a polyadenylation region sequence (Hoffmann et al, 2000; Hoffmann & 
Webster, 2000; Neumann & Kawoaka, 2001). Transfection of eight plasmids for the eight 
viral segments resulted in two types of RNA transcripts. Transcription by the pol I resulted in 
negative-sense vRNA synthesis, and transcription by pol II yielded positive-sense mRNA 
synthesis (Figure 1.14) (Hoffmann et al, 2000; Hoffmann & Webster, 2000; Neumann & 
Kawoaka, 2001). This system reduces the number of plasmids required for virus generation, 
because the viral RNA segment and the viral protein can be expressed from the same 
plasmid (Engelhardt, 2013). 
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Figure 1.13: Generating influenza virus entirely from cloned cDNAs.  
Cells were transfected with eight plasmids, each one encoded for one of the viral RNAs 
under the control of pol I promoter. Cells were co-transfected with four (PA, PB1, PB2 and 
NP) or nine plasmids (including the plasmids in brackets) for the expression of viral proteins, 
resulting in the production of infectious viral particles.  
Figure obtained from Neumann and Kawoaka (2001). 
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Figure 1.14: The pol I/pol II eight plasmids system for the generation of influenza virus. 
Each plasmid contains one viral cDNA inserted in a negative-sense orientation with regard 
to the RNA pol I promoter and terminator, and in a positive-sense orientation with regard to 
the pol II promoter. This system yields synthesis of negative vRNA and positive mRNA from 
the same plasmid. Transfection of these plasmids into cells results in the generation of 
infectious viral particles.  
Figure adapted from Hoffmann et al (2000). 
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Although the helper virus independent reverse genetic system eliminates the need for helper 
virus infection and thus no selection system is needed, generation of influenza virus entirely 
from cloned cDNAs requires the designing of plasmids for each of the vRNA segments 
(Neumann et al, 1999). Also, transfecting the cells with many plasmids requires a cell line 
with high transfection efficiency (Hoffmann et al, 2000). 
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1.6 Influenza as a vaccine delivery vector 
Since the development of reverse genetics for negative-strand RNA viruses, the use of 
influenza virus as a delivery vehicle for immunization against important pathogens has 
become an attractive approach (Stukova et al, 2006). There are a number of advantages to 
utilizing influenza virus as a vaccine vector (Martinez-Sobrido & Garcia-Sastre, 2007). 1) In 
contrast to DNA viruses, the influenza virus genome does not have a DNA phase during 
replication. Thus, it is unable to integrate into the host chromosome, avoiding modification of 
host DNA and risk of cancer or adverse mutation (Martinez-Sobrido & Garcia-Sastre, 2007). 
2) Influenza virus does not cause chronic or persistent infection that may lead to unpredicted 
effects (Martinez-Sobrido & Garcia-Sastre, 2007). 3) In the case of illness caused by the 
influenza virus, the infection can be treated with the available antiviral drugs (Martinez-
Sobrido & Garcia-Sastre, 2007). 4) The licensed live influenza vaccine for children and 
adults, which is composed of three cold-adapted attenuated vaccine strains, induces strong 
humoral and T-cell immune responses (Stukova et al, 2006). In theory, this vaccine strain 
can be engineered to express additional antigens derived from other pathogens (Kittel et al, 
2004; Stukova et al, 2006). 5) Influenza vaccine can be regularly used for immunization, due 
to the continuous genetic changes of the hemagglutinin (HA) and neuraminidase (NA) 
surface proteins (Li et al, 2013). 6) Influenza virus can be produced in large quantities using 
embryonated chicken eggs (Li et al, 2013).  
 
Expression of foreign epitopes from recombinant influenza virus can be achieved through 
different techniques (Figure 1.15). One approach that can be used is by the addition of an 
extra influenza-like viral segment, which expresses the heterologous polypeptide (Martinez-
Sobrido & Garcia-Sastre, 2007). However, this approach may not be successful, as this 
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Figure 1.15: Foreign peptide and polypeptide expression in influenza virus 
vector. 
A) Heterologous epitope expressed as part of virus glycoproteins HA and NA. 
Insertion of the epitope within antigenic site B of the HA protein induces a B-cell 
response (black box), whereas insertion in antigenic site E or the stalk region of 
NA may elicit a T-cell response (red boxes). B) Foreign polypeptides can be 
expressed from an additional viral-like segment (the segment is showed in pink). 
C) Foreign polypeptides (green boxes) are expressed as a fusion to the viral 
protein (as shown with HA and NS proteins), or as a separate protein by 
designing a bicistronic viral segment (as shown with NA and NS segments). The 
white boxes represent the viral proteins; the purple boxes represent the viral 5` 
and 3` noncoding regions. 
Figure adapted from Martinez-Sobrido and Garcia-Sastre (2007). 
HA: hemagglutinin, M: matrix; NA: neuraminidase, NP: nucleoprotein, NS: non-structural, PA, PB1, 
PB2: viral polymerase subunits.  
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additional genome segment is not essential for virus replication or survival, and thus it can 
be lost (Walpita & Flick, 2005). Another common method is the insertion of the foreign 
peptide within a selected viral segment, which can be expressed as part of the influenza 
virus protein (Martinez-Sobrido & Garcia-Sastre, 2007). The third approach is to express a 
full-length exogenous protein by either inserting an internal ribosomal entry site (IRES), or 
inserting the 2A epitope of foot and mouth disease virus between the viral gene and the 
foreign gene (Walpita & Flick, 2005; Li et al, 2013). The 2A peptide mediates intra-ribosomal 
cleavage of polypeptides, which directs the production of separate proteins from one poly-
protein (de Felipe et al, 2003). 
 
In order to generate viable recombinant influenza virus, it is crucial to identify a viral protein 
that can tolerate gene manipulation, as well as the sites within the viral gene that allow 
deletion or insertion without affecting the virus protein function (Martinez-Sobrido & Garcia-
Sastre, 2007). The segments of the influenza virus that have most commonly been used for 
the incorporation of heterologous genes are the hemagglutinin (HA), the neuraminidase (NA) 
and the non-structural protein (NS) segments (Li et al, 2013).  
 
Several studies have generated recombinant influenza virus carrying a foreign epitope within 
the antigenic domains of the HA (Table 1.6: Antigenic domains are described in Section 
1.5.5.1). A study has generated a chimeric influenza virus expressing a highly conserved 
epitope from ectodomain gp41 of HIV-1 from antigenic site B of the HA protein (Muster et al, 
1994). The recombinant virus was able to induce specific antibody against the heterologous 
epitope in mouse models (Muster et al, 1994). The same chimeric virus was used for 
intranasal immunization and elicited strong mucosal antibody responses in the respiratory, 
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Table 1.6: A list of different epitopes that have been inserted into the influenza virus HA protein, resulting in a recombinant virus being 
successfully generated. 
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Table 1.6-Cont.: A list of different epitopes that have been inserted into the influenza virus HA protein, resulting in a recombinant virus being 
successfully generated. 
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intestinal and vaginal tracts (Muster et al, 1995). A sustained level of specific 
immunoglobulin A was also detectable for more than a year after immunization (Muster et al, 
1995). Another study produced a chimeric influenza-carrying epitope from the outer 
membrane protein F of Pseudomonas aeruginosa within the globular domain of HA (Staczek 
et al, 1998; Gilleland Jr. et al, 2000). It was shown that mice immunized with the chimeric 
virus and then challenged with the pathogen had significantly fewer lung lesions when 
compared with unimmunized mice (Staczek et al, 1998; Gilleland Jr. et al, 2000). 
Furthermore, large polypeptides of Bacillus anthracis protective antigen (PA) domain 1 and 
domain 4 were inserted into the HA1 subunit of HA. Both generated chimeric HA and 
showed functional phenotypes similar to the wild-type HA. Animals immunized with DNA 
plasmids encoding for the chimeric HA proteins and the recombinant virus expressing the 
same proteins resulted in the induction of immune responses against both HA and PA (Li et 
al, 2005). Also, Influenza virus has been investigated as a vector to express selected 
tumour-associated antigens (TAAs). Chimeric influenza virus expressing a model TAA 
induced cytotoxic T cells (CTL), which resulted in the regression of established pulmonary 
metastases in mice. Also, animal survival with a high tumour load was extended when 
treated with these chimeric influenza viruses, and animals with lower tumour burden showed 
complete tumour regression when compared with untreated animals (Zheng et al, 2000).  
 
Foreign peptides from several pathogens have been also expressed from the NA and NS 
proteins. A study expressed a CTL-specific epitope of lethal lymphocytic choriomeningitis 
virus (LCMV) in the NA stalk region (Castrucci et al, 1994). Mice immunized with a single 
dose of chimeric influenza virus were protected against LCMV challenge for around four 
months (Castrucci et al, 1994). In addition, it has been considered that the NS protein is an 
ideal target for genetic manipulation (Stukova et al, 2006). NS is the smallest RNA segment 
fragment of the influenza virus genome, and it encodes for two proteins: NS1 and Nep. NS1 
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is a non-structural protein, and it can tolerate insertions of up to 250 amino acids, which 
makes it an attractive choice for heterologous insertion (Stukova et al, 2006). The only 
disadvantage is its intracellular localization, which possibly makes it less efficient for 
presenting the associated antigen via the MHC class II (Stukova et al, 2006). However, the 
insertion of A2 auto-cleavage peptide may help to overcome this disadvantage, as the 
foreign protein can be produced separately from the NS gene. Stukova et al. (2006) 
designed chimeric influenza virus carrying Mycobacterium tuberculosis early secretory 
antigenic target (ESAT-6) protein and A2 peptide within the NS gene (Stukova et al, 2006). 
Mice were immunized with two different chimeric influenza virus subtypes incorporating the 
same heterologous antigen, and it resulted in a significant level of protection after 
challenging with M. tuberculosis (Stukova et al, 2006). 
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1.7 Aims of the project 
The use of a viral vector to deliver specific disease proteins is a promising approach due to 
the natural ability of viruses to deliver their genomes into the infected host cells effectively. 
Advances in gene technology and bioinformatics have made it possible to modify viral 
genomes and insert foreign epitopes without affecting the virus infectivity. The cold-adapted 
influenza virus that is used as the basis for the live attenuated influenza virus vaccine offers 
many advantages as a live delivery vector: 1) It is licensed for human use; 2) it is genetically 
stable; 3) its replication is limited only to the upper respiratory tract (Beyer et al, 2002; 
Voeten et al, 2010). Moreover, The LAIV produces strong immune responses systemically 
and at the mucosal surfaces (Pena et al, 2013). Also, influenza A viruses frequently undergo 
antigenic drift, and have 18 HA subtypes, which make boost vaccination possible (Pena et 
al, 2013). 
 
The main aim of this project is to generate a recombinant influenza A virus expressing a 
foreign epitope within its HA protein. Due to commercial constraints, the helper virus-based 
method was selected for this study. Development of an effective selection system to isolate 
the generated recombinant influenza virus from the background of helper influenza virus is 
essential as the first step to continue the development of influenza viral vector vaccines. The 
selection systems proposed by previous studies (Section 1.6.1.3) are limited to particular 
strains of influenza virus or cell lines. In order to use the cold-adapted influenza virus as a 
vaccine vector, an effective selecting system needs to be developed. The selecting system 
should not require the acquisition of a specific genome from a particular virus strain to 
provide selectivity, which may modify the approved attenuated influenza virus strain. A 
widely used purification technique is the insertion of an affinity tag consisting of hexahistidine 
within recombinant proteins (Bornhorst & Falke, 2000). This is a powerful, effective method 
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that yields high protein purification (Bornhorst & Falke, 2000). The tag is short (six histidine), 
but it is long enough to result in high-affinity interactions with a specific matrix (Bornhorst & 
Falke, 2000). In theory, inserting an affinity tag within a selected influenza protein could be 
used for recombinant virus purification. Specifically, addition of the his6 tag within the 
globular domain of the HA1 subunit, where the antigenic region is located, may result in a 
tagged virus that can be effectively isolated. However, this approach has never been 
investigated with influenza virus, although it was successfully applied to baculovirus and 
adeno-associated viruses (reviewed in Section 3.1) (Hu et al, 2003; Koerber et al, 2007).  
 
The objective of this study is to create a helper virus that can be easily and efficiently 
isolated, and that will help to overcome the issue of selection for the desired recombinant 
virus (i.e., expressing immunogenic antigen) using the helper virus-based system. The 
generation of a recombinant virus containing a His-tag is to be selected positively using the 
IMAC technique. Then, future production of recombinant influenza viruses incorporating 
specific disease proteins is to be generated by using this tagged virus as the helper virus, 
which can be negatively selected from the tagged helper virus. 
 
In this study, the HA gene of influenza virus A/Puerto Rico/8/34 (PR8) is used to generate 
the recombinant influenza virus. The his6 tag is incorporated within a selected antigenic site 
of the HA1 subunit. Results from this study may be applied in the future with the cold-
adapted influenza vaccine strain to generate a tagged helper virus. 
 
The aim of this project includes: 
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1. Genetically engineered a recombinant HA protein expressing hexahistidine affinity 
tag. 
2. Generating the recombinant influenza virus using the RNA polymerase I system with 
the helper virus. 
3. Evaluating the ability to select for the produced tagged influenza virus using 
immobilized-metal affinity chromatography (IMAC) technique. 
 
 
 
 
  
 
Chapter Two 
 
General Materials and 
Methods 
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2.1 General procedures 
General materials and methods detailed here, with specific details for methods listed in the 
respective chapters. All Chemicals used for solution preparation were of analytical or 
molecular grade and were stored at room temperature unless otherwise stated. 
 
All autoclavable materials including glassware, solution and media were sterilised by 
autoclaving at 121°C for 20 min. All reagents and media were prepared with deionized water 
from the Millipore Milli-Q® water system (Millipore, Australia) unless otherwise stated. All 
glassware was washed with pyroneng detergent (Gallay Scientific, Australia) and then 
washed with a dishwashing machine. 
 
Solutions were dispensed using Finnpipette® digital pipettes (ThermoFisher Scientific, 
U.S.A.) which included ranges of 0.5-10‎μL,‎5-50‎μL,‎20-200‎μL,‎100-1000‎μL,‎1-5 mL, 2-10 
mL, and BioPetteTM Plus Autoclavable Multichannel Pipettes (Labnet International, U.S.A.) 
which included 5-50 uL, and 20-200 uL multi-channel pipettes. Volumes greater than 10 mL 
measured with a measuring cylinder. 
 
Solution volumes of 1.5 mL or less were separated by centrifugation with the Eppendorf 
microcentrifuge 5415D. Volumes up to 50 mL were separated by centrifugation by the 
Beckman‎Allegra™‎21R‎centrifuge,‎the‎Heraeus‎Multifuge 1S-R centrifuge or the Sigma 2-6 
Compact Centrifuge. High-speed centrifugation was performed using a Beckman Optima L-
80 XP Ultracentrifuge.   
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Weighing of solids less than 2 g was performed using the Sartorius Model BP 210 S Semi-
Micro Balance top loading analytical balance, and weighing of solids greater than 2 g was 
performed using the ISSCO Model 300 top loading balance. Media containing supplements 
were autoclaved and cooled to approximately 50°C before the addition of any supplements. 
All media was prepared using aseptic techniques and stored at 4°C until required. 
 
2.2 Equipment 
Balance:  
Balance (capacity 300 g – 0.01 g) ISSCO, Australia 
Semi-Micro Balance (capacity 210 g-0.01 
mg) 
Sartorius, Germany 
Centrifuges and Mixers:  
Allergra 21R centrifuge Beckman Coulter, U.S.A. 
Eppendorf centrifuge (maximum speed 
16,000 x g) 
Eppendorf, Germany 
Heraeus Multifuge 1S-R centrifuge Thermo Electron Corporation, 
U.S.A. 
Optima L-80 XP Ultracentrifuge Beckman Coulter, U.S.A. 
Orbital Mixer Ratek, Australia 
Sigma 2-6 Compact Centrifuge Sigma Centrifuges, U.K. 
Roller Mixer Ratek, Australia 
Vortex Mixer Ratek, Australia 
Cell counting:  
CountessTM Automated Cell Counter Invitrogen Corporation, U.S.A. 
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Electrophoresis unit - DNA:  
DNA mini gel (Mini-sub cell GT cell) BioRad Laboratories, U.S.A. 
Dry Bock Heater Ratetk, Australia 
Electroporation cuvettes (0.2 cm) Molecular Bio Products, U.S.A. 
Gel Doc Image System BioRad Laboratories, U.S.A. 
Pulse controller & Gene pulser apparatus BioRad Laboratories, U.S.A. 
Electrophoresis unit - Protein:  
iBlot® Gel Transfer Device Invitrogen, U.S.A. 
Mini-Protein Tetra Cell BioRad Laboratories, U.S.A. 
Trans-blot electrophoretic transfer cell 
(mini) 
Ratek, Australia 
Electrophoresis power supply:  
Power PAC 300 BioRad Laboratories, U.S.A. 
PP Basic BioRad Laboratories, U.S.A. 
Incubators:  
Sanyo CO2 Incubater, Model MCO-17AI Sanyo Electric Corporation, Japan 
Bioline Incubator Shaker with Universal 
Platfrom 
Bioline Global Pty Ltd, Australia 
Laminar air flow cabinets:  
Horizontal laminar flow cabinet class II, 
BH2000 series 
Clyde-Apac, Australia 
Aura 2000 M.A.C. Vertical Laminar Air 
Flow Hood class II  
EuroClone S.P.A., Italy 
Photometers:  
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BioPhotometer Eppendorf, Germany 
NanoDrop™ 2000 Spectrophotometer Thermo Scientific, U.S.A. 
PCR Machine:  
G-Storm GS1 Thermocycler G-Storm, U.K. 
GeneAmp PCR system 2400 Applied Biosystem, U.S.A. 
Microscopes:  
Olympus Inverted Microscope, with Canon 
digital camera attached 
Olympus Corporation, U.S.A. 
Confocal Laser Scanning Microscope 
(Nikon A1R equipped with Nikon Eclipse 
Ti Flourescence Microscope 
Nikon Instruments Inc., U.S.A. 
Epiflourescence Microscope (DM2500) Leica Microsystems Pty Ltd, 
Australia 
Other instruments:  
pH meter  Metrohm AG, Switzerland 
Waterbath Ratek, Australia 
Software:  
Visual Molecular Dynamics (VMD)   
Swiss-Pdb Viewer   
Clone manager  
NIS- Element advanced for CLSM images  
 
2.3 Supplies 
Amersham Hyperfilm ECL GE Healthcare, Sweden 
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Centrifuge tubes  
1.5 microfuge tubes Sarstedt, Australia 
10 mLcentrifuge tubes Sarstedt, Australia 
15 mL centrifuge tubes Corning, U.S.A. 
50 mL centrifuge tubes Corning, U.S.A. 
Ultra-Clear centrifuge tubes 13.2 mL, 
open-top, thinwall 
Beckman Coulter, U.S.A. 
Cover slips Mediglass, Australia 
Countess cell counting chamber slides Life Technologies, U.S.A. 
Cryovial (1.8mL)  Iwaki, Japan 
Electroporation cuvettes (0.2 cm) Molecular Bio Products, U.S.A. 
iBlot® Transfer Stack, nitrocellulose, mini Life Technologies, U.S.A. 
Microscope slides LOMB Scintific Co., Australia 
Parafilm sealing film Interpath, Australia 
PCR tubes (0.2 mL), flat-cap Quantum Scintific 
Petri dish (90 x 14 mm), sterilized BioLab, Australia 
Syringe  (3, 5, 10 and 50 mL) Terumo, Australia. 
Syringe Filter (0.22 µm, 0.45 µm) Sarstedt, Australia 
Tissue culture flask (25 cm2 and 75 cm2), 
vented 
Greiner bio-on, U.S.A. 
6 wells-plate, sterile, corning Greiner bio-on, U.S.A. 
24 wells-plate, sterile, corning Greiner bio-on, U.S.A. 
96 wells-plate, sterile, corning (flat-bottom) Greiner bio-on, U.S.A. 
96 wells-plate, sterile, corning (U-bottom) Greiner bio-on, U.S.A. 
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96 wells-plate, polystyrene, clear (V-bottom) Greiner bio-on, U.S.A. 
 
2.4 Reagents and Buffers  
Acetic acid: (BDH, U.S.A.). 
Acrylamide/Bis-acrylamide: 40% acryl/bis, stored at 4°C (Amresco, U.S.A.). 
Acquastain: protein staining reagent, (Bulldog Bio Inc., U.S.A.), stored at 4°C 
Agar (Bacteriological): 1.5% w/v, (Oxoid, England).  
Agarose gel: 1.5-2.5 % (w/v) DNA grade agarose (Bioline, U.S.A.) in 1x TAE buffer, 
dissolved by heating in a microwave. 
Ammonium chloride: (Merck, Germany)  
Ammonium persulfate: 10% (w/v) ammonium persulphate (Sigma-Aldrich, Germany), 
stored at 4°C. 
Ampicillin: 100 mg/mL ampicillin stock solution (CSL, Australia) in mH2O, filtered through a 
0.2‎μm‎filter.‎Working‎concentration‎of‎100‎μg/mL,‎aliquots‎stored‎at‎-20°C. 
Bovine albumin fraction V:  7.5% solution (Gibco, U.S.A.).  
Chemiluminescent detection solutions: 
Chemiluminescent peroxidase substrate-3: stored at 4°C. Working solution 
prepared by mixing 1 part of the Chemiluminescent Reagent with 1 part of the 
Chemiluminescent Reaction Buffer. Mixed well and equilibrated at room temperature 
for 30 minutes before use (Sigma-Aldrich, Germany). 
Developer: 12.5% (v/v) Carestream Kodak autoradiography GBX 
developer/replenisher (Sigma-Aldrich, Germany), 87.5% dH2O. Stored at room 
temperature in dark.  
Fixative solution: 1 volume of G354 rapid fixer (AGFA healthcare, France), to 4 
volume of dH2O. Stored at room temperature in dark. 
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Dulbecco's Modified Eagle Medium, high glucose (DMEM): without sodium pyruvate, 
GlutaMax supplement, high glucose (Gibco, U.S.A.). 
Dimethyl Sulfoxide (DMSO): (Merck, Germany). 
DNA loading buffer (6x): 0.25% (w/v) Bromophenol Blue (BDH, U.S.A.), 0.25% (w/v) 
Xylene Cyanol (BioRad Laboratories, U.S.A.), 50% (w/v) Sucrose (BDH, U.S.A.), 10 mM 
Tris-HCL (pH 8.0) (Merck, Germany). 
10 x Dulbecco's phosphate-buffered saline (DPBS): (Gibco, U.S.A.) 1 x DPBS working 
solution add 9 volume of sterilized Milli-Q water to 1 volume of 10 x DPBS, filtered through a 
0.2‎μm‎filter. 
Ethanol: 70% (v/v), 95% (v/v), 100% (v/v) (Merck, Germany). 
Ethidium bromide (EtBr): 6 mg EtBr (Sigma-Aldrich, Germany) in 2 L MQ water. 
Ethylenediaminetetra-aetate (EDTA): 0.5 M EDTA (Merck, Germany), pH 8.0. 
Fetal bovine serum, heat inactivated (HI FBS): Australian Origin or US Origind (Gibco, 
U.S.A.).  
Formaldehyde: 37% (w/v) (Sigma-Aldrich, Germany). 
Geneticin® (G418) sulphate: 50 mg/mL G418 stock solution (Gibco, U.S.A) in mH2O, 
filtered‎through‎a‎0.2‎μm‎filter.‎Working‎concentration‎of‎500‎μg/mL,‎aliquots‎stored‎at‎-20°C. 
Hyperladder™ 50 bp: stored at -20°C‎ (Bioline,‎ England),‎ 5‎ μL aliquots used on a DNA 
agarose gel.  
Immunoblotting solutions: 
Blocking buffer: 5% (w/v) skim milk in PBS. 
Antibody diluent: 1% (w/v) skim milk in PBS. 
Washing buffer: 1% (w/v) skim milk in PBS. 
TMB single solution: substrate for Horseradish Peroxidase (Invitrogen, U.S.A.). 
Western Blue® Stabilized: substrate for Alkaline Phosphatase (Promega, U.S.A). 
Glycerol: 70% (v/v) sterile glycerol (BDH, U.S.A.). 
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GoTaq® Green Master Mix (M712): stored at -20°C (Promega, U.S.A.). 
Lambda (λ) DNA: stI/λ-DNA‎ marker‎ was‎ prepared‎ by‎ incubating‎ 20‎ μg‎ λ-DNA (New 
England‎Biolabs,‎USA),‎18‎μL‎NEBuffer‎ 3.1‎ (New‎England‎Biolabs,‎USA),‎ 10U‎PstI (New 
England‎ Biolabs,‎ USA)‎ and‎ mH2O‎ up‎ to‎ 180‎ μL,‎ at‎ 37°C‎ overnight.‎ The‎ digestion‎ was‎
terminated by heating‎at‎80°C‎for‎20‎minutes,‎and‎20‎μL‎of‎6x‎DNA‎loading‎buffer‎was‎then 
added. 10 μL DNA marker aliqute was stored at -20°C. 
Lipofectamine® 2000 Transfection Reagent: stored at -20°C (Invitrogen, U.S.A.). 
Methanol: 100% (Merck, Germany). 
Molecular grade water (MGH2O): Distilled water, DNAse and RNase free (Invitrogen, 
U.S.A.). 
Phosphate-buffered saline (PBS): one tablet‎Dulbecco’s‎ A‎PBS‎ (Oxoid,‎ UK)‎ in‎ 100‎mL‎
H2O (sodium chloride 0.8%, potassium chloride 0.02%, disodium hydrogen phosphate 
0.115%, potassium dihydrogen phosphate 0.02%). Autoclaved if required. 
Penicillin-Streptomycin (10,000 U/mL): stored at -20°C (Gibco, U.S.A.). 
Opti-MEM® I Reduced Serum Medium: stored at 4°C (Gibco, U.S.A). 
Precision Plus ProteinTM KaleidoscopeTM prestained standard: 10 μL‎per‎well‎ (BioRad‎
Laboratories, U.S.A.), stored at -20°C. 
Precision Plus ProteinTM Dual color standard: 10 μL‎ per‎ well‎ (BioRad‎ Laboratories,‎
U.S.A.), stored at -20°C. 
Precision Plus ProteinTM standard: 10 μL‎per‎well‎(BioRad‎Laboratories,‎U.S.A.),‎stored at 
-20°C. 
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Revercell (3% and 15%) Reagent red blood cells: stored at 4°C (CSL, Australia). 0.75% 
(v/v) RBC working solution prepared in PBS. Washed twice with PBS, centrifuged at 3000 x 
g for 4 minutes, prepared before use. 
SDS-PAGE solutions: 
Loading buffer (5x): 60 mM Tris-HCL (pH 6.8) (Merck, Germany), 25% (v/v) glycerol 
(BDH Chemicals, U.S.A), 2% (w/v) SDS (BDH Chemicals, U.S.A). 14.4 mM β-
mercaptoethanol (BioRad Laboratories, Australia), 0.1% (w/v) bromophenol blue 
(Sigma-Aldrich, U.S.A). 
Separating gel (8%, 10%, and 12%): 375 mM Tris-HCL (pH 8.8) (Merck, Germany), 
0.1% (w/v) SDS, 8%, 10%, or 12% (v/v) bis acrylamide with setting agent added prior 
to pouring: 0.06% (w/v) ammonium persulfate, 0.03% (v/v) TEMED. 
Stacking gel (5%): 125 mM Tris-HCL (pH 6.8) (Merck, Germany), 0.1% (w/v) SDS 
and 5% bis acrylamide   with setting agents added prior to overlaying of separating 
gel: 0.06% (w/v) ammonium persulfate, 0.03% (v/v) TEMED. 
Running buffer stock (10x): 0.25 M Tris-HCL (Merck, Germany), 1.92 M glycine 
(BDH Chemicals, USA), 1% (w/v)   SDS (BDH Chemicals, USA). The pH was adjusted 
to 8.3. 
Skim milk: (Bolnac Foods Limited, Australia). 
Sucrose cushion for virus purification: 
TNE buffer: 50 mM Tris (BDH Chemicals, USA), 140 mM NaCl, 5 mM EDTA (BDH 
Chemicals, USA). 
20% Sucrose cushion: 20% high-grade sucrose (BDH Chemicals, USA) in TNE 
buffer. Filtered through 0.2 μm filter and stored at 4°C. 
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Sodium acetate (NaOAc):  3 M NaOAc (pH 4.6) (BDH, U.S.A.). 
Sodium chloride (NaCl): 5 M stock solution of sodium chloride (BDH, U.S.A.). 
Sodium dodecyl sulfate (SDS): 10% (w/v) (Merck, Germany) in mH2O. Filtered through 
0.45 μm filter. 
Silver staining solutions: 
Fixative solution: 40% (v/v) methanol (BDH Chemicals, U.S.A.), 10% (v/v) acetic 
acid (BDH Chemicals, U.S.A.), 50% (v/v) mH2O. 
Washing solution: 30% (v/v) absolute ethanol (BDH Chemicals, U.S.A.), 70% (v/v) 
mH2O. 
Reductant: 0.02% (w/v) sodium thiosulfate (BDH Chemicals, U.S.A.), in mH2O. 
Silver reagent: 0.2% (w/v) silver nitrate (Sigma-Aldrich, U.S.A.), 0.02% (v/v) 
formaldehyde (Sigma-Aldrich, U.S.A.) in mH2O. Stored in dark at 4°C. 
Developer: 3.2% developer reagent (BioRad Laboratories, U.S.A.) in mH2O. Made for 
immediate use. 
Stopping solution: 5% (v/v) acetic acid (Fisher Scientific, Australia) in mH2O. 
TEMED (N,N,N’,N’-tetramethylethylenediamine): Electrophoresis purity (BioRad 
Laboratories, U.S.A.). 
TPCK treated-trypsin stock solution (2 mg/mL): dissolve 20 mg TPCK-trypsin (Sigma-
Aldrich, USA) in 10 mL DMEM medium. Filtered through‎a‎0.22‎μm‎syringe‎filter.‎Aliquots‎in 
eppendorf tubes and stored at -20°C. 
Tris (hydroxymethyl) aminomethane (Tris-HCL): 2 M stock solution (Merck, Germany), 
adjusted to pH 8.0. 
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Trypan blue (0.4%): for‎ use‎ with‎ the‎ Countess™‎ Automated‎ Cell‎ Counter‎ (Invitrogen, 
U.S.A.). 
0.25% Trypsin-EDTA (1x), phenol red: (Gibco, U.S.A.). Stored at -20°C. 
 
2.5 Antibodies 
Goat anti-rabbit IgG – AP: stored at 4°C (Abcam, England). 
Mouse anti-His IgG: stored at -20°C (GE Healthcare, Sweden). 
Rabbit anti mouse IgG – HRP: stored at -20°C (Abcam, England). 
Rabbit anti mouse IgG – AP: stored at -20°C (Abcam, England). 
Rabbit influenza (A/Puerto Rico/8/34) antiserum: stored at -20°C (provided by the WHO 
Collaborating Centre for Reference and Research on Influenza). 
 
2.6 Commercial Kits 
Isolate II plasmid mini kit: (Bioline, England). 
Isolate II RNA mini kit: (Biloline, England). 
MycoFlour™ mycoplasma detection kit: stored at -20°C (Molecular Probes, U.S.A.). 
Thermoscript™ RT-PCR system: (Invitrogen, U.S.A.). 
 
2.7 Restriction Enzymes 
Restriction‎ enzymes‎ were‎ used‎ in‎ the‎ supplied‎ buffer‎ according‎ to‎ the‎ manufacturer’s‎
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instructions and stored at -20°C. The restriction enzymes used in the study are listed in 
Table 2.1.‎Approximately‎1‎μg‎of‎plasmid‎DNA‎was‎digested‎with‎1‎U‎of‎enzyme‎supplied‎
with‎1X‎buffer‎in‎a‎total‎volume‎of‎20‎μL‎in‎a‎37°C‎water‎bath‎for‎around‎three‎hours. 
 
2.8 Microorganisms, Mammalian cells and DNA vectors used in this 
study 
2.8.1 Bacterial strains  
 
Bacterial strain Genotype Source / Reference 
Escherichia coli DH5α sup‎E44,‎ΔlacU169‎
(ΦlacZΔM15),‎recA1,‎endA1,‎
hsdR17, thi-1, gyrA96 
Biotechnology lab, 
RMIT University 
Bunddora west campus 
/ Hanahan (1983) 
 
2.8.2 Mammalian Cells  
 
Cell type Supplier 
Madin Darby Canine Kidney cells (MDCK) Sigma, Cat# 84121903 
 
 
2.8.3 DNA plasmid vectors  
 
Plasmid Size (bp) Description Source 
pRNA-CMV3.1/Neo 
 
5195 siRNA expression vector in 
mammalian cell lines, AmpR, 
NeoR. 
Genscript, 
Cat# SD1231 
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Where ▼ represent the point of cleavage. 
 
Table 2.1: Restriction enzymes used in this study and their recognition sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restriction enzyme Recognition sequence 
ApaI (New England 
Biolabs, U.K.)  
 
HindIII (New England 
Biolabs, U.K.)  
 
NdeI (New England 
Biolabs, U.K.)  
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Plasmid Size (bp) Description Source 
pCDNA/HAPR8-His6 
pol I  
 
 
 
 
 
 
 
7226 Derived from pRNA-
CMV3.1/Neo. Cloned the 
designated construct HAPR8-
His6 pol I into the NdeI (233) and 
HindIII (644) sites of the pRNA-
CMV3.1/Neo vector. (Designing 
the HAPR8-His6 pol I construct 
is described in Chapter 3). 
Genscript 
pCDNA5frt-EGFP-
N1 (CAT) 
6549 Plasmid DNA expression vector 
with EGFP reporter gene, AmpR. 
Health 
Innovations 
Research 
Institute, RMIT 
University 
 
2.8.4 Virus strains  
 
Viral strain Description Source 
A/Puerto Rico/8/34 
influenza virus, 
H1N1 (PR8) 
PR8 has had over 100 passages in 
each of mice, ferrets and 
embryonated chicken eggs. The 
result of such a passage history is 
complete attenuation of the virus 
and its inability to replicate in 
humans  
Department of 
Biotechnology and 
Environmental biology 
RMIT University 
 
 
 
2.9 Bacterial methods 
2.9.1 Bacterial media 
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Luria-Bertani (LB) broth: 0.5% (w/v) yeast extract (Oxoid, UK), 1% tryptone (Oxoid, UK), 
0.5% sodium choride (BDH Chemicals, UK). 
Luria-Bertani (LB) agar: 0.5% (w/v) yeast extract (Oxoid, UK), 1% tryptone (Oxoid, UK), 
0.5% sodium chloride (BDH Chemicals, UK), 1.2% (w/v) bacteriological agar (Oxoid, UK). 
 
2.9.2 Bacterial growth condition 
E. coli strains were grown in LB broth or on LB Agar at 37°C overnight, shaking at 180 rpm 
on an orbital‎shaker.‎Ampicillin‎(100‎μg‎/mL) was added to the agar plates and LB broth for 
the selection of bacterial cells transformed with DNA plasmids of interest. 
2.9.3 Bacterial storage condition 
E. coli DH5α strain was stored at -80°C with LB media containing 20% glycerol in cryogenic 
vial for long term storage. 
 
2.10 Mammalian cells and tissue culture 
2.10.1 General maintenance  
The Tissue culture procedures were all performed inside the Biosafety cabinet class II. All 
the relevant equipment and the cabinet were disinfected by 70% ethanol, and were exposed 
under UV light for 20 minutes before starting work. Refer to Phelan (2007) for more details of 
tissue culture techniques. 
 
Cells monolayer were maintained in 75 cm2 tissue culture flask with complete medium 
(DMEM, 10% (v/v) HI FBS, 1x Penicellin-Streptomycin) and incubated at 37°C with 5% CO2 
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in a humidified incubator. Cells were treated with trypsin-EDTA, and sub-cultured when cells 
reached around 80% confluent monolayer. 
 
2.10.2 Treating cells with trypsin and subculturing from a monolayer  
Culture medium was removed from the cell monolayer by decanting. Cells monolayer was 
washed gently two times with pre-warmed 1x DPBS to ensure the removal of any FBS 
residues that may inhibit the trypsin action. Four mL of pre-warmed trypsin-EDTA solution 
was added to the adherent cell monolayer, and incubated between 7-8 minutes at 37°C with 
rocking the flask every two minutes. The cell layer was checked for detachment by 
positioning the flask against light, and gently tapping to assist the detachment process. The 
detached cells were collected in 10 mL tube, and up to 5 mL of complete medium added to 
stop the trypsin action. The cells suspension was centrifuged at 800 x g for three minutes, 
and the cells pellet was resuspended with 1 mL of complete medium. The cells suspension 
was divided between 3 and up to 7 new 75 cm2 tissue culture flasks (depending on the 
experiment requirement), and appropriate volume of complete medium was added. Cells 
were incubated in humidified incubator at 37°C, 5% CO2, and passages of the secondary 
culture performed by repeating the previous steps, when cell layer reached 80% confluent. 
 
2.10.3 Cell stock freezing and resuscitation  
Cell monolayer were treated with trypsin-EDTA, and pelleted at 800 x g for three minutes. 
Cells were resuspended in DMEM supplemented with 20% FBS and 10% DMSO, aliquoted 
in cryovial, and immediately placed on dry ice for 30 minutes. Then, it was frozen at -20°C 
for two hours, then at -80°C for 1-3 days before long-term storage in liquid N2. For cells 
resuscitations, cryovial was rapidly thawed at 37°C water-bath, and then centrifuged at 800 x 
g for three minutes. Cell pellet was resuspended in complete medium, and then inoculated 
into tissue culture flask with appropriate medium volume. Flask containing cells was 
CHAPTER 2 
 
 
 90 
incubated at 37°C for 24 hours. Next day, medium was replaced with fresh one to remove 
any traces of DMSO. 
 
2.10.4 Mycoplasma detection 
Testing the cells for mycoplasma contamination was performed several times throughout this 
study in order to maintain healthy cells. The MycoFluor™ mycoplasma detection kit 
(Molecular Probes) was used for the identification of mycoplasma infection. The protocol 
was‎performed‎according‎to‎the‎manufacturers’‎instruction.‎In‎a‎six-well tissue culture plate, 
a sterilized coverslip was seeded in one well of the plate. Then, MDCK cells were cultured 
as described in Section 2.10.1, and cells were maintained with DMEM supplemented with 
10% FBS. The plate was incubated at 37°C with 5% CO2 until the cells reached around 75% 
confluency on the coverslip. One volume of the 20x MycoFlour reagent was added to 19 
volumes of culture medium. The cells were incubated with the reagent for 10 minutes at 
37°C. Next, the cultured coverslip was removed gently and was placed on a sterilized 
microscopic slide (cells facing the inside). The sides of the coverslip were sealed using a nail 
polish. The cells were examined under a fluorescence microscopy, and the mycoplasma 
present was identified as round/small blue color, which appeared in similar size and shape. 
 
2.10.5 Cell counting 
Cell counting‎was‎performed‎using‎ the‎Countess™‎automated‎cell‎ counter.‎ ‎The‎counting‎
measurements are based on cell viability using the trypan blue method of dead-cell staining.  
For each sample processed, a number of data are provided including: live and dead cell 
concentration, total cell concentration and cell viability percentage. The following procedure 
was‎performed‎according‎to‎the‎manufacturers’‎instructions‎(Invitrogen,‎U.S.A.). 
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After the cell monolayer was treated with trypsin, pelleted and resuspended in DMEM,‎10‎μL‎
of‎cell‎suspension‎was‎added‎to‎10‎μL‎trypan‎blue‎stain,‎and‎mixed‎gently‎by‎pipetting‎up‎
and‎ down.‎ Then,‎ 10‎ μL‎ of‎ the‎ sample‎mixture‎ was‎ loaded‎ into‎ the‎ chamber‎ port‎ on‎ the‎
Countess™‎ cell‎ counting‎ chamber‎ slide,‎ and‎ ensure‎ that‎ the‎ whole‎ counting area was 
covered with cell suspension. The slide was then inserted on the instrument for cell counting 
process. Cells with bright centers were counted as live cells, whereas cells that completely 
stained with blue color were counted as dead cells. Then, the cells counting results viewed 
on‎the‎instruments’‎screen,‎and‎from‎that‎desired‎cell‎concentration‎can‎be‎calculated.‎ 
 
2.11 Virological methods 
2.11.1 Virus growth media (VGM) 
To a 50 mL DMEM medium: 
Reagent Volume Final concentration 
Penicillin-streptomycin  0.5 mL 1 x 
Bovine albumin fraction V  (7.5%) 1250 mL 0.2 % 
TPCK-trypsin solution (2 mg/mL) 50‎μL 2‎μg/mL 
 
2.11.2 Virus propagation in MDCK cells 
The virus propagation protocol was adapted from the published protocol (Szretter et al, 
2006). A confluent monolayer of MDCK cells (around 80% confluent cells) was infected with 
virus diluted in VGM at an appropriate multiplicity of infection. Prior to infection, the cell 
monolayer was washed twice with pre-warmed 1X DPBS and once with pre-warmed VGM to 
remove all traces of FBS serum. Then, cells were infected with 1:1000 diluted virus stock 
(original HA titer = 6400). For a 75 cm2 flask, a 4 mL diluted virus stock was required to 
completely cover the monolayer. The cells were incubated at 37°C, 5% CO2 for 1 to 1.5 
hours with gentle hand rocking every 20 minutes. The medium was discarded and washed 
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once with DMEM. Pre-warmed VGM was added and the infected cells were incubated at 
37°C, 5% CO2 for up to four days, with regular observation for cytopathic effect (typical CPE 
by influenza viruses include rounding up and detachment of infected cells in the flask). 
Incubation was stopped when 70-80% of the monolayer cells were detached from the 
bottom. The flasks were frozen at -80°C until purification. 
 
2.11.3 Virus purification 
Infected MDCK cells were subjected to two cycles of freeze and thaw, and centrifuge at 
3,000 x g for three minutes to remove cell debris. The supernatant was filtered through 0.2 
μm‎filter.‎The‎processed‎supernatant‎was‎gently‎loaded‎onto‎a‎layer‎of‎2 mL 20% sucrose 
buffer in an Ultra-ClearTM thinwall tube. The tubes were loaded onto a Beckman Coulter SW 
41 Ti rotor and centrifuged at 28,000 x g, 4°C in a Beckman Coulter Optima L-80 XP 
Ultracentrifuge for 2 hours. After centrifugation, the media and the sucrose cushion were 
carefully removed, and the virus pellet was resuspended in 20 μL TNE buffer and aliquoted 
in eppendorf tubes. 
 
2.11.4 Virus storage condition 
Purified virus samples was stored at -80°C in TNE buffer. 
 
2.12 Methods of DNA analysis 
2.11.1 Plasmid extraction 
DNA plasmids transformed into E. coli DH5α‎were‎extracted‎using‎the Isolate II plasmid mini 
kit‎(Bioline)‎as‎per‎the‎manufacturer’s‎instructions. A 5 mL bacterial LB culture was pelleted 
at 11,000 x g, the supernatant was discarded. Then, the lysis buffers were added separately 
(P1, P2, and P3), and the tube mixed by inverting it several times after adding each of the 
lysis buffers. After centrifugation, the sample was pipetted into a mini spin column, placed in 
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a collection tube and was centrifuged and the flowthrough was discarded. Next, the 
membrane was washed with two washing buffers, and then the spin column was centrifuged 
for 2 minutes to dry the membrane. Finally, the DNA plasmid was eluted with the elution 
buffer.  
 
2.12.2 Agarose gel electrophoresis  
Agarose gels ranging from 1% - 2% were used to separate and/or visualise DNA and RNA 
samples.‎5‎or‎10‎μl‎of‎DNA‎or‎RNA‎samples‎mixed‎with‎1‎or‎2‎μl‎6x‎DNA‎loading‎buffer,‎was‎
loaded into the gel in a mini-gel or midi-gel unit filled with fresh 1x TAE buffer. A current 
ranging from 70 V to 100 V was applied to the gel, and the gel was then stained with 3 
mg/mL EtBr water bath for 5 minutes. Then the gel was destained under running water for 
30 minutes.  
The DNA products were visualised with a Biorad GelDoc transilluminator and photographed 
with the gelDoc imaging system. The DNA fragments sizes were estimated by the addition of 
the λ-PstI marker or the Hyperladder™ to the gel before electrophoresis (Appendix 2 and 3). 
 
2.12.3 Spectrophotometric quantification of nucleic acids 
The Eppendorf BioPhotometer or the NanoDrop Spectrophotometer was used to determine 
the optical density (OD) of a DNA or RNA solution at wavelength of 260 nm, which is the 
optimal wavelength for nucleic acids. Protein contamination was determined by reading at 
280 nm in order to estimate the DNA or RNA quality. A good quality DNA or RNA was 
indicated by ration of 1.8-2.0 (Sambrook & Russell, 2001). An OD of 1.0 was equivalent to 
50‎μg/mL‎double-stranded DNA. 
 
2.12.4 DNA plasmids storage condition 
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The pCDNA/HAPR8-His6 pol I was received in dry form. The cDNA plasmid was dissolved in 
20‎μl‎molecular‎grade‎water‎and‎aliquot‎ in‎sterilised‎1.5‎μl‎microcentrifuge‎tubes.‎All‎DNA 
plasmids were stored at -20°C in molecular grade water.  
 
2.13 DNA manipulation 
2.13.1 Electrocompetent cell preparation 
Bacterial cells were prepared for electrotransformation according to the method supplied 
with the Gene‎ Pulser‎ apparatus‎ user’s‎ manual (BioRad Laboratories, U.S.A.) with minor 
alterations. In brief, 1 in 100 volume of an overnight bacterial culture was inoculated into 200 
mL of Luria-Bertani (LB) borth. The cells were grown with vigorous shaking at 37°C until 
reaching an OD600 of 0.5-0.7 (early to mid-log phase). Then, the bacterial culture was 
cooled on ice for 30 minutes, and the culture pelleted by 4,000 x g centrifugation at 4°C for 
10 minutes. The supernatant was removed, and an equal volume of ice-cold sterile Milli Q 
water (mH2O) was used to resuspend the pellet. Next, the cell suspension was centrifuged 
at 4,000 x g at 4°C for eight minutes. The supernatant was discarded, and the pellet 
resuspended in 4 mL ice-cold 10% glycerol. Then, the cells centrifuged at 3,500 x g at 4°C 
for six minutes and pelleted as above. The pellet resuspended with 10% glycerol in a final 
volume‎of‎200‎μL, and divided into 50‎μL aliquots for immediate use.  
 
2.13.2 Electrotransformation 
The method was obtained from Gene‎Pulser‎apparatus‎user’s‎manual‎(BioRad‎Laboratories,‎
U.S.A.). Two μL‎of‎purified‎DNA‎plasmids‎were mixed with electrocompletent cells prepared 
above and transferred to an ice-cold electroporation cuvette and tapped gently to settle the 
mixture to the bottom.‎The‎pulse‎settings‎used‎to‎deliver‎DNA‎into‎the‎cells‎were,‎25‎μF, 2.4 
kV‎ and‎ 200‎Ω. The sample was pulsed once, and immediately a pre-warmed (37°C) LB 
broth was added to the cells to a total volume of 1 mL. Sample was transferred to a 1.5 mL 
CHAPTER 2 
 
 
 95 
eppendorf tube and was incubated at 37° C for one hour with 50 rpm shaking. Fifty μL,‎100‎
μL‎ and‎ 200‎ μL‎ of‎ the‎ transformed culture were plated out onto LB agar containing the 
selective antibiotic. The remaining contents of transformed mixture were pelleted by 
centrifugation at 4,000 x g for five minutes, and the cell pellet was resuspended‎in‎150‎μ‎of‎
supernatant, then plated onto LB agar containing the appropriate selective antibiotic, and 
incubated overnight at 37°C. 
 
2.14 Protein methods 
2.14.1 Polyacrylamide gel electrophoresis (SDS-PAGE) 
Virus proteins were separated by one-dimensional 8% 10% or 12% reducing SDS-PAGE. 
After pouring the resolving gel, distilled water was placed over the gel to ensure the gel 
interface was even after it set. After the gel had set, the water removed.  Then, the 5% 
stacking gel was layered over the top of the resolving gel and a cast was inserted between 
the glass slides to form the wells. The protein gel system was assembled according to the 
manufacturer’s‎ instruction (BioRad Laboratories), and then placed inside the gel tank 
containing 1 x SDS-PAGE running buffer. Protein samples were mixed with 5 x SDS loading 
buffer, heated to 100°C for 5 minutes, and then loaded into the gel together with a Precision 
Plus ProteinTM All Blue Standard (Appendix 4). For immunoblotting the prestained 
KaleidoscopeTM protein standard (Appendix 5), or Precision Plus ProteinTM Dual Colour 
Standard (Appendix 6), was used, while for Coomassie staining, the unstained Precision 
Plus ProteinTM standard was used. Electrophoresis was performed at 60 V for 30 minutes, 
and then 180 V for up to 70 minutes.  
 
CHAPTER 2 
 
 
 96 
2.14.2 Coomassie instant stain 
To stain the gel, appropriate amount of Acqua Stain (enough to cover the gel) was used for 
staining SDS-PAGE gels after electrophoresis. Bands were visible within 20 minutes, 
however the instant stain was allowed to resolve bands overnight. A de-staining step was 
not required with the use of Acqua Stain.  
 
2.14.3 Silver staining 
The SDS-PAGE gels were placed into a glass tray, and an enough amount of Fixative 
solution was added to cover the gels and was incubated for 40 minutes or overnight. Direct 
contact with gel was absolutely avoided. Then, gels were washed with the Washing solution 
three times, 20 minutes each. Next, gels were soaked in Reductant for one minute and 
rinsed under running distilled water thoroughly for around 2 minutes. The gels then soaked 
with Silver Reagent and incubated for 30 minutes, and again were rinsed with distilled water. 
Then, gels were soaked in fresh developer, until desired intensity of protein bands were 
reached. The gels were rinsed with running water for two minutes, and a Stop solution was 
added for a minimum of 20 minutes. 
 
2.14.4 Immunoblotting 
Western blotting was performed after completion of SDS-PAGE (refer to Section 2.14.1) 
using the iBlotTM Dry Blotting System. The gel was placed onto the bottom stack (Anode) on 
top of pre-placed nitrocellulose membrane, and iBlot filter paper (pre-soacked in deionised 
water) was placed on top of the SDS-PAGE gel, and the top stack (Cathode) was placed on 
top of the filter paper. A provided disposable sponge was attached to the lid of the 
apparatus, and the blotting roller was used to remove any air bubbles from the stack. The lid 
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was then closed and the transfer was initiated and was completed within seven minutes 
using the default program.  
After that, the nitrocellulose membrane was removed and soaked in Blocking buffer for a 
minimum of one hour. The membrane was then soaked in primary antibody for two hours or 
overnight at 4°C. The primary antibody was diluted to 1:10000 or 1:6000 in antibody diluent 
buffer (depending on the antibody used). 
The blot was washed three times with washing buffer, 20 minutes each, and then incubated 
with secondary antibody (diluted to 1:10000 or 1:6000 in antibody diluent buffer) conjugated 
with AP or HRP for one hour in dark. Then, the blot was washed three times with washing 
buffer 20 minutes each. For AP conjugated antibody, the membrane was developed with 
western blue stabilized substrate, and for HRP conjugated antibody the TMB‎ (3,‎ 3‎ ,‎ 5,‎ 5‎ -
tetramethylbenzidene) was used. The membrane was incubated with the substrate until the 
desired signal resolution was reached. The blot was gently washed with water to stop the 
reaction. 
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3.1 Introduction 
 
Influenza A viruses are segmented viruses and contain eight vRNA segments with negative-
sense polarity (Zhou et al, 1998). The 3` and 5` end nucleotides are highly conserved 
among the eight vRNAs segments and it has been shown that these regions contain the 
promoter function and vRNA packaging signals (Enami et al. 1990, Zhou et al. 1998; 
Neumann & Kawaoka, 2002). 
 
Using influenza virus as a viral vector has several advantages as stated in the previous 
chapter. The major one is the ability of virus to stimulate strong cellular and humoral immune 
responses (Martinez-Sobrido & Garcia-Sastre, 2007; Li et al, 2013). 
 
Cloned genes can be incorporated into negative strand viruses using the reverse genetics 
system. This has been established by many researchers (Castrucci et al, 1992). 
Recombinant influenza viruses started to be constructed in the late 1980s (Li et al, 2013). 
Formation of the pol I transcription system allowed the influenza virus cDNA template to be 
transcribed and RNP complexes to be produced by the cellular RNA polymerase complex 
(Hoffmann et al, 2000a; Hoffmann et al, 2000b). 
 
Generating a recombinant influenza virus via DNA plasmid transfection, which encodes for a 
selected viral segment, requires the use of helper virus to provide the remaining viral 
proteins and RNA segments. Therefore, creating a strong selection system is essential to 
get the desired generated recombinant viruses from the background of helper viruses 
(Neumann et al, 1999, Fodor et al, 1999, Hoffmann et al, 2000a; Hoffmann et al, 2000b; de 
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Wit et al, 2007). For constructing the pol I plasmid, the influenza virus cDNA is cloned in a 
negative sense, and flanked by RNA polymerase I promoter and terminator sequences 
(Neumann et al, 1999; Martinez-Sobrido & Garcia-Sastre, 2007). These flanking sequences 
are used to ensure the correct intracellular expression for the start and end sequences of the 
vRNA (Neumann et al, 1994; Martinez-Sobrido & Garcia-Sastre, 2007). 
 
HA is a major glycoprotein of influenza virus and a primary immune target structure for 
inducing the protective immunity (Caton & Browniee, 1982; Neumann & Kawaoka, 2002; 
Sriwilaijaroen & Suzuki, 2012). Specific antigenic domains of the HA are targeted by the 
antibodies after host infection (Martinez-Sobrido & Arcia-Adolfo, 2007). Foreign epitopes 
have been inserted in these different antigenic sites for immunological ab\nalysis. The main 
reason makes the HA protein a suitable candidate for epitope insertion is that it contains five 
antigenic sites, and more importantly these sites can tolerate the insertion of foreign 
sequences without disturbing the overall function and structure of the generated 
recombinant HA (Garcia-Sastre, 2000; Sriwilaijaroen & Suzuki, 2012). This is because these 
antigenic sites do not have conserved amino acid sequences among the influenza A virus 
different strains (Garcia-Sastre, 2000). Many studies had successfully expressed inserted 
foreign epitopes mostly in the globular head within or near antigenic site B of the HA1 
subunit (Table 1.6 in Chapter 1) (Rodrigues et al, 1994; Li et al, 2005; Martinez-Sobrido & 
Arcia-Adolfo, 2007). 
 
Propagating influenza viruses in MDCK cells has become commonly used because they 
support efficient growth of all strains of influenza viruses, and they are resistant to the toxic 
effects of trypsin (Tobita et al, 1975; Hossain et al, 2010).  Also, MDCK cells are approved 
cells, are used to generate pandemic and seasonal influenza vaccines, and have higher 
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plasmid transfection efficiency compared with Vero cells (Murakami et al, 2008; 
Suphaphiphat et al, 2010). 
 
The commonly used RNA polymerase I promoter for the influenza reverse genetics 
technology is the human pol I which supports the influenza rescue in embryonic kidney 293T 
cells (Suphaphiphat et al, 2010). Due to the host specificity of RNA pol I, the human pol I 
promoter is generally not expected to function well in MDCK cells according to published 
reports (Heix & Grummt, 1995; Wang & Duke, 2007; Murakami et al, 2008). On the contrary, 
Suphaphiphat et al (2010) showed that human pol I can function and allows efficient 
generation of influenza virus in canine cells.  
 
Murakami et al (2008) have established a reverse genetics system for influenza A virus in 
MDCK cells using the canine polymerase I promoter. They have replaced the‎human‎pol‎ Ι‎
promoter in the pHH21 plasmid with the predicted canine pol‎Ι‎promoter‎sequence,‎and‎they 
showed that a pol I construct with nucleotides 1 to 457 may contain an additional enhancer 
element compared to a construct with nt 1 to 250 (Figure 3.1). The virus titer detected was 
more than 5 x 103 PFU/mL (Murakami et al, 2008). 
 
Almost all of the reverse genetics systems that have been successfully applied using the 
RNP transfection method with the helper virus were performed with influenza virus 
A/WSN/33 (H1N1) (de Wit et al, 2004). Selecting the HA transfectant viruses requires using 
different HA subtypes for the RNP and helper virus. Therefore, the helper virus or the 
recombinant virus can be selected by using specific antibodies against it (Garcia-Sastre, 
2000).  
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Figure 3.1:  Canis lupus familiaris gene for RNA polymerase I, promoter region, partial 
sequence (Genbank: AB430549).   
http://www.ncbi.nlm.nih.gov/nuccore/AB430549 
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Isolation of the desired generated viruses could be made by insertion of specific epitope on 
the virus surface, and then isolate it using a method such as immobilised metal affinity 
chromatography (IMAC), as this is an effective and rapid technique (Block et al, 2009; 
Segura et al, 2011).  
 
Several researchers have developed an efficient purification method using the affinity 
chromatography system by inserting a His tag in the viral surface proteins. Although this 
approach has never been done with influenza virus, a number of other viruses have been 
successfully generated incorporating a hexahis tag  and‎ the‎ viruses’ general function and 
infectivity were not affected. Hu et al (2003) has generated a recombinant baculovirus 
containing His6 within the viral envelope protein gp64 and it was purified by IMAC with high 
purity rate (~87%). Ye et al (2004) have generated chimeric retroviruses displaying a His tag 
on the virus envelope protein. The tagged virus vectors were purified using a Ni-NTA 
column, and around 56% were recovered from the total of chimeric viruses that were 
produced (Ye et al, 2004). Recently, adeno-associated viruses were engineered to contain a 
His6 tag on the virus capsid. The recombinant viruses were successfully purified by one-step 
IMAC purification with a 90% yield of infectious viral particles (Koerber et al, 2007; Jang et 
al, 2010).  
 
In this study, influenza virus A/Puerto Rico/8/34 (PR8) will be used, as it is a very common 
laboratory adapted strain and can be easily propagated in MDCK cells (de Wit et al, 2004). 
The molecular weight for the HA1 and HA2 subuntis of the HA PR8 virus are 46,000 Daltons 
and 27,000 Daltons respectively (Caton & Browniee, 1982). For the H1 subtypes viruses the 
immunodominant epitopes (See section 1.5.5.1 for more details) were defined as Sa, Sb, 
Ca1, Ca2 and Cb (Figure 3.2)  (Caton & Browniee, 1982; Ellebedy & Ahmed, 2012). These 
antigenic domains are situated in the exposed loops of the HA1 subunit that extend out from 
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Figure 3.2: Location of antigenic sites in the HA trimer, top and side view respectively, of H1 
subtype virus. Antigenic sites Sa (red), Sb (green), Ca1 (cyan), Ca2 (blue) and Cb (yellow) 
are shown as coloured bubbles.  
Figure obtained from Guarnaccia et al (2013). 
 
 
 
 
CHAPTER 3 
 
 105 
the viral surface, where insertion, substitution and deletion of amino acids can occur (Notkins 
& Oldstone, 1986). 
 
In 1982, site-directed mutagenesis study was performed on A/Puerto Rico/8/34 has resulted 
in identification of 32 amino acids on the identified antigenic regions (recently called 
laboratory epitope residues) and were considered as antigenically unique amino acids 
(Caton & Browniee, 1982; Huang et al, 2012). Deem and Pan (2009) then extended these 
residues to 161 in 2009 using an entropy-based technique and mapped the epitopes from 
H3 HA to H1 HA subtypes (Table 3.1). 
 
Recently, studying and comparing these antigenic sites with different HA subtypes become 
more of an interest. A recent study has made a sequence alignment between H1N1 and 
H3N2. Antigenic sites for H1N1 can be assigned from sites Sa, Sb, Ca and Cb into antigenic 
sites B+D, B, A+C+D and A+E of H3N2 HA respectively  (Huang et al, 2012). Stray and 
Pittman (2012) showed that Sb and Sa sites were structurally analogous to the B site of H3 
that are located to the top of the HA globular head. Also, the Ca2 site in H1 subtype is 
similar to the antigenic site A in H3, and the Cb antigenic site in H1 is analogous to site C in 
H3 (Stray & Pittman, 2012). However, Caton and Browniee (1982) have formerly showed 
that it is only an approximate equivalent to assign these antigenic sites between the H1 and 
H3 subtypes and some of these sites (or part of them) do not have equivalents. Thus, for 
ease of further discussion, in this study we will refer to the selected insertion site according 
to the identified antigenic amino acid in the Caton and Browniee (1982) study. 
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Epitope Amino acids number 
A 118 120 121 122 126 127 128 129 132 
133 134 135 137 139 140 141 142 143 
146 147 149 165 252 253 
 
B 124 125 152 153 154 155 156 157 160 
162 183 184 185 186 187 189 190 191 
193 194 195 196 
 
C 34 35 36 37 38 40 41 43 44 45 269 270 
271 272 273 274 276 277 278 283 288 
292 295 297 298 302 303 305 306 307 
308 309 310 
 
D 89 94 95 96 113 117 163 164 166 167 
168 169 170 171 172 173 174 176 179 
200 202 204 205 206 207 208 209 210 
211 212 213 214 215 216 222 223 224 
225 226 227 235 237 239 241 243 244 
245 
 
E 47 48 50 51 53 54 56 57 58 66 68 69 70 
71 72 73 74 75 78 79 80 82 83 84 85 86 
102 257 258 259 260 261 263 267 
 
Table 3.1: Amino acids in epitopes A, B, C, D and E of H1 (A/California/04/2009). For 
A/PR/8/1934 numbering, amino acids numbers above 130 would have 1 subtracted from 
them.  
Table modified from Deem and Pan (2009). 
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In this study, a recombinant HA protein of influenza A virus (A/Puerto Rico/8/34(H1N1)) 
containing a hexahistidine epitope was designed, and a pol I construct with canine pol I 
promoter was made. 
 
The work described in this chapter were as follows: 
- To insert a His6 tag in an exposed site in the globular head of the HA1 region. 
- To design the pol I construct by locating the HA-His6 cDNA between the canine Pol I 
promoter and mouse pol I terminator, and clone the construct in the pRNA-
CMV3.1/Neo vector. 
- To confirm the correct product within the DNA plasmid. 
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3.2 Materials and Methods 
 
3.2.1 Studying influenza PR8 HA sequence features, and selecting the site for His6 tag 
insertion  
The HA gene used in this study is for A/Puerto Rico/8/34 (H1N1) influenza virus. The 
nucleotide and amino acid sequence of the HA gene from PR8 in the mRNA sense were 
obtained from NCBI sequence database (Genebank: EF467821.1). Sequence features were 
collected from Uniprot (http://www.uniprot.org/uniprot/P03452) and the following studies; 
Caton & Brownie, (1982), Gamblin et al (2004), Lin et al (2009), Sriwilaijaroen and Suzuki 
(2012). The important domains of the PR8-HA gene sequence were marked, including HA1 
and HA2 subunits, cleavage site, antigenic epitopes, receptor binding sites, glycosylation 
sites and conserved residues. After that, a His6 tag insertion site was selected according to: 
a) the unique antigenic residues defined by Caton and Brownie (1982), b) building a 
structural model for HA protein showing the selected residues are within an exposed area, c) 
reviewing previous studies results for generating recombinant HA (Table 1.6 in Chapter 1).  
 
For building the PR8 HA structural model, first the HA protein sequence was uploaded to the 
Swiss-Model Workspace for homology modeling (Arnold et al, 2006). To predict the model, a 
BLAST was first done to search for related structures matching the target sequence in 
protein data bank. Then, a number of templates were selected (usually 2 or 3) from a large 
group of templates that have been found. The selection is based on the higher score 
alignment and quality features between the target sequence and the selected templates 
sequences, and the templates with higher quality were selected. The next step was to build 
a model based on target-template alignment. The conserved residues between the target 
and the template are copied from the template to the model. Using a fragment library, 
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deletions and insertions were remodeled and side chains were then rebuilt. The last step 
was regulating the geometry of the resulted model using the force field (Guex & Peitsch, 
1997; Altschul et al, 1997; Benkert et al, 2011). This was resulted in the generation of the 
crystal structure model, and it was available as a PDB file (protein data bank) (Arnold et al, 
2006). Generally, three models can be generated with high quality ranking. Each one comes 
with model information, such as the template used, model residue range, sequence identity 
and the QMEAN4-score. To visualize the 3D structure model, the generated PDB file was 
used and uploaded into Visual Molecular Dynamics software (VMD) (Humphrey et al, 1996).  
 
3.2.2 Insertion of the His6 tag within the HA protein sequence and building HA-His6 
crystal structure 
The sequence for the PR8 hemagglutinin that was obtained from the NCBI was for the cDNA 
derived from cRNA HA. The cRNA is a positive strand, and it is a complementary sequence 
to the vRNA sequence. We will refer to this sequence as cRNA as it is represented in NCBI. 
For inserting the 6x His sequence, the nucleotide sequence for the His6 tag 
(caccaccaccaccaccac) was added using the SECentralTM Clone Manager software, after the 
selected nucleotide S158 (S158 means that the amino acid at position 158 is S). The 
insertion was made into the cRNA as it represents the same sequence for the mRNA (with 
the exception of the poly (A) tail), which will be translated in the host cell to make the viral HA 
protein.  
 
According to Newumann et al (1999), the cDNA sequence which to be cloned into the 
plasmid vector should encodes for the vRNA segment (negative strand). Also, it should be 
inserted in the antisense orientation between the RNA polymerase I promoter and terminator. 
From that construct, a negative sense RNA is expected to be synthesised, which then will be 
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used as the template for the vRNA polymerase to generate the two types of positive sense 
RNAs (cRNA and mRNA) (Hofmann & Webster, 2000). An online tool was used to make the 
reverse-complement for the modified cRNA sequence. In order to show the inserted His6 tag 
within the HA protein, and to confirm that the addition of His6 has not affected the HA overall 
structure, a hypothetical structure model was built for the HA-His6 translated protein 
sequence using Swiss-Model. The model was then visualized using the VMD software as 
described previously.  
 
3.2.3 Making the RNA polymerase I sequence construct  
Since the transfection experiment will be performed in MDCK cells, canine RNA polymerase I 
promoter sequence (Figure 3.1) was cloned prior to the 5` end of the vRNA sequence. For 
the pol I terminator, the mouse RNA polymerase I terminator sequence was cloned next to 
the 3` end of the vRNA. The mouse pol I terminator region has been identified by Grummt et 
al (1985) and only part of this terminator sequence is essential for influenza vRNA 
transcription (Zobel et al, 1993; Neumann et al, 1994). The cloned terminator region was 
from nt 571 to 745 relative to the 3` end of the 28S coding position in the mouse system  
(Figure 3.3) (Neumann et al, 1994). Insertion of the RNA polymerase I promoter and 
terminator sequences to the vRNA was performed using SECentralTM Clone Manager 
software  
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Figure 3.3: Mouse 28S ribosomal gene termination region (GenBank: M12074). Terminator 
sequence‎used‎for‎this‎study‎is‎from‎nt‎571‎to‎nt‎745‎relative‎to‎the‎3’‎end‎of‎28S ribosomal 
DNA (highlighted with yellow color). The terminators T1 and T2 (highlighted in green and 
blue respectively) are the first two repeats from the eight repeats of the conserved 18 bp 
sequence, which is called the Sal box. These are essential for termination and also serve as 
binding sites for the termination factor TTFI, a factor that mediate termination of mouse 
ribosomal DNA transcription (Grummt et al, 1985; Zobel et al, 1993; Neumann et al, 1994).  
 
 
 
 
1    ctctgcgggc tttcccgtcg cacgcccgct cgctcgcacg cgaccgtgtc gccgcccggg 
61   cgtcacgggg gcggtcgcct cggcccccgc gcggttgccc gaacgaccgt gtggtggttg 
121  ggggggggat cgtcttctcc tccgtctccc gaggacggtt cgtttctctt tccccttccg 
181  tcgctctcct tgggtgtggg agcctcgtgc cgtcgcgacc gcggcctgcc gtcgcctgcc  
241  gccgcagccc cttgccctcc ggccttggcc aagccggagg gcggaggagg gggatcggcg  
301  gcggcggcga ccgcggcgcg gtgacgcacg gtgggatccc catcctcggc gcgtccgtcg 
361  gggacggccg gttggagggg cgggaggggt ttttcccgtg aacgccgcgt tcggcgccag  
421  gcctctggcg gccggggggg cgctctctcc gcccgagcat ccccactccc gcccctcctc  
481  ttcgcgcgcc gcggcggcga cgtgcgtacg aggggaggat gtcgcggtgt ggaggcggag 
541  agggtccggc gcggcgcctc ttccattttt tcccccccaa cttcggaggt cgaccagtac 
601  tccgggcgac actttgtttt ttttttttcc cccgatgctg gaggtcgacc agatgtccga 
661  aagtgtcccc cccccccccc ccccccggcg cggagcggcg gggccactct ggactctttt 
721  tttttttttt tttttttttt ttaaattcct ggaaccttta ggtcgaccag ttgtccgtct 
781  tttactcctt catataggtc gaccagtact ccgggtggta ctttgtcttt ttctgaaaat 
841  cccagaggtc gaccagatat ccgaaagtcc tctctttccc tttactcttc cccacagcga 
901  ttctcttttt tttttttttt tttggtgtgc ctctttttga cttatataca tgtaaatagt 
961  gtgtacgttt atatacttat aggaggaggt cgaccagtac tccgggcgac actttgtttt 
1021 tttttttttt tccaccgatg atggaggtcg accagatgtc cgaaagtgtc ccgtcccccc 
1081 cctccccccc ccgcgacgcg gcgggctcac tctggactct tttttttttt tttttttttt 
1141 tttaaatttc tggaacctta aggtcgac 
!
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3.2.4 Gene synthesis and cloning  
After designing the HA-His6 pol I construct, the electronic sequence was sent to GenScript
® 
for gene synthesis and cloning. Gene synthesis is performed by synthesising a DNA strand 
chemically base by base without a template strand (GenScript®, U.S.A.). The main steps for 
gene synthesis as depicted in Figure 3.4 include:  
1) Sequence optimisation and oligo design. After optimising the sequence, sequence 
analysis is performed in order to divide the whole gene construct into fragments, which then 
be synthesised separately for later assembly. This step is performed by using oligo design 
software (GenScript®, U.S.A.).  
2) Oligo synthesis. Prepared via phosphoramidate chemistry by the addition of nucleotide 
monomers to form the short fragments of nucleic acids. This technique uses modified 
oligonucleotides, called phosphoramidates, to prevent unwanted side reactions and to 
confirm that the nucleotide assembled in the right way (GenScript®, U.S.A.). 
3) Gene assembly. Oligo fragments assembled into the complete gene (GenScript®, U.S.A.). 
4) Sequence verification and error correction. It is mainly done by cloning the newly 
synthesised sequence into a plasmid vector. Our synthesised HA-His6 pol construct was 
cloned into pUC57 plasmid using KpnI and HindIII restriction sites. A number of analyses 
were made to confirm the correct sequence insert. This includes sequence alignment, 
restriction digestion, PCR amplification and DNA quality assesment (GenScript®, U.S.A.). 
5) Preparing the synthetic gene for downstream application. The synthesised gene is to be 
cloned into the vector of choice. Our chosen vector for this study is described in the following 
section (GenScript®, U.S.A.`m,,). 
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Figure 3.4: Gene synthesis steps.  
Obtained from GenScript
®
, accessed in 2015. 
http://www.genscript.com/gsh.html 
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3.2.5 Sub-cloning the HA-His6 pol I construct into pRNA-CMV3.1/Neo vector 
The pRNA-CMV3.1/Neo plasmid vector was selected (GenScript) for cloning the synthesised 
gene construct, which will be used for the transfection experiment in this study (Figure 3.5). 
As the construct contains the required promoter and terminator sequences, the CMV 
promoter in the pRNA-CMV3.1/Neo is no longer required, and it has to be inactivated. This 
plasmid contains two unique restriction sites, NdeI (nucleotide number 233) and HindIII 
(nucleotide number 644). More importantly, these restriction enzymes will not digest the 
designated gene construct (Figures 3.6 and 3.7). By using these two sites, part of the CMV 
promoter will be substituted by the cloned HA-His6 pol I construct sequence. Accordingly, we 
have previously included these restriction enzyme sites in our construct (NdeI and HindIII) at 
the 5` and 3` end. GenScript also has completed the sub-cloning process. The HA-His6 pol I 
construct was sub-cloned using the NdeI and HindIII restriction sites. This plasmid will refer 
to it as pCDNA/HAPR8-His6 pol I. Confirmation of the correct insert was performed by 
digesting the plasmid with NdeI and HindIII restriction enzymes. 
 
3.2.6 Amplifying the pCDNA/HAPR8-His6 pol I plasmid in DH5α and confirming the 
correct plasmid 
pCDNA/HAPR8-His6 pol I plasmid was transformed into electrocompetent E. coli DH5α 
(described in Section 2.13.2). The transformed cultures were plated out into LB agar 
containing Ampicillin (100‎μg‎/mL) and incubated at 37° C for 24 hours. Then, 2 or 3 colonies 
were grown in LB broth containing Amp (100‎μg‎/mL) and was incubated at 37° C with 180 
rpm shaking for 18 hours. For the DNA plasmid isolation, the isolate II mini kit (Bioline, 
England) was used following the manufacturer instructions (Section 2.11.1). The plasmids 
were then digested with NdeI and HindIII restriction enzymes (Section 2.7), and the digested 
DNA fragments were separated on a 1% DNA grade agarose gel in order to confirm the 
insert within the correct plasmid (Section 2.12.2). 
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Figure 3.5: Map of pRNA-CMV3.1/Neo plasmid (Genscript). The NdeI and HindIII restriction 
sites used for cloning the synthesised gene construct. 
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Figure 3.6: Restriction sites map for pRNA-CMV3.1/Neo plasmid. NdeI and HindIII sites are 
marked with blue box.  
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Figure 3.7: Restriction sites map for the HA-His6 pol I gene construct. 
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3.3 Results 
 
3.3.1 PR8-HA sequence features analysis and His6 tag insertion site 
Important sequence features were mapped within the HA sequence and depicted in Figure 
3.8. The N-terminal hydrophobic signal peptide position 1 to 17 (numbering from the first 
methionine) is critical for the synthesis and processing of membrane proteins. It is cleaved in 
the endoplasmic reticulum by a signal peptidase during the co-translation process (Huang et 
al, 2010). HA1, where the antigenic domains are located, start at position 18 and end at 
amino acid 342 (length 325). HA2 start from aa 344 to aa 565 (length 222). A disulphide 
bridge (21 and 480) links HA1 and HA2 subunits. The noncoding domain at the 3` and 5` 
termini contains the highly conserved promoter region, which is recognised by the vRNA 
polymerase (Zhao et al, 2014).  
 
Glycosylation occurs at certain highly conserved positions, and it has been shown that they 
play an important role in the formation and structural stability of the HA (Schulze, 1997; 
Jayaraman et al, 2012). Also, glycans are involved in masking the antigenic sites on the 
globular head of HA (Jayaraman et al, 2012; Tate et al, 2014). 
 
The receptor binding region (RBR) pocket is formed by the 190-helix, 130-loop and 220-loop 
secondary structures. These structures are also associated with anchoring the sialic acid 
(Soundararajan et al, 2011). The receptor binding residues are critical for the receptor 
binding specificity (Sriwilaijaroen & Suzuki, 2012). Also, they are vital determinants for the 
HA in terms of host receptor binding affinity (Soundararajan et al, 2011). 
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Figure 3.8: HA sequence features of influenza virus A/Puerto Rico/8/34. Amino acid 
numbering start form the first methionine and the nucleotide numbering start from the first 
nucleotide. The selected amino acid for His6 tag insertion is marked with the pink triangle. 
 
 
 
 
 
 
Stop codon 
 
UGCAUGGAAAGUGUA AGAAAUGGGACUUAU GAUUAUCCCAAAUAU UCAGAAGAGUCAAAG UUGAACAGGGAAAAG 
 C  M  E  S  V   R  N  G  T  Y   D  Y  P  K  Y   S  E  E  S  K   L  N  R  E  K  
GUAGAUGGAGUGAAA UUGGAAUCAAUGGGG AUCUAUCAGAUUCUG GCGAUCUACUCAACU GUCGCCAGUUCACUG 
 V  D  G  V  K   L  E  S  M  G   I  Y  Q  I  L   A  I  Y  S  T   V  A  S  S  L   
GUGCUUUUGGUCUCC CUGGGGGCAAUCAGU UUCUGGAUGUGUUCU AAUGGAUCUUUGCAG UGCAGAAUAUGCAUC 
 V  L  L  V  S   L  G  A  I  S   F  W  M  C  S   N  G  S  L  Q   C  R  I  C  I  
UGAGAUUAGAAUUUC AGAGAUAUGAGGAAA AACACCCUUGUUUCU ACU 
 *  D  *  N  F   R  D  M  R  K   N  T  L  V   S  T 
 
 
 Signal peptide  Cleavage site 
 Conserved glycosylation site  Fusion peptide 
 Glycosylation site  Heptad repeat 
 Disulphide bridge:  Transmembrane 
 21, 480   HA1 subunit start (18 – 342 aa) 
 59, 291  HA2 subunit start (344 -565 aa) 
 72, 84 …... Extracellular domain 
 107, 152   Cb site 
 487, 491  Sa site 
   Sb site 
 A highly conserved residue  Ca1 site 
 Important residues for receptor binding   Ca2 site 
 Cytoplasmic tail  Amino acid selected 
    xx  Noncoding region   
 
Figure 3.8: Sequence features of influenza virus A/Puerto Rico/8/34. Amino acid 
numbering s art orm the f rst methionin and the nucleotid  umbe ing start from he 
first nucleotide. The selected amino acid for His6 tag insertion is marked with the pink 
triangle. 
"
1500"
1575"
1650"
1725"
515"
540"
565"
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The fusion peptide, heptad repeat and the transmembrane domains are situated in the HA2 
subunit. The fusion peptide sequence (FP) (position 345 to 366) is highly conserved in HIN1 
viruses, and it is rich in glycine, which provides flexibility (Isin et al, 2002; Sriwilaijaroen & 
Suzuki, 2012). The FP is hidden during the resting stage at neutral pH, but at low pH it is 
exposed from the hydrophobic pocket and inserted into the target membrane. The heptad 
repeat domain (HR) in the activated state undergoes extensive refolding in order to form the 
hairpin structure (Chang et al, 2008; Sriwilaijaroen & Suzuki, 2012). This refolding leads to 
both viral and cellular membranes proximity and possibly delivers free energy, which results 
in the two membrane merging (Chang et al, 2008; Sriwilaijaroen & Suzuki, 2012). The 
general function for the transmembrane domain (TMD) (position 529 to 549) is to support the 
full membrane fusion during the late phase of fusion. A study has found that the highly 
helical TMD structure was inserted into the lipid bilayer of the target cells membrane, and 
this would probably results in forming pores. There is an association between the TMD and 
FP, which secures the FP within the viral membrane (Chang et al, 2008). 
 
The cytoplasmic tail (CT) residues (position 554 to 565) is a highly conserved region. It has 
been shown that the CT has a critical role in membrane fusion activity, and also during the 
last step of the virus assembly and budding (Imai et al, 2012; Gomila et al, 2013). 
 
The sequence features for PR8-HA were reviewed in order to select an appropriate site for 
inserting the His tag and ensuring the selected site will not interfere with vital domains of the 
HA sequence structure. Amino acid S158 was selected for epitope insertion (numbering from 
the first methionine). This amino acid was identified by Caton and Brownie, (1982) as a 
unique antigenic residue within antigenic site Ca2. Figures 3.9 and 3.10 show that the 
selected amino acid is located within an exposed area on the HA structure. We have 
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Figure 3.9: Model structure of PR8 hemagglutinin monomer (side view). The selected amino 
acid S158 (serine) for His6 tag insertion site is highlighted in yellow. 
 
 
 
 
158 SER 
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Figure 3.10: Model structure of PR8 hemagglutinin monomer (top view). The selected amino 
acid S158 for His6 tag insertion site is highlighted in yellow. 
 
 
 
 
 
 
 
 
 
158 SER 
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selected the generated model number two, because this model structure has the higher 
residue range coverage from aa 18 to 511 with 18 is the first amino acid of the HA1 subunit. 
The template code was 2wr0, and it is annotated as homo-trimer. However, Swiss-Model 
was not able to build the model as a homo-trimer, and thus the model was built as a single 
chain. The sequence identity given by Swiss-Model Workspace was 64.96 %. 
 
3.3.2 PR8-HA sequence after the addition of His6 tag and HA-His6 structure 
The 6x His sequence is added after nucleotide number 506 (numbering from the first 
nucleotide for the HA sequence) (Figure 3.11). Then, the modified cRNA sequence was 
converted into the vRNA sequence in an antisense orientation shown in Figure 3.12, which 
includes the His6 tag in the reverse-complement form. Expasy translation tool was used to 
translate the nucleotide sequence for the modified HA (Figure 3.13).  
 
The monomer structural model for the HA protein showing the His tag location are shown in 
figures 3.14 and 3.15. We have selected the generated model number three. This model has 
a residue range coverage from 18 to 517. The first two models have lower residue coverage, 
which was from 315 to 510 for the first model, and from 18 to 346 for the second model. The 
template code for the selected model was 2wr0. The sequence identity was 64.7% and the 
QMEAN4 score was -1.6. The QMEAN4 global score is protein structure model quality 
estimation. It calculates both global (entire structure) and local (per-residue) error estimates 
on the basis of single models (Benkert et al, 2011). The estimate model reliability is between 
0-1 (Benkert et al, 2011). 
 
The template structure is a homo-trimer, but as previously stated, Swiss-Model could not 
build a homo-trimer model structure, and thus a single chain model was built. 
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Figure 3.11: Addition of His6 nucleotide sequence into the cRNA for PR8-HA nucleotide 
sequence (positive strand). The sequence is in the 5` to 3` direction. The His6 is highlighted 
with yellow color, inserted after nucleotide 506 cytosine (amino acid S158). The initiation 
codon highlighted with cyan color, and the stop codon highlighted with green. 
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Figure 3.12: The vRNA sequence, which is the reverse-complement sequence for the cRNA 
containing the His6 tag. It is a negative strand and 5` to 3` direction (antisense). The His6 is 
highlighted with yellow color, initiation codon highlighted with cyan color and stop codon 
highlighted with green color. 
 
CHAPTER 3 
 
 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Sequence translation for the HA-His6 nucleotides. Highlighted the 6x His, 
initiation codon and stop codon in yellow, cyan and green respectively. 
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Figure 3.14: Model structure for the HA (side view) with the addition of the His6 tag. The 6x 
His is (highlighted in yellow) are representing nucleotides 159 to 164 in the modified HA 
protein. 
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Figure 3.15: Model structure for the HA (top view) with the addition of the His6 tag. The 6x 
His is highlighted in yellow. 
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3.3.3 RNA polymerase I construct sequence and cloning it into the pRNA-CMV3.1/Neo 
vector 
Figures 3.16 and 3.17 represent the virus cDNA derived from vRNA HA and it is in the 
antisense orientation relative to the canine promoter and the mouse terminator sequences. 
The NdeI and HindIII were included at the 5` and 3` ends respectively within the HA pol I 
construct. The final construct size was 2442 bp. 
 
3.3.4 The synthesised gene quality and sub-cloning 
The synthesised gene was cloned into the pUC57 vector using KpnI and HindIII restriction 
enzymes (Figure 3.18). The correct size of the inserted fragment was confirmed by digesting 
it with EcoRI (Figure 3.19). Sequence alignment was performed and it was consistent with 
the targeted inserted sequence. The DNA quality was performed using miniprep and the 
OD260/280 was 1.7 ~ 2.0. 
 
The synthesised gene was then successfully sub-cloned into pRNA-CMV3.1/Neo plasmid 
using NdeI and HindIII restriction enzymes. The correct insert was confirmed by restriction 
enzyme digestion (figure 3.19) 
 
 
3.3.5 Confirming the correct plasmid after plasmid amplification in DH5 alpha 
Transformation of the pCDNA/HAPR8-His6 pol I plasmid was successfully done. The 
expected fragments size for the digested DNA plasmid with NdeI and HindIII were 4783 bp 
and 2450 bp and this is shown in Figure 3.20. 
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Figure 3.16: The final designated HA/His6 pol I construct sequence. The 6 x His and 
initiation codon are highlighted with yellow and cyan respectively. 
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Figure 3.17: Schematic representation of the HA/His6 pol I construct. The HA is in the 
antisense orientation between the canine pol I promoter (P) and the mouse pol I terminator 
(T). CT= cytoplasmic tail, SP= signal peptide. 
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Figure 3.18: Map of pUC57. The synthesised gene was cloned in the plasmid at the KpnI 
and HindIII restriction enzymes.  
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Figure 3.19: Restriction enzyme digestion. A) Confirming the size of the insert within the 
pUC57 in agarose gel. B) Confirming the insert within the pRNA-CMV3.1/Neo I agarose gel. 
 
 
 
 
 
bp 
bp 
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Figure 3.20: Confirming the DH5α‎amplified plasmid by restriction enzyme digestion. 
Lane M: Lambda ladder. Lane 1: un-cut plasmid. Lane 2 and 3: plasmid digest by NdeI and 
HindIII.  
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3.4 Discussion 
 
In this study, designing an RNA polymerase I construct encoding for a 6x histidine tagged 
viral HA protein was successfully completed. The HA is the dominant glycoprotein on the 
influenza virus surface (Sguazza et al, 2013). The HA1 subunit is the exposed part that 
contains the receptor binding region and the five antibody recognition sites. From the HA 
structure model, it was demonstrated that the added His6 peptide is within a highly exposed 
surface on the HA globular head domain.  
 
Engineering a recombinant HA protein with His6 tag in order to generate a tagged influenza 
virus has never been studied before. However, many studies have shown that mutation and 
addition of foreign epitopes within the identified HA antigenic domains do not affect viral 
infectivity and resulted in generation of chimeric viruses exposing the foreign epitopes 
(Rodrigues et al, 1994; Muster et al, 1995; Miyahira et al, 1998; Gilleland Jr. et al, 2000; 
Thomas et al, 2006). 
 
The selected S158 amino acid residue for inserting the His6 tag has been identified within 
the Ca2 antigenic region, which is known to be from the most accessible hypervariable 
region (Caton & Browniee, 1982; Xu et al, 2013). We have chosen this amino acid residue 
because it is located within an exposed external loop. Many studies revealed that most of 
the antigenic epitopes contain highly flexible, protruding loops, and shape changing might 
not alter the virus stability with the exception of antigenic sites Ca1 and Cb (Xu et al, 2010; 
Stray & Pittman, 2012).  Moreover, it was found that amino acid S159 (next to the selected 
S158) is also recognised as an epitope residue within the Ca2 site (Deem & Pan, 2009; 
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Matsuzaki et al, 2014). This viewed that the inserted epitope is located between two 
antigenic amino acid residues, possibly making it an accessible target to specific antibodies 
and easier for antibody binding. 
 
The insertion of the viral cDNA in negative or positive orientation with respect to the pol I 
promoter will result in different synthesised molecules. With a polymerase I promoter with 
viral cDNA inserted in the negative sense, transcription by the cellular RNA polymerase I will 
result in the negative influenza vRNA molecule with recognition parts at both ends of the 
viral polymerase protein. This situation resembles the natural influenza infection when 
infection with helper virus vRNP is transported to the nucleus and vRNA act as a template 
for cRNA and mRNA synthesis (Hoffmann et al, 2000b; Hoffmann & Webster, 2000). On the 
other hand, if the viral cDNA inserted in the positive sense direction this will result in 
synthesising the positive influenza cRNA, and in this case it needs to be replicated into 
vRNA in order to generate the mRNA (Hoffmann et al, 2000b; Hoffmann & Webster, 2000).  
 
After transfecting the designated pCDNA/HAPR8-His6 pol I plasmid, it is expected that the 
chimeric vRNA with the correct 3` and 5` ends to be synthesised in the MDCK cells nucleus 
by the cellular RNA polymerase. As the canine pol I promoter sequence (host specificity) 
was included upstream the gene construct sequence. When the transfected cells are then 
co-infected with helper PR8 virus, recombinant His tagged PR8 viruses are likely to be 
generated. Then, the His tagged virus is to be positively selected from the majority of parent 
PR8 viruses (wild-type) by using an IMAC column.  
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4.1 Introduction 
 
Generating recombinant influenza viruses expressing foreign epitopes was undertaken for 
the first time in 1989 using the viral RNP transfection method (Garcia-Sastre & Palese, 
1993). This has led to a significant improvement in understanding the molecular 
characteristics for these viruses and more importantly the evolution for generating negative-
strand viral vector vaccines (Walpita & Flick, 2005).  
 
In the previous chapter, an influenza virus HA protein encoding for additional His6 sequence 
within the HA1 subunit was genetically engineered. Figure 4.1 illustrates the reverse 
genetics technique for generating the recombinant PR8 influenza virus.   
 
To outline what is expected to arise from the transfection/co-infection experiment, confluent 
MDCK cells are transfected with pCDNA/HAPR8-His6 pol I plasmid, which has been 
previously isolated from E. coli DH5α.‎Then,‎ the‎ transfected‎cells‎ are‎ infected‎with‎helper‎
influenza PR8 virus (wild-type PR8) at a defined multiplicity of infection (MOI). The viral 
RNA-dependent RNA polymerase complex (PB1, PB2 and PA) and the nucleoprotein (NP), 
which will be provided from the helper virus transcribes and replicates the synthesised 
recombinant vRNA in the host cells nucleus by binding to the promoter region at both 
conserved ends (Garcia-sastre & Palese, 1993; Fodor et al, 1999; Martinez-Sobrido & 
Garcia-Sastre, 2007). At a later step, recombinant RNP will be reconstituted, which then will 
be packaged into new virions with the remaining viral proteins and segments, which also 
delivered from the helper virus (Garcia-sastre & Palese, 1993; Fodor et al, 1999; Martinez-
Sobrido & Garcia-Sastre, 2007). The expected final result is a combination of parent viruses  
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Figure 4.1: Schematic diagram of the pol I transfection method for generating polyhistidine 
tagged PR8 viruses. 
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and the newly generated recombinant viruses, however the majority will be the helper (wild-
type) viruses. 
 
Transfecting foreign nucleic acids (i.e DNA) into cells can be performed using cationic lipids, 
which facilitate their delivery into cells (Dalby et al, 2004). The general cationic lipid structure 
consists of a hydrophobic anchor that represents one or two hydrocarbon chains, a head 
group with a positive charge and a linker that connects the hydrophobic anchor and the head 
group (Chesnoy & Huang, 2000; Dalby et al, 2004). The cationic lipids are regularly 
formulated with co-lipid that has neutral charge (Chesnoy & Huang, 2000). The interaction 
between the lipid and the nucleic acid results in a lipid-DNA complex, mediated by the 
positively charged head group of the cationic lipid and the negatively charged phosphate 
backbone of the nucleic acid (Chesnoy & Huang, 2000; Dalby et al, 2004).  
 
For successful transfection of DNA into the cell, the lipid-DNA complex must undergo 
several steps: binding of nucleic acid to the cell membrane, escape into the cytoplasm and 
entry to the nucleus (Chesnoy & Huang, 2000; Dalby et al, 2004). The contact between the 
negatively charged cell membrane and the positive charge on the liposome surface 
facilitates the contact of the DNA to the cell (Chesnoy & Huang, 2000; Dalby et al, 2004). 
The fusion of the liposome is mediated by the co-lipid, which leads to the effective release of 
the foreign DNA into the cell (Chesnoy & Huang, 2000; Dalby et al, 2004).  
 
The commercially designed cationic lipid Lipofectamine® 2000 (Invitrogen U.S.A.) was used 
for this study in order to achieve efficient DNA plasmid transfection into the cells.  
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Selecting the successfully generated poly-His tagged viruses is to be performed using the 
IMAC purification technique, and this method has never been done before with influenza 
viruses. Proteins tagged with poly-His generally have high yield affinity interaction with the 
immobilised metal matrix, thus can be rapidly purified (Bornhorst & Falke, 2000). In our 
case, using native conditions, the tagged viruses are to be purified at the same principle. 
The helper viruses (non-tagged viruses) theoretically should not bind to the column. 
Whereas, the His tagged viruses will bind to the metal matrix, which then easily eluted 
(Figure 4.2).  
 
The aim of work described in this chapter were to: 
- Propagate influenza PR8 virus using MDCK cells and purify it with 20% sucrose 
cushion. 
- Quantify the PR8 influenza virus titer and determine the amount of infectious virus by 
50% tissue culture infective dose (TCID50), and estimate the virus multiplicity of 
infection (MOI). 
- Test the ability to select the transfected cells using G418 antibiotic. 
- Transfect the pCDNA/HAPR8-His6 pol I plasmid into MDCK cells and co-infect with 
helper PR8 viruses. 
- Confirm the presence of the generated His6 tagged viruses using protein detection 
techniques including SDS-PAGE, immunoblotting with anti-His antibodies. 
-  Detect the presence of the recombinant viral mRNA by designing specific primers 
that can target the His tagged region and amplify it using PCR. 
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Figure 4.2: Schematic diagram illustrating the possible method for isolating the His6 tagged 
influenza viruses using the IMAC column. 
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4.2 Materials and Methods 
 
4.2.1 MDCK cells, and influenza PR8 propagation and purification 
MDCK cells were cultured in 75 cm2 tissue culture flask and were maintained in DMEM 
media supplement with 10% FBS (as described in Section 2.10.1 and Section 2.10.2). The 
cells were confirmed to be mycoplasma-free (see Section 2.10.4). Cells were incubated until 
reaching around 80% confluent cells monolayer (usually takes between two to four days 
depending on the amount of cells seeded). After that, culture medium was washed and 
replaced with virus growth medium (VGM). Cells were then infected with PR8 virus as 
described in Section 2.11.2. A large amount of PR8 virus was required for the 
transfection/co-infection experiment. Accordingly, PR8 virus propagation was performed in 
multiple batches as well as concentration and purification of virus through the 20% sucrose 
cushion (see Section 2.11.3). The final step was combining all the purified virus samples 
together and then re-aliquot them in eppendorf tubes. Virus titration and quantification 
assays were then performed as described in the following sections. 
 
4.2.2 Hemagglutination assay 
The RBCs (erythrocytes) have many sialic acid receptors for influenza virus hemagglutinin. 
When a series of virus dilutions are mixed with a constant amount of RBCs, agglutination 
occurs and the level of influenza virus in the sample can be determined (Klimov et al, 2012). 
 
To perform the assay, a U-bottom or V-bottom 96-well microtiter plate is required (it is 
recomended to use the U-bottom with human type influenza viruses) (Klimov et al, 2012). 
Then, 100 mL of PBS diluted virus sample was added into the first well of the plate, and 50 
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μL‎PBS‎was‎added‎to‎well‎2‎through‎well‎12‎in‎the‎same‎row.‎Then‎a‎two-fold serial dilution 
of‎the‎virus‎sample‎was‎performed‎throughout‎the‎same‎row,‎disposing‎the‎final‎50‎μL‎from‎
the‎last‎well.‎This‎resulted‎in‎50‎μL‎serially diluted virus samples over this row. After that, 50 
μL‎of‎0.75%‎diluted‎RBCs‎(Section‎2.4)‎was‎added‎to‎all‎wells.‎The‎plate‎was‎tapped‎gently‎
for proper mixing, and it was incubated for one hour at room temperature (RT). The RBCs 
will settle to the bottom of a well forming a button in negative samples, and in positive 
samples it will agglutinate and from a lattice (Klimov et al, 2012). The HA unit  (HAU) was 
expressed as the highest virus dilution in which complete hemagglutination was observed 
(Figure 4.3). 
 
4.2.3 Virus quantification by TCID50 assay and calculating the MOI 
The amount of infectious virus particles in a sample can be determined using a traditional 
cell culture-based method, the TCID50 (Szretter et al, 2006). It is measured by determining 
the highest dilution of the virus sample, which can infect 50% of cells. The TCID50 titer is 
then calculated using the Reed-Muench calculation method. The end point of the TCID50 
(observing CPE with the highest virus dilution) can be confirmed by the HA assay, which 
delivers better reliability (Szretter et al, 2006; Abdoli et al, 2013). 
 
The TCID50 assay protocol was adapted from a published protocol with minor modification 
(Szretter et al, 2006). 5 x 103 MDCK‎ cells‎ in‎ a‎ 100‎ μL‎ volume‎ (section‎ 2.10.4‎ for‎ cell‎
counting) were seeded into each well of 96-well tissue culture plate and cells were 
maintained‎ in‎100‎μL‎DMEM‎with‎10%‎FBS‎(Section‎2.10‎for‎cell‎maintenance),‎and‎were 
incubated for one day. Next day, MDCK culture medium was removed and cell monolayer 
was washed‎twice‎with‎200‎μL‎VGM.‎Next,‎100‎μL‎VGM‎was‎added‎to‎all‎wells,‎except‎the‎
first well of each row. Influenza virus sample was diluted into 1:100 in VGM.
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Figure 4.3: An example of the hemagglutination assay. Two-fold serially diluted PR8 virus 
sample. HA unit is the dilution factor of the last well showing complete hemagglutination, and 
that is well number six. Therefore, the HAU is 3200. 
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146‎μL‎diluted‎virus‎was‎added‎into‎the first well of each row seeded with cells, and ½ log10 
dilution‎series‎was‎performed‎by‎transferring‎46‎μl between wells with disposing of the final 
46‎μL.‎In‎the‎first‎row‎of‎the‎plate,‎only‎two‎wells‎were‎seeded‎with‎MDCK‎cells‎and‎were‎not‎
infected, as these wells were the cell control for the assay. The plate was incubated for two 
hours at 37°C with 5% CO2. After that, the culture media of infected cells was removed 
gently‎and‎200‎μL‎fresh‎VGM‎was‎added‎to‎all‎wells,‎and‎the‎plate‎was‎incubated‎for up to 
three days until observing the highest CPE. In order to confirm the end point result, an HA 
assay‎was‎performed‎to‎all‎infected‎wells.‎The‎HA‎assay‎was‎prepared‎by‎transferring‎50‎μL‎
from each infected well into a new 96-well plate with U- or V-bottom in the same position. 
Then,‎50‎μL‎of‎0.75%‎diluted‎RBC‎was added and the plate was incubated at RT for one 
hour. The HA result was interpreted as described previously (Figure 4.4). The end point of 
CPE was recorded by comparing it with the result obtained from the HA assay and the 
TCID50 was calculated according to Reed-Muench‎using‎the‎following‎Karbers’‎formula: 
 
Proportional distance formula = [(% positive value > 50%) – 50%] /  
[(% positive value > 50%) – (% positive value <50%)] 
log infectious dose 50 = (log dilution > 50%) + proportional distance x log dilution factor) 
The reciprocal of this number is used to express the titer in infectious units per unit volume.  
 
In order to obtain the MOI, the TCID50 titer has to be converted to the mean number of 
PFU/ml by multiplying the titer by 0.7 (American Type Culture Collection, www.atss.org). As 
the plaque forming units defines the estimated number of infectious particles per volume, the 
total number of infectious units can then be estimated. Therefore, by dividing the number of 
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Figure 4.4: Illustrating the TCID50 assay, and confirming the CPE endpoint by HA assay. 
MDCK cell monolayers in a 96-well tissue culture plate are infected with influenza virus at 
increasing dilution (i.e. five replicate wells are infected with each dilution in the range 102 to 
107). The plate incubated up to 3 days and the presence or absence of CPE is examined. 
The results obtained from the TCID50 plate are confirmed by transferring 50 μL from each 
well into HA plate at the same position.  
-ve = negative control (well not infected with virus). 
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infectious particles with the number of cells to be infected the MOI was obtained  (American 
Type Culture Collection, www.atss.org). 
 
4.2.4 Transfecting the pCDNA/HAPR8-His6 pol I plasmid and examining the possibility 
of selecting the transfected cells with G418 antibiotic 
The pCDNA/HAPR8-His6 pol I plasmid carries a Neomycin resistance gene, which might be 
used to select for the plasmid transfected cells expressing the Neomycin. For mammalian 
cell selection the Neomycin gene confers resistance to G418 (Geneticin®), as the Neomycin 
cannot be used for mammalian cell culture selection (Chen et al, 2001). Therefore, selection 
of the transfected cells was tested by the addition of G418 antibiotic to the culture medium. 
 
The‎ plasmid‎ DNA‎ transfection‎ protocol‎ was‎ adapted‎ from‎ Invirogen™‎ for‎ using‎ the‎
lipofectamine® 2000 transfection reagent. One day before the transfection, 1 x 105 MDCK 
cells were seeded into each of the six wells used from the 12-well tissue culture plate so that 
cells will be 90 – 95% confluent at the time of transfection. Cells were maintained in 1 mL 
DMEM with 10% FBS without antibiotics, and the plate was incubated for 24 hours at 37°C. 
Next day, cell culture medium was replaced with serum-free medium. 1.6‎ μg‎ DNA‎ (for‎
quantifying‎DNA‎ concentration‎ see‎Section‎ 2.12.3)‎was‎ diluted‎ in‎ 100‎ μL‎ of‎Opti-MEM® I 
reduced‎ serum‎medium‎ and‎mixed‎ gently.‎ Also,‎ 4‎ μL‎ of‎ lipofectamine® 2000 transfection 
reagent was diluted in 100‎μL‎of‎Opti-MEM® I reduced serum medium. The two mixtures 
were incubated at room temperature for five minutes. After that, the diluted DNA and the 
diluted lipofectamine were combined and mixed gently (total volume was 200‎ μL).‎ The‎
mixture was incubated for 20 minutes at RT. For each transfection sample, this complex was 
prepared.‎Next,‎to‎each‎well‎containing‎cells‎and‎media,‎200‎μL‎of‎the‎complex‎was‎added‎
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and it was mixed by rocking the plate gently. Two wells were not transfected and were used 
as negative controls. The plate was incubated for 24 hours at 37°C with 5% CO2. 
 
Next day, the transfected and the non-transfected cells were treated with trypsin and sub-
cultured into six separate 25 cm2 tissue culture flasks (one well into one culture flask). For 
maintaining the sub-cultured cells, two different cultures DMEM medium were prepared. 
Both were supplemented with 10% FBS, but one with the addition of G418 (500 μg/mL) and 
the second one without adding G418. The flasks containing the non-transfected cells: one 
was maintained in medium supplemented with G418 and the other without the selectable 
antibiotic. The four flasks with the transfected cells: three were maintained in DMEM with 
G418 and the fourth flask was maintained in media without G418. All the flasks were 
incubated at 37°C with 5% CO2 and the media was replaced every third day. Cells growth 
was observed daily for selectivity progression. 
 
4.2.5 Co-infection with PR8 helper viruses, virus titration and purification  
After reaching around 80% confluent monolayer of the resistant cells, the culture medium 
was removed from the flasks. The flasks with no cells survived or overgrown cells were not 
used for the co-infection experiment. Therefore, only three flasks remained containing cells 
resistant to G418. The cell monolayer was washed once with DPBS and once with VGM. 
Next, the cells were infected with helper PR8 virus at MOI 0.1, and they were maintained in 
VGM without antibiotics. The flasks were incubated for 1.5 hours at 37°C with 5% CO2, with 
gentle rocking every 20 minutes. Then, the culture medium was discarded and replaced with 
fresh VGM without antibiotics, and they were incubated at 37°C with 5% CO2 for up to four 
days or until observing maximum CPE.  
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When >80% CPE observed, virus purification and HA assay titration was done for all the 
flasks containing infected cells (Section 2.11.3 and Section 4.2.2). 
 
4.2.6 Modifying the pCDNA/HAPR8-His6 pol I transfection procedure, and no cell 
selection 
The DNA plasmids were transfected into MDCK cells as previously described and following 
the manufacturers’‎ protocol.‎ However,‎ 24-well tissue culture plate was used for this 
experiment, thus the cell seeding density, reagents volume and DNA amount were different 
and were defined in the following sentences. 5 x 104 MDCK cells were seeded into each well 
of 24-well plate, and cells were maintained in 500 μL‎DMEM‎as‎described‎in‎Section‎4.2.4.‎
0.8‎ μg‎DNA‎was‎ transfected‎ on‎ the‎ next‎ day.‎The‎DNA‎and‎2‎μL‎of‎ lipofectamine® 2000 
transfection‎reagent‎were‎diluted‎in‎50‎μL‎Opti-MEM® I reduced serum separately, and then 
mixed‎together.‎100‎μL‎was‎the‎total‎volume‎added‎to‎the‎transfection‎sample,‎and‎as‎stated‎
before, the complex was prepared for each sample to be transfected. Two wells were not 
transfected and were used as negative controls. The plate was incubated for 24 hours at 
37°C with 5% CO2. 
 
In order to evaluate the transfection efficiency, an EGFP plasmid containing the enhanced 
green florescent protein was used. It was amplified and then isolated as described in 
Sections 2.13 and 2.11.1. Also, confirming the correct plasmid was undertaken by restriction 
enzyme digestion (ApaI and HindIII), and the DNA fragments were separated in 1% DNA 
grade agarose gel (Sections 2.7 and 2.12.2).  
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The whole transfection experiment was repeated as described previously, and two wells 
containing cells were used for EGFP transfection. After 24 hours incubation, cells were 
examined using the confocal laser scanning microscopy (CLSM) in order to observe the 
green fluorescence expression (two laser channels were used and the emission were 425 - 
475 and 500 - 550).  
 
4.2.7 Co-infection with PR8 helper viruses, virus re-propagation, titration and 
purification  
After 24 hours from DNA plasmid cell transfection, the cultured media was removed from all 
the wells and cells were washed once with DPBS and once with VGM. In order to define the 
optimum MOI for the transfection experiment, six wells (second row) from the 24-well plate 
with transfected cells were infected with helper PR8 virus at MOI 1.0, and another six wells 
(third row) were infected with PR8 at MOI 0.1. The two negative control wells were not 
infected. The cells and the virus were maintained in VGM without antibiotics. The plate was 
incubated for 1.5 hours at 37°C with 5% CO2, with gentle rocking every 20 minutes. Then, 
the media was discarded and replaced with fresh VGM without antibiotics, and the infected 
cells were incubated for 48 hours or until observing maximum CPE at 37°C with 5% CO2 
(Figure 4.5). 
 
After observing >80 % CPE, the media from the infected cell culture (in the 24-well plate) 
was transferred into 75 cm2 tissue culture flask containing cells, to obtain higher virus titer. 
Seven 75 cm2 tissue culture flasks were previously cultured with MDCK cells, and cells were 
80–85% confluent at the time for transferring the culture media from the infected cells. 
Before the transfer, the 75 cm2 flasks containing cells were washed once with DPBS and 
once with VGM. Then, culture medium from the wells containing infected cells was
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Figure 4.5: Schematic illustration of the plasmid DNA transfection experiment in this study 
using the 24-well tissue culture plate. All the colored wells were seeded with MDCK cells 
one day before transfecting the plasmids. 24 hours post-transfection, only the blue wells 
were co-transfected with PR8 helper virus at defined MOI. 
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Figure 4.5: Schematic illustration of the plasmid DNA transfection experiment in this 
Negative control wells, not transfected with DNA plasmid 
and not infected with PR8 virus 
 
Wells transfected with pCDNA/HAPR8-His6 Pol I plasmid, 
and co-infected with PR8 virus 
 
 
Wells transfected with EGFP plasmid only 
 
 
Unused wells 
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transferred into the tissue culture flasks. Supernatant from two wells was transferred into 
one 75 cm2 tissue culture flask with the addition of extra 3 mL VGM to completely cover the 
cell monolayer. The medium from the two negative controls wells was also transferred into 
one flask. All the flasks were incubated for 1.5 hours, and VGM was replaced with fresh 
VGM and it was supplemented with TPCK-trypsin (2 μg/mL). Addition of TPCK-trypsin to the 
medium is to support efficient virus replication of the low pathogenicity virus form by cleaving 
the HA0 (precursor protein) (Chawaree et al, 2009; Sun et al, 2010). 
 
The flasks were incubated until observing maximum CPE (see Section 2.11.2). After that, 
virus purification and virus titration (HA assay) were performed for all the flasks containing 
infected cells (Sections 2.11.3 and 4.2.2). 
 
4.2.8 SDS-PAGE and Immunoblotting 
SDS-PAGE and immunoblotting were used to detect the presence of the generated His 
tagged PR8 viruses among the helper PR8 viruses (Section 2.14.1). The SDS-PAGE gels 
(8%, 10% or 12%) were loaded with purified virus samples.  The PR8 helper virus (wild-type 
virus) was used as a negative control, and His tag recombinant protein was used as positive 
control. 
 
The loaded gels were subjected to either silver staining or Coomassie instant staining, and 
immunoblotting.‎The‎amount‎of‎ the‎virus‎sample‎loaded‎ into‎the‎gel‎was‎either‎5‎or‎10‎μL‎
from the purified virus samples according‎to‎the‎HAU‎obtained‎(10‎μL‎for‎6400‎HAU‎and‎5‎
μL‎for‎12800‎HAU).‎ 
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After electrophoresis, one gel was stained with silver staining (Section 2.14.3) or with 
coomassie instant staining (Section 2.14.2). The second gel was transferred onto 
nitrocellulose membrane for immunoblotting. The membrane was divided into two parts: one 
for immunoblotting with mouse anti-His IgG antibody (GE Healthcare, Sweden) diluted 
1:10000 in diluent, and the second part for immunoblotting with rabbit influenza (A/Puerto 
Rico/8/34) antiserum (WHO) diluted 1:6000 in diluent (see Section 2.14.4). The membranes 
were incubated with the primary antibody for two hours at RT or overnight at 4°C in the dark 
on a roller mixer.  
 
For the immunobloting assay with anti-His antibody, the secondary antibody used were 
rabbit anti-mouse IgG-HRP conjugate (Abcam, England) or rabbit anti-mouse IgG-AP 
conjugate (Abcam, England) diluted 1:10000 in diluent. For immunoblotting with PR8 
antiserum, the secondary antibody used was goat anti-rabbit-AP conjugate (Abcam, 
England) diluted 1:6000. The assay was developed using TMB single solution (Invitrogen, 
U.S.A.) for the HRP conjugated antibodies or using Western blue stabilized substrate 
(Promega, U.S.A.) for AP conjugated antibodies (refer to Section 2.14.4). 
 
4.2.9 Primers  
Forward and reverse primers were designed using the Sci ED Central software program 
(Table 4.1). The primers were used to detect the presence of the generated recombinant 
mRNA HA among the helper PR8 viruses. The primers were designed to target and amplify 
the HA mRNA domain containing the His6 tag. Primers were obtained as lyophilized samples 
from Geneworks, Australia. 
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Name Sequence 5`- 3` Description 
His6 forward CACCACCACCACCACCACAGT 
Forward primer for 
amplification of influenza 
PR8 HA-His6 domain 
His6 reverse CCTCCCAGCTTGATCTCTTACTTTG 
Reverse primer for 
amplification of influenza 
PR8 HA-His6 domain 
 
Table 4.1: The primers for the amplification of influenza PR8 HA-His6 domain used for this 
study. The blue sequence indicating a sequence encoding for His6 tag. 
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4.2.10 Virus RNA extraction  
The Isolate II RNA Mini kit (Bioline, Australia) was used to isolate the influenza PR8 RNA. 
The protocol used was obtained from the manufacturer with minor modifications and all the 
reagents‎used‎were‎provided‎with‎the‎kit.‎In‎an‎eppendorf‎tube,‎50‎μL‎purified‎virus‎samples‎
were‎ loaded‎ and‎mixed‎with‎ 350‎ μL‎ lysis‎ buffer.‎ The‎ viruses‎ samples‎ used‎were‎ for‎ the 
viruses propagated from the reverse genetics experiment and the wild-type PR8 virus. 
Sample was vortexed vigorously. Next, the sample lysate was transferred into a filter column 
placed in a collection tube (provided with the kit), and then centrifuged 11,000 x g for1 
minute.‎Then,‎350‎μL‎70%‎ethanol‎was‎added‎to‎the sample filtrate and mixed by vortexing. 
A clean mini column was placed in a collection tube, and then the sample lysate was loaded 
into the column and centrifuged at 11,000 x g for 30 seconds in order to bind the RNA to the 
silica membrane. Next, to dry the‎membrane,‎350‎μL‎membrane‎desalting‎buffer‎was‎loaded‎
in the column and centrifuged at 11,000 x g for 1 minute. After that, three washing steps 
were‎performed‎using‎washing‎buffers.‎The‎first‎wash‎was‎made‎with‎200‎μL‎wash‎buffer‎
named‎“RW1”.‎The‎second‎and‎third‎washes‎were‎made‎with‎600‎μL‎and‎250‎μl‎wash‎buffer‎
named‎“RW2”.‎After‎the‎first‎and‎second‎washes,‎the‎sample‎was‎centrifuged‎at‎11,000‎x‎g‎
for 30 seconds and the third wash 11,000 x g for 2 minutes. The final step was eluting the 
RNA with 40 μL‎RNAase-free water (supplied with the kit).  
 
The RNA quantity was measured using the NanoDrop 2000 spectrophotometer following the 
manufactures’‎instructions‎(Thermo‎Scientific,‎U.S.A).‎The‎Optical‎density‎(OD)‎of‎a‎solution‎
of RNA was estimated at a wavelength of 260 nm. The extracted RNA was visualized by 
loading the sample‎(5‎μL)‎on‎a‎2%‎agarose‎gel‎using‎a‎voltage‎of‎70‎and‎it‎was‎run‎for‎one‎
hour and 45 minutes. 
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4.2.11 Reverse-transcriptase (RT-PCR) 
Reverse transcription was performed to convert the vRNA into cDNA using the Thermoscript 
RT-PCR commercial system (Invitrogen, U.S.A). The protocol was adapted from the 
manufactures’‎ instructions‎ and‎ all‎ the‎ reagents‎ used‎were‎ supplied‎with‎ the‎ system.‎ In‎ a‎
PCR tube the following components were combined‎together;‎1‎μL‎oligo‎(dt)20,‎2‎μL‎10‎mM‎
dNTP‎mix,‎RNA‎(‎between‎10‎pg‎to‎5‎μg),‎and‎then‎the‎final‎volume‎was‎adjusted‎to‎12‎μL‎
with DEPC-treated water. Two samples of RNA were used: the RNA isolated from the virus 
propagated from the reverse genetics and the RNA isolated from the wild-type PR8 virus 
Next, the RNA was denatured by incubating at 65°C for five minutes using the GeneAmp 
PCR system 2400 and then placed on ice. This PCR machine was used for all the heating 
cycles during the cDNA synthesis procedure. Then, a master mix was prepared in another 
tube‎by‎adding‎4‎μL‎5x‎cDNA‎synthesis‎buffer,‎1‎μl‎0.1‎M‎DTT,‎1‎μL‎RNAseOUT™‎(40‎U/ 
μL),‎1‎μL‎DPEC-treated‎water‎and‎1‎μL‎Thermoscript™‎RT‎(15‎U/ μL).‎After‎that,‎8‎μL‎of‎the‎
master mix was pipetted into the previous reaction tube on ice, and then was heated for 50 
minutes at 50°C for cDNA synthesis. Then, the reaction was terminated by incubating at 
85°C‎for‎5‎minutes.‎1‎μL‎of‎RNase‎H‎was‎added‎and‎the‎tube‎was‎incubated‎for‎20‎minutes‎
at 37°C. The cDNA synthesis reaction was stored at -20°C until use. 
 
The synthesised cDNA was visualized on agarose gel as described is Section 2.12.2. 
 
4.2.13 PCR  
The PCR was performed according to the Taq polymerase‎ manufacturers’‎ instruction‎
(Promega, U.S.A). The reaction mix and the amplification conditions are listed in Table 4.2 
and Table 4.3. For the reactions, less than 200 ng DNA template was used, and the final 
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Reagent Volume (μL) 
Final 
concentration 
Go Taq® Green Master Mix, 2x 12.5  1x 
Forward primer (10 μm) 1 0.4 μm 
Reverse primer (10 μm) 1 0.4 μm 
DNA template 1-3 <200 ng 
Nuclease-free water to 25 N.A. 
Total reaction volume 25 N.A. 
 
Table 4.2: 25 μL‎reaction‎components for DNA amplification. 
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Step Temp (°C) Time 
Initial denaturation 95 1 min 
Denaturation 95 15 sec 
Annealing 55 15 sec 
Elongation 72 15 sec 
Number of cycles 35 N.A. 
Hold 4 ∞ 
 
Table 4.3: Amplification conditions for PCR.  
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reaction volume prepared was 25 μL.‎Reagent‎preparation‎was‎made‎aseptically,‎and‎the‎G-
storm PCR machine was used to amplify the DNA. 
 
Samples used for amplification were: cDNA for the vRNA extracted from virus propagated 
after the reverse genetics experiment, cDNA for the vRNA extracted from the wild-type PR8 
viruses (as a negative control), pCDNA/HAPR8-His6 pol I plasmid (as a positive control) and 
water (as a negative control). 
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4.3 Results 
 
4.3.1 Cell culture and virus propagation 
Maintaining healthy adherent cells free from contamination was successfully accomplished, 
and infecting the cells with the virus was done in cells showing around 80% confluency 
(Figure 4.6). Cytopathic effect (CPE), i.e. rounding up of cells and detachment of cells from 
the culture flask, was apparent between two to four days after infection. Incubation of the 
infected cells was stopped when CPE was observed on more than 80% of the cells (Figure 
4.7). The propagated viruses were isolated and successfully purified via 20% sucrose 
cushion, and the purification was performed for two  (75 cm2) flasks at the same time. The 
purified virus samples were stored at - 80°C until use.  
 
4.3.2 HA titration  
The purified viruses samples were obtained from a total of 12 (75 cm2) flasks, and all the 
samples were combined together in order to unify the final virus titer. After performing the 
HA assay, the result indicated a titer of 6400 HAU (Figure 4.8) that originated from infecting 
around 80% confluent cell monolayers with a 1:1000 diluted influenza virus stock (originally 
6400 HAU). 
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Figure 4.6: Photographic images of healthy MDCK cells under 4x magnification with: A) 
50% confluent cells, B) between 80 – 90% confluent cells and C) 100% confluent cells. 
Image B represents the ideal cells confluency for infecting with influenza virus. 
 
A 
B 
C 
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Figure 4.7: Photographic images under 10x magnification of: A) infected MDCK cells after 3 
days of around 80% confluent monolayer, and B) negative control MDCK cells, where no 
virus was introduced. 
 
 
 
 
 
 
 
A 
B 
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Figure 4.8: HA assay result for the propagated and purified influenza PR8 virus. The two 
wells in the first row are negative control (no virus introduced), and the test was performed in 
duplicate. The highest virus dilution showing complete hemagglutination is 1:6400, which 
represents the HAU (6400). 
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 4.3.3 Estimating the titer of the viral stock by TCID50 and the volume of the virus 
sample required at certain MOI 
The wells of the 96-well tissue culture plate were examined for the presence or absence of 
CPE, and were noted as positive or negative results. The end point of the CPE was 
recorded, which represents the highest viral dilution showing CPE of 50% of the cells. In 
order to confirm the results obtained from the TCID50 plate, an HA assay was performed by 
transferring culture medium from each well from the TCID50 plate to HA test plate as 
described Section 4.2.3 (Figure 4.9).  
 
Using the Reed-Muench method, the TCID50 titer was determined in the following: 
The proportional distance = 0.371 
Log infectious dose50 = 6.317 
Infectious dose50 titer = 10
7.317 ID50/mL 
Then, the TCID50 titer was converted to PFU and the result was 14,524,394.622 PFU/mL.  
From that, the virus amount required for certain MOI was calculated in Table 4.4. 
 
This virus stock was used throughout the whole study as the helper virus to generate the 
recombinant virus. 
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Figure 4.9: HA test for confirming the TCID50 results, which was undertaken by observing 
the highest viral dilution can infect 50% of the cells. The TCID50 was done in 5 times 
replicates‎and‎50‎μL‎ from‎each‎well‎was‎ transferred‎ into‎ the‎HA‎ test‎plate.‎The‎CPE‎end‎
point was between -6 and -7 of the log of viral dilution. 
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Culture dish 
Cells at 
confluency* 
Virus sample 
amount at MOI 1.0 
Virus sample 
amount at MOI 0.1 
96-well plate 3 x 104 2.06‎μL 0.20‎μL 
24-well plate 2 x 105 13.76‎μL 1.37‎μL 
12-well plate 4 x 105 27.53‎μL 2.75‎μL 
 
Table 4.4: Determining the virus sample amount required for certain MOI with different 
culture dishes. This was calculated following the result obtained from the TCID50 assay.  
* The number of cells was adapted from Life Technologies Corporation 2013. 
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4.3.4 pCDNA/HAPR8-His6 pol I plasmid transfection, and the transfeted-cell selection 
with G418 
The DNA plasmid was transfected the next day from seeding the cells, and the cell 
monolayer was around >95% confluent. 24 hours post-transfection, the cells from each well 
were sub-cultured into 25 cm2 tissue culture flasks and were maintained with the addition or 
without the addition of the G418 selectable antibiotic as described in Section 4.2.4. The cells 
(both transfected and non-transfected with DNA plasmid) maintained with media that does 
not include the G418 were overgrown (crowded) on the culture flask after five days 
incubation (Figure 4.10), and the non-transfected cells in the negative control flask were 
completely dead after 13 days from adding the selectable medium (Figure 4.11). The flasks 
containing the transfected cells and maintained with selectable medium, only the resistant 
clones survived and remained healthy. However, the resistant cells grew slowly, and it took 
17 days to obtain around 80% to 90% confluent cell monolayer (Figure 4.11). 
 
4.3.5 Co-infection with the helper virus, purification and virus titration 
The transfected cells that were selected using the G418  (refer to Section 4.3.4), were 
successfully co-infected with helper viruses. The CPE reached around 80% on the infected 
cells after 4 days of incubation. Then, the viruses were purified via a 20% sucrose cushion 
and virus titration was performed using the HA assay. The HAU obtained was 200, and this 
was considered a slightly low viral titer. 
 
 
 
 
CHAPTER 4 
 
 170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Photographic images under 10x magnification of cells after 5 days from 
maintaining the cells with culture medium supplemented or not supplemented with G418.   
A) Cells transfected with pCDNA/HAPR8-His6 pol I plasmid and maintained with selectable 
medium. B) Cells transfected with pCDNA/HAPR8-His6 pol I plasmid but no G418 added to 
the medium. C) Cells not transfected with the plasmid and no G418 was added to the 
medium. D) Cells not transected with the plasmid and maintained with selectable medium. 
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Figure 4.11: Photographic images under 10x magnification of selection for the 
pCDNA/HAPR8-His6 Pol I plasmid transfected cells by maintaining with culture medium 
supplemented with G418.  
A) Transfected cells after 13 days incubation. B) Non-transfected cells after 13 days 
incubation. C) Transfected cells after 17 days incubation. 
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4.3.6 Detection of the generated His tagged viruses by Immunoblotting 
The virus sample used for immunoblotting was the virus generated from reverse genetics 
experiment described in Sections 4.2.4 and 4.2.5 (transfected cells were selected using 
culture medium supplemented with G418 antibiotic before virus co-infection). The virus 
proteins were separated on SDS gel (see Section 4.2.6) and some of the viral major proteins 
were visualized on the gel after silver staining (Figure 4.12). HA protein was visualised as 
the uncleaved (HA0) form, which is approximately 75–80 kDa, and the cleaved HA1 and 
HA2 forms with an approximate molecular weight 46–50 kDa for HA1 and 27 kDa for HA2 
(Yewdell et al, 1988; Shaw et al, 2008; Hsu et al, 2011; Abdoli et al, 2014). However, on the 
Western blot membrane there was no band observed using the anti-His antibody, which 
suggests that the present of the recombinant viruses were not detected (Figure 4.13). 
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Figure 4.12: SDS-PAGE for purified PR8 influenza viruses. Samples were loaded into 8% 
polyacrylamide gel and stained with silver staining. HA could be seen in the uncleaved form 
(HA0 ~ 75 to 76 kDA) and the cleaved forms (HA1 ~ 42 to 46 kDA and HA2 = 27 kDa).  
Lane 1: recombinant His tagged protein (glycosylated, hence a smear) Lane 2: protein 
marker. Lane 3: purified PR8 virus sample after the reverse genetics experiment. Lane 4: 
purified parent PR8 virus sample. 
* Protein band assignments based on literature data (Caton & Browniee, 1982; Shaw et al, 2008; Hsu 
et al, 2011; Abdoli et al, 2014). 
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Figure 4.13: Western Blot for purified PR8 influenza viruses after reverse genetics 
experiment. Anti-His antibody was used for Western Blot in order to detect the presence of 
the His tagged influenza viruses. However, no band was observed. 
Lane 1: recombinant His tagged protein (control). Lane 2: protein marker. Lane 3: purified 
virus sample after the reverse genetics experiment. Lane 4: purified parent PR8 virus 
sample (negative control). 
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4.3.7 Re-transfection of the pCDNA/HAPR8-His6 Pol I plasmid and co-infection with 
helper viruses 
The transfection and the helper virus co-infection were repeated with some changes made 
to the methods described in Section 4.2.6 and Section 4.2.7. 
 
The efficiency of the plasmid DNA transfection was evaluated by transfecting a DNA plasmid 
encoding for green fluorescent protein (GFP). 24 hours post-transfection, the cells were 
examined under CLSM for the green fluorescent expression, and around 35-40% of the cells 
were seen with green color (Figure 4.14). This indicated that around 35-40% of the cells 
were successfully transfected with the plasmid, which may also mean that the 
pCDNA/HAPR8-His6 Pol I plasmid could be transfected into the cells with a similar 
percentage.  
 
The wells containing transfected cells (total of 12 wells) were infected with helper PR8 virus 
at MOI 0.1 and at MOI 1.0 (six wells for each MOI). After 48 hours incubation, the infected 
culture media was transferred into 75 cm2 tissue culture flasks as described in Section 4.2.7. 
The CPE was observed on 80% of the infected cells after incubation for 2 days. Then 
purification of the virus from the cell culture was performed, and HA assay titration was 
done. For the cells infected at MOI 0.1 and the cells infected at MOI 1.0, the HAU obtained 
was 12800 for both. Thus, apparently there was no difference from infecting the cells at MOI 
1.0 or at MOI 0.1, and therefore MOI 0.1 will be used for performing the reverse genetics 
experiment when required again.  
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Figure 4.14: Photographic images of the EGFP 24 hours post-transfected cells under 4x 
magnification using the confocal laser scanning laser microscopy (CLSM).  
(A) Image for cells with the laser scanning only. (B) Image for cells with laser and bright field 
light. 
 
A 
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4.3.8 SDS-PAGE and Immunoblotting 
The purified virus samples used here were the one propagated from the previous reverse 
genetics experiment (Section 4.3.7). The virus was loaded into 10% polyacrylamide gel. The 
separated viral proteins were visualized on the gel that was stained with Coomassie instant 
stain (Figure 4.15), and the proteins bands appeared on the gel were more defined 
comparing them with the bands visualized using the silver staining on 8% SDS gel. The 
separated viral proteins that were observed on the gel possibly represents: the HA dimer 
(molecular weight around 137 kDa), HA precursor (HA0 with a M.W. around 75 kDa), 
nucleoprotein (M.W. around 60 kDa), neuraminidase (M.W. around 55 kDa) and the cleaved 
HA forms HA1 and HA2 (M.W. around 42 to 46 kDa and 27 kDA respectively) (Caton and 
Browniee, 1982; Yewdell et al, 1988; Palamara et al, 2005; Shaw et al, 2008; Hsu et al, 
2011; Abdoli et al, 2014).  
 
 The immunobloting was performed using anti-His antibody and PR8 antiserum as primary 
antibodies (Figure 4.16). The PR8 antiserum was successfully recognised HA, NA (or could 
be NP) and M1 (matrix protein) viral proteins. The virus antiserum was used in order to 
confirm the immunoblotting efficiency and the present of the virus particles. However, the 
membrane probed with anti-His antibody again failed to detect the possible generated 
recombinant virus. 
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Figure 4.15: Influenza virus proteins separated with SDS-PAGE. Samples were loaded into 
10% polyacrylamide gel and stained with Coomassie instant stain. The protein bands 
possibly represents: HA dimer (~ 137 kDa), uncleaved HA0 (~ 75 kDa), NP (~ 56-60 kDa), 
NA (~ 55 kDa) and the cleaved HA1 and HA2 (~ 42-46 kDA for HA1 and 27 kDa for HA2). 
Lane 1: purified PR8 virus sample after the reverse genetics experiment and cells were 
infected at MOI 1.0. Lane 2: purified PR8 virus sample after the reverse genetics experiment 
and cells were infected at MOI 0.1. Lane 3: purified parent PR8 virus sample. Lane 4: 
protein marker. 
* Protein band assignments based on literature data (Caton & Browniee, 1982; Yewdell et al, 1988; 
Palamara et al, 2005; Shaw et al, 2008; Hsu et al, 2011; Abdoli et al, 2014). 
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Figure 4.16: Western Blot for purified PR8 influenza viruses after reverse genetics 
experiment.  
A) The immunoblot using PR8 antiserum. B) The immunoblot using anti-His antibody. The 
PR8 antiserum was used as a control for the Western Blot efficiency. There was no band 
detected using the anti-His antibody. 
Lane 1: purified parent PR8 virus sample (negative control). Lane 2: purified PR8 virus 
sample after the reverse genetics experiment and cells were infected at MOI 0.1. Lane 2: 
purified PR8 virus sample after the reverse genetics experiment and cells were infected at 
MOI 1.0. Lane 4: protein marker. 
* Protein band assignments based on literature data (Yewdell et al, 1988; Palamara et al, 2005; Shaw 
et al, 2008; Hsu et al, 2011; Abdoli et al, 2014). 
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4.3.9 Viral RNA isolation and cDNA synthsis 
The vRNA was successfully isolated using the Isolate II RNA Mini kit (Bioline, Australia). The 
isolated RNA concentration was estimated using a Nanodrop 2000 spectrophotometer at 
260 nm, and the results indicated that the sample contained an average of 30 ng/μL‎of‎RNA.‎
A range between 100 to 350 ng RNA was used as a template for cDNA synthesis using the 
Thermoscript RT-PCR‎system‎(Invitrogen,‎U.S.A).‎An‎approximate‎of‎1.8‎μg/μL‎cDNA‎was‎
generated from the reaction. A 2% agarose was prepared to visualize the isolated RNA 
(Figure 4.17) and a 1.5% agarose was used to observe the cDNA (Figure 4.18). Both RNA 
and cDNA were successfully observed on the agarose gel. 
 
4.3.10 Detecting the presence of the synthesised recombinant cDNA from the parental 
recombinant mRNA using PCR 
Immunoblotting using the anti-His antibody failed to detect the present of the His tagged 
influenza PR8 viruses. In order to confirm if there was a recombinant mRNA, which indicates 
the presence of the recombinant HA protein, specific primers were designed to target and 
amplify part of the mRNA from the HA protein containing the 6x His. Before that, the vRNA 
was converted to cDNA by performing reverse transcription (Section 4.3.9). The PCR was 
performed as described in Section 4.2.13 and the amount of cDNA used for the amplification 
was less than 200 ng per one reaction. After the PCR was completed, the amplified samples 
were visualized on 1.5% agarose gel (Figure 4.19). The expected size of the amplified 
region was 269 bp. The correct band size was successfully observed on the gel only for the 
sample containing the cDNA of the viruses produced from the reverse genetics experiment. 
This indicated that the recombinant mRNA of the HA with the His6 was present. 
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Figure 4.17: The isolated RNA on 2% agarose gel.  
Lane 1: PstI/λ-DNA marker. Lane 2 & 3: extracted RNA from PR8 viruses after the reverse 
genetics experiment. Lane 4: extracted RNA from wild-type (parent) PR8 viruses. 
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Figure 4.18: The generated cDNA on 1.5% agarose gel.  
Lane 1: PstI/λ-DNA marker. Lane 2 & 3: synthesised cDNA originated from PR8 viruses after 
the reverse genetics experiment. Lane 4: synthesised cDNA originated from wild-type 
(parent) PR8 viruses. 
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Figure 4.19: PCR amplification of the 6 x His region from the cDNA synthesised from the 
extracted vRNA. The size of the expected amplified area is 269 bp. 
Lane‎ 1:‎ Hyperladder™‎ II‎ marker.‎ Lane‎ 2:‎ pCDNA/HAPR8-His6 Pol I plasmid (positive 
control). Lane 3: viral cDNA synthesised from the extracted viral mRNA from viruses 
propagated after reverse genetics experiment. Lane 4: cDNA synthesised from the extracted 
viral mRNA from the wild (parent) PR8 virus (negative control). Lane 5: water (negative 
control). 
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4.4 Discussion 
 
Propagating the influenza PR8 virus in MDCK cells and having a moderately high virus titer 
was successfully achieved. However, some factors were noticed to somehow affect the 
influenza virus propagation and resulted in a low virus titer (HAU between 100 – 400) (data 
not shown). Infecting cells having a >90% confluent cell monolayer, at 24 hours post-
infection cells were overgrown and there was no obvious CPE observed in the infected cells 
until the third or fourth day. Also, the CPE was observed at less than 50% confluence of the 
infected cells monolayer (results not shown). This indicated that the ideal percentage for the 
cell monolayer to be infected with the influenza virus is around 80%, because when the cells 
are overlapping they will be less sensitive to virus infection (Szretter et al, 2006, Krauss et 
al, 2012). Moreover, the culture medium for maintaining the cells and the virus growth after 
virus infection is preferred to be without sodium pyruvate. It had been noticed that the virus 
growth medium supplemented with sodium pyruvate was changed from red (neutral pH) to 
orange (low pH) after incubation for 2 days (results not shown) during virus propagation. The 
low pH medium has affected the health of the cells, and thus virus propagation was also 
affected. Therefore, it is recommended to use culture medium not supplemented with 
sodium pyruvate during influenza virus propagation to obtain high virus titer level.  
 
Quantifying the number of viral infectious particles in the purified virus stock was achieved 
using the TCID50 method. Although it is an old technique and time consuming, it is an 
important step in viral experiments and preparation. As shown from the results, the 
transfected cells that were co-infected with helper viruses at MOI 1.0 did not achieve a 
higher virus HAU in comparison to co-infection at MOI 0.1. A study was undertaken to 
monitor the influenza virus shedding at different times and also to optimise the virus MOI by 
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infecting MDCK cells with five different MOI (Abdoli et al, 2013). They have considered 
infection at MOI 1.0 and 0.1 as a high MOI inoculation, where as infecting at MOI 0.01, MOI 
0.001 and MOI 0.0001 were considered as low MOI inoculation (Abdoli et al, 2013). 
However, after 48 hours post-infection, the HA units for all the MOI were the same (Abdoli et 
al, 2013). This is in agreement with the findings here, where on MOI of 1.0 and 0.1 gave the 
same final HAU. 
 
The ability to increase the chances of generating recombinant viruses at higher titer among 
the helper viruses was not successful. It was performed by selecting for the cells that were 
positively transfected with the pCDNA/HAPR8-His6 pol I plasmid, and then co-infected with 
helper viruses. The cell clones that were resistant to G418 antibiotic were successfully 
selected from the non-transfected cells. However, the long time incubation required for the 
cell selection may have resulted in the loss of the synthesised viral like vRNA within the cell 
nucleus, and thus no recombinant virus would be generated. The Neo resistant gene is 
under the control of SV40 promoter, and after a successful cell transfection it will be 
integrated‎with‎the‎host’s‎DNA‎and‎will‎be‎carried‎along‎the‎cell‎division‎cycles‎and‎promote‎
cellular resistant to G418 (Chen & Okayama, 1987).  
 
Most of the studies used to select for the transfected cells are with recombinant retroviruses. 
Retroviruses genomes are able to integrate into the host cell genome (Jern & Coffin, 2008). 
Therefore, when it is synthesised from a cDNA, it will be stably transfected, and remain 
carried and expressed for along period of time (Cone & Mulligan, 1984; Morgenstern & 
Land, 1990). However, in the case of synthesising the influenza vRNA from cloned cDNA, it 
is only a transient transfection, as the viral genome not able to integrate with the host cell 
genome.  Moreover, the low HAU obtained after cell selection experiment could be related to 
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the fact that cells were under selective pressure, and cells might be less sensitive to viral 
infection under this condition. 
 
The transfection efficiency was assessed by transfecting the cells with a DNA plasmid 
encoding an EGFP protein, and the positively transfected cells were expressing green 
fluorescence protein. From that, it was expected that approximately 35-40% of the cells were 
successfully transfected with pCDNA/HAPR8-His6 Pol I plasmids. The percentage obtained 
for the transfected cells was a little lower than the percentage estimated by the 
Lipofectamine® 2000 manufacturer (Invitrogen, U.S.A), which is 43% (Table 4.5). However, 
this is an acceptable transfection frequency. 
 
After 24 hours from transfecting the cells with the pCDNA/HAPR8-His6 pol I plasmid, the 
cells were co-infected with helper influenza viruses. These helper viruses will provide the 
RNA polymerase and the NP, which is expected to transcribe and replicate the previously 
transfected recombinant vRNA in the host cell nucleus. After the replication of the 
recombinant vRNA, RNP will be synthesised and then exported from the cell nucleus to be 
packaged along with the remaining vRNAs (Hutchinson & Fodor, 2013).  
 
Detecting the possible generated His tagged PR8 viruses by immunoblotting using anti-His 
antibody was failed. There are many possibilities that could lead to the unsuccessful 
detection of the recombinant viruses. Generating recombinant viruses using cDNA cloned 
for recombinant vRNA, and with the need for helper viruses, will result in progeny viruses of 
which the large majority are helper viruses (Li et al, 2013). Therefore, the recombinant 
viruses could be generated but were in very low titer, and they were below the Western blot 
detection limit. It also may be that the antibody affinity to the target His tag was low
CHAPTER 4 
 
 187 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5: Lipofectamine® 2000 cell list and transfection efficiency.  
Table adapted from Invitrogen
™
.  
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and this led to low detectabion levels. The other prospect is that the recombinant vRNAs 
were not packaged into new virions and were eliminated due to insufficient packaging 
signals from the modified vRNAs. One of the factors that could affect the segment-specific 
packaging signals is mutation and therefore the vRNA may not be selected for virion 
packaging (Hutchinson et al, 2010). Also, during genome packaging RNAs have to compete 
in order to be selected in terms of having significant replicative advantages (Hutchinson et 
al, 2010). When having a mixture of parent (wild-type) RNAs and modified RNAs, the parent 
RNAs may be more likely to be selected for. This could explain why the majority of produced 
viruses are wild-type viruses (helper viruses). 
 
In order to investigate the possible presence of the recombinant PR8 viruses, primers 
targeting the His6 region within the viral mRNA HA were designed. For performing the PCR 
amplification, the parent (wild-type) PR8 vRNA was used as a negative control to ensure 
that the amplification will be made only for the recombinant mRNA. As shown in the results, 
a correct band size was observed only with the virus cDNA sample obtained from the 
reverse genetics experiment. Therefore, the previous concept suggesting that the modified 
vRNA may not be packaged is declined here, as the recombinant mRNA was detected. This 
indicated that the recombinant vRNA HA was packaged and it was assembled into virion 
along with the remaining vRNAs. 
 
There are two possibilities that can be proposed from the results obtained in this chapter: 1) 
the recombinant viruses could be present but in a very low level that cannot be detected, 2) 
the His tagged epitope is not within an exposed region or partially exposed on the virus 
surface, and it is not located as it was predicted by the structural model.  
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In summary, the presence of the recombinant viral mRNA was successfully detected by 
PCR. More work is needed in order to confirm that the recombinant virus can be captured by 
the anti-His antibody, and it can be detected with the anti-His antibody. The sensitivity level 
of the immnunobloting may not be sufficient to detect the His tagged virus. Thus, developing 
Western Blot using the enhanced chemiluminescence (ECL) is to be performed. Also, using 
a monoclonal anti-His antibody targeting partially exposed His6 tags is to be explored. 
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5.1 Introduction 
 
The generation of recombinant influenza virus using the helper virus-based method results 
in combination of helper and recombinant progeny viruses. However, the majority of progeny 
viruses are helper viruses (Neumann & Kawaoka, 2001; Li et al, 2013).  
 
In the previous chapter, the generation of the His tagged PR8 virus was confirmed by 
detecting the recombinant viral mRNA using PCR. However, using an immunological 
technique, the Western blot, the tagged protein was not detected. Improving the detection 
ability of the viral His tagged protein might be achievable using other techniques.  
 
As the His tagged virus would be present in a low level amongst the wild-type virus, finding a 
method to concentrate the His tagged viruses may increase the chance of the detection 
using an anti-His antibody. A small-scale batch affinity purification method is suitable for the 
applications that involve a small sample volume. The wash and elution fractions are 
separated from the beads by centrifugation, and the purified product can be analysed by 
Western blot detection technique. 
 
Also, another technique can improve the His tagged protein immunodetection, is by using 
the enhanced chemilumenescence (ECL) assay for Western blot membrane development. 
The interaction between a low-abundance target protein and an enzyme conjugated 
antibody may produce a higher sensitivity signal. ECL detection reagents have higher 
sensitivity compared to standard colorimetric reagents for detecting low signals on the 
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Western blot membrane. Moreover, commercially available monoclonal antibodies with high 
affinity, which can bind to even partially accessible His tags within the recombinant proteins, 
may enhance immunodetection. 
 
Molecular dynamics (MD) simulation is an important tool that allows studies of protein 
structure by tracking the molecular motion on an atomic scale (Lindahl, 2008). MD provides 
a link between the macroscopic observation (laboratory) and the microscopic behaviour 
(atomic level) (Adcock & McCammon, 2006; Cuendet, 2008). In another words it act like a 
bridge between theory and experiment (Lee et al, 2009).  Aspects of bimolecular structure 
that can be analysed using MD include protein stability, folding and conformational changes 
(Adcock & McCammon; 2006; Cuendet, 2008).  
 
The main purpose of performing the MD simulation is to confirm the stability of the HA after 
the poly-His tag addition at physiological conditions, and to assess the stability by comparing 
it with the wild-type HA during simulation.  
 
The aims of work described in this chapter were as follows: 
- To examine the ability to isolate the His tagged viruses using the batch purification 
technique. 
- To develop the Western blot method using the chemiluminescence assay. 
- To use a high affinity anti-His antibody with the Western blot procedure. 
- To employ a prediction technique to analyse the predicted recombinant HA 
secondary structure. 
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- To apply a new structural model for the recombinant HA protein and compare it with 
the one generated earlier (three years ago).  
- To build a molecular dynamics simulation system for the HA protein, and determine 
the stability of the mutant protein relative to the wild-type one. 
- To perform the reverse genetics experiment, and use the previously generated virus 
(containing a mixture of helper and recombinant viruses) as the helper virus. 
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5.2 Materials and Methods 
 
5.2.1 Batch affinity purification 
The following protocol was obtained from Thermo Fisher Scientific with some 
modification.150 μL‎ of‎ pre-charged 50% Ni-NTA agarose (Invitrogen, U.S.A.) was loaded 
into microcentrifuge tube. The resin was washed twice with 20 mM binding buffer [0.50 mL 2 
M imidazole, pH 7.4 (GE Healthcare, Sweden), 6.25 mL phosphate buffer stock solution, pH 
7.4 (GE Healthcare, Sweden), and up to 50 mL dH2O], and was centrifuged for 2-3 minutes 
at high speed.‎Next,‎ a‎100‎μL‎of‎ the‎purified‎ virus‎ sample,‎which‎was‎produced‎ from‎ the‎
reverse‎genetics‎experiment‎ (HAU‎12800),‎was‎diluted‎with‎100‎μL‎20‎mM‎binding‎buffer‎
and then added to the washed resin. The virus-resin mixture was gently flicked and 
incubated for two hours at 4°C with agitating to allow the binding of the His6 tagged viruses 
to the charged resin.  The mixture was then centrifuged at high speed for 2 minutes, and the 
supernatant was carefully removed and saved in microcentrifuge tube for analysis.  
Afterwards,‎ a‎ 75‎ μL‎ of‎ 50‎ mM‎ washing‎ buffer‎ [1.25‎ mL‎ 2‎ M‎ imidazole,‎ pH‎ 7.4‎ (GE‎
Healthcare, Sweden), 6.25 mL phosphate buffer stock solution, pH 7.4 (GE Healthcare, 
Sweden), and up to 50 mL dH2O] was added, and centrifuged for 1 minute at high speed. 
The washing step was repeated three times and the washed solution was saved for 
analysis.‎Finally,‎ a‎50‎μL‎of‎ 500‎mM‎elution‎buffer‎ [12.50‎mL‎2‎M‎ imidazole,‎ pH‎7.4‎ (GE‎
Healthcare, Sweden), 6.25 mL phosphate buffer stock solution, pH 7.4 (GE Healthcare, 
Sweden), and up to 50 mL dH2O] was added and incubated for five minutes at room 
temperature. The tube was then centrifuged at high speed for one minute and the 
supernatant (eluted sample) was transferred to a clean tube for analysis. 
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5.2.2 Developing Western blot membrane using enhanced chemiluminescent 
(ECL) assay 
ECL was performed after the completion of SDS-PAGE (as described in Section 2.14.1), 
and the immunoblotting (as described in sections 2.14.4 and 4.2.8) until the washing of the 
secondary antibodies. The secondary antibody used was HRP conjugated. 
 
The membrane was then placed in a container and incubated with 1 mL chemiluminescent 
Peroxidise Substrate-3 mixture (Sigma-Aldrich, Germany) in a dark room for 3-5 minutes 
(refer to Section 2.4). Then, it was placed between transparent sheets inside a photographic 
cassette. An X-ray film (Amersham Hyperfilm ECL) was placed on top of the transparent 
sheet and allowed to expose for up to five minutes. The exposed film was developed by 
placing it in a developer solution (refer to Section 2.4) for up to one minute, and then rinsed 
with water for one minute. The film was then placed in fixer solution (refer to Section 2.4) for 
five minutes, and rinsed with water for 10 minutes. The film was allowed to dry and then 
analysed. 
 
5.2.3 Detecting the tagged-virus using high affinity anti-His antibody 
The™‎ His-tag mAb (Genscript®) was applied for detection. This antibody has higher 
sensitivity and reactivity than the previously used anti-His Ab (GE Healthcare, Sweden). It 
can bind to a partially exposed His tag and can recognise His tagged proteins at levels of 5 
ng/mL.  
 
The SDS-PAGE and immunoblotting was performed as previously described (Section 4.2.8), 
with the exception of the primary antibody used. The primary antibody‎(The™‎His-tag mAb, 
Genscript®) was diluted 1:10000 in antibody diluent buffer, and was incubated with the 
membrane for two hours at RT. The secondary antibody used was rabbit anti-mouse IgG. It 
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was either an HRP or AP conjugated antibody. The HRP conjugated antibody was used with 
the membrane to be developed with ECL, while the AP conjugated was used with the 
membrane to be developed using Western Blue® stabilized substrate. The ECL assay was 
performed as described in the previous section (Section 5.2.2). For the x-ray film exposure 
step, several exposure times (2, 5, 20, and 60 minutes) were tested to detect the desired 
band.  
 
5.2.4 Analysing of selected profiles of the predicted secondary structure using 
I-TASSER approach 
I-TASSER is a hierarchical method for the prediction of protein structure and function based 
on multiple threading alignment approaches (Zhang, 2008; Yang & Zhang, 2015a). For a 
given query sequence, the output from the I-TASSER server prediction of each residue 
includes secondary structure prediction, solvent accessibility and normalized B-factor (Roy 
et al, 2011). Other output data generated by I-TASSER includes threading alignment for top 
10 homologous protein templates identified using the LOMETS method, and up to five full-
length atomic models (Roy et al, 2011).  
 
Secondary structure is predicted using the protein secondary structure prediction program 
(PSSpred), which is based on combining seven neural network predictors from multiple PSI-
BLAST and parameters (Yang & Zhang, 2015b). The result is presented as: alpha-helix (H), 
beta-strand (S) or coil (C), and it includes a prediction confidence score for each residue 
ranging from 0 to 9, where 0 represents low confidence and 9 represents high confidence 
(Roy et al, 2011).  
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Solvent accessibility of the target sequence is predicted by the SOLVE program at different 
cutoffs (Yang et al, 2015). Predicted solvent accessibility values range from 0 to 9, where 0 
represents a buried residue and 9 represents a highly exposed residue (Roy et al, 2011).  
 
The B-factor distribution or the flexibility profile of a protein provides an important indicator of 
the‎protein’s‎structure,‎which‎suggests‎ its‎dynamics‎and‎flexibility‎ (Yuan,‎et al, 2005). The 
normalized B-factor (or so-called B-factor profile, BFP) predicted by ResQ uses a 
combination of template-based assignment and profile-based prediction (Yang & Zhang, 
2015a). Residues with negative or close to zero BFP values are often structurally more 
stable, whereas BSP values higher than zero are more flexible (Yang & Zhang, 2015a; Yang 
& Zhang, 2015b).  
 
The protein sequence for the His tagged HA and the wild-type HA was submitted to the I-
TASSER server to compare and analyse the predicted secondary structure, solvent 
accessibility and normalized B-factor for both proteins. 
 
5.2.5 Predicting a latest HA-His6 structural model by Swiss Model 
The protein sequence of the recombinant HA was submitted to the Swiss Model workspace 
in November 2014 to predict the latest tertiary structure model as described in Section 3.2.1. 
The newly obtained model was compared with the earliest one that was predicted in late 
August 2011. 
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5.2.6 Generating a molecular dynamics simulation system for the His tag HA 
and the wild-type HA proteins 
Molecular dynamics is a method that computes the motions of each individual atom or 
molecule‎ according‎ to‎ Newton’s‎ integrated‎ equations‎ of‎ motion‎ as‎ below‎ (Lindahl,‎ 2008;‎
Durrant & McCammon, 2011), 
 
        
  
  
   
   
   
 
 
where    is the force acting upon the particle at time  ,    is the mass of the particle,    is 
the velocity and     is the particle position. Updating the position of each atom can be 
defined‎by‎numerically‎solving‎Newton’s‎equation‎at‎each‎step‎ time.‎The‎molecular‎ forces‎
acting on each atom rules the atoms movement and changes their position at each time 
frame (Drrant & McCammon, 2011). These potential (force fields) are arisen from bonded 
(chemical bonds, atomic angles) and non-bonded (Lennard-Jones 6-12 potential, 
electrostatic) atomic interaction, which can be solved using various numerical integration 
methods (Lindahl, 2008; Drrant & McCammon, 2011). 
 
The simulation system used for this study was the classical MD with the GROningen 
Machine for Chemical Simulations (GROMACS) package. GROMACS is an MD package 
that was designed for proteins, lipids and nucleic acid simulation. GROMACS version 4.6.3 
with the CHARMM36 force field was used to perform the calculations required to build the 
simulation system. The MD simulation consists of: 1) preparation of the starting structure, 2) 
creating a simulating box, 3) neutralizing the system, 4) energy minimization, 5) equilibrating 
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the structure with simulation, and 6) analysing the trajectory data (Figure 5.1) (Lindahl, 
2008).  
 
Both proteins have been simulated at 310 K for 100 ns. Therefore, two sets of trajectories 
have been obtained using GROMACS. 
 
After making the topology file from the PDB structure for both proteins, a simulation box was 
constructed with selected proportions. The dimension of each box was 120 x 120 x 120 Å. 
Water molecules were gradually added in the box until water density reached ~1.0 g/cm3 to 
solvate the protein. Then, counter ions (Cl-) were added to the system to neutralize the net 
charge. Before running the simulation, energy minimization was applied to remove any steric 
clashes or inappropriate geometries  (Lindahl, 2008). Steepest descent energy minimization 
method was performed to reach the lowest possible local energy point. 
 
The starting proteins structures used were for the His tag HA and the wild-type HA, which 
were built by Swiss Model in late 2014 (Section 3.2.1 and Section 5.2.5).  
 
The equilibration of the system consists of constant pressure simulation at T = 310 K, P = 1 
bar with protein atoms restrained to allow the solvent around the solute to relax. The system 
was equilibrated when the protein was allowed to move. At the end of the simulation, 
stability of the His tag HA protein was compared to the wild-type HA protein by analysing the 
RMSD (root mean square deviation). Structural representation and visualization of both 
systems was performed using VMD (Humphrey et al, 1996). The time-steps of 2 ps were 
 
CHAPTER 5 
 
 200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Molecular dynamics simulation workflow. 
Figure obtained Manchester Institute of Biotechnology, accessed in 2015. 
http://2013.igem.org/Team:Manchester 
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used to integrate the equation of motion, and the simulation was updated every 10 steps. 
The pressure and thermostat coupling used were the Parrinello-Rahman barostate and the 
Bussi’s‎thermostat,‎respectively‎‎(Parrinello‎&‎Rahman,‎1980;‎Bussi‎et al, 2007). For treating 
the electrostatics, Particle Mesh Ewald summation was used (Essmann et al, 1995). 
 
5.2.7 Performing the reverse genetics experiment using the virus propagated 
from previous R.G. experiment as the helper virus, and investigating the 
persistence of the His tagged virus  
The purified virus sample that was obtained after reverse genetics (R.G.) experiment (refer 
to Section 4.2.6) contains a combination of progeny helper virus (wild-type virus) and His 
tagged virus. As it was previously confirmed that this sample contains a recombinant virus 
by PCR detection (Section 4.3.10), it was used as the helper virus for the R.G. described 
here. This experiment was performed to test whether using the first-generation viruses from 
the reverse genetics makes it possible to increase the production of the second-generation 
recombinant viruses amongst the non-recombinant viruses, which then increase the 
detection ability using an anti-his antibody. 
 
One day before transfecting the pCDNA/HAPR8-His6 pol I plasmid, a 24-well tissue culture 
plate was seeded with 4.5 x 104 MDCK cells, expecting the cells to be ~ 90% confluent at the 
time of transfection.  The transfection was performed as described earlier in Section 4.2.6. 
Two wells were transfected with EGFP plasmid to evaluate the transfection efficiency. After 
24 hours from plasmid transfection, cells were co-infected with helper virus. Four wells 
containing transfected cells were infected with wild-type PR8 helper virus at MOI 0.1 (1.37 
μL/‎ each‎ well,‎ refer‎ to‎ Table‎ 4.4).‎ Another‎ four‎ wells‎ were‎ infected‎ with‎ the‎ generated‎
influenza virus (G.PR8) from the last reverse genetics experiment as the helper virus 
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(containing a mixture of wild-type PR8 and His tagged PR8). The amount of G.PR8 used to 
co-infect‎the‎cells‎was‎1‎μL/‎each‎well‎(original‎HAU‎6400),‎as‎the‎PFU‎for‎the‎G.PR8‎was‎
unknown (see Section 4.2.7 for co-infection protocol). The performed reverse genetics is 
illustrated in Figure 5.2. After completing the transfection and co-infection experiments, the 
culture media of infected cells were collected from two wells and transferred into one 75 cm2 
flask containing ~ 80% confluent cell monolayer (refer to Section 4.2.7 for more details). The 
flasks were incubated until observing maximum CPE on cells.  
 
Virus purification and HA assay were performed for all flasks containing infected cells as 
described in Sections 2.11.3 and 4.2.2.  After that, RNA isolation, cDNA synthesis and PCR 
were performed to detect the presence of the generated recombinant HA mRNA as 
explained in Sections 4.2.10, 4.2.12 and 4.2.13. 
 
SDS-PAGE and immunoblotting were performed to detect the presence of the His tagged 
HA‎protein‎using‎The™‎His-tag mAb (Genscript®) as the primary antibody (refer to Section 
4.2.8 and Section 5.2.3 for more details). Two membranes were prepared, one was 
developed using the Western Blue® stabilized substrate and the other was developed using 
the ECL assay as described previously (Section 5.2.2 and Section 5.2.3). 
 
The presence of the His tagged virus was investigated by passaging the generated virus 
from reverse genetics (described in Section 4.2.6 and Section 4.2.7) for the third time 
(starting from the first generation produced after the R.G.). The virus re-propagation was 
performed in MDCK cells as described in Section 2.11.2. The presence of the recombinant
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Figure 5.2: Reverse genetics experiment workflow.
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virus among the third generation-propagated viruses was examined by PCR and Western 
blot techniques along with the previous R.G. experiment.  
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5.3 Results 
 
5.3.1 Isolation of the His tag virus by batch purification  
The separated supernatant from incubating the virus-resin mixture, the solution saved from 
all three washing steps and the eluted sample were loaded into a 12% SDS gel. After protein 
separation (Figure 5.3), the viral protein bands from the supernatant sample were the 
highest in intensity comparing to the other samples (with the exception to the virus sample 
loaded as a control). The band intensity indicates the quantity of the viral proteins available 
within the loaded sample, hence, the virus amount. The virus quantity was decreased with 
the three washes, and in the third wash, the viral proteins were hardly observed. With the 
eluted virus sample, faint bands for the viral proteins were observed that possibly represents 
the isolated His tagged virus. 
 
5.3.2 Immunodetection for the isolated His tagged virus 
Viral proteins were transferred into two membranes for Western blot detection. First 
membrane was developed with substrate for AP conjugated antibody (see Section 5.2.3), 
and the second membrane was developed by ECL assay as described in Section 5.2.2. 
 
From the scanned Western blot membrane and the membrane exposed to an x-ray film 
(Figure 5.4), there were no His tagged proteins detected. The His tagged HA was not 
observed with the eluted sample from the batch affinity purification technique, as well as all 
the loaded samples. 
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Figure 5.3: Influenza virus proteins separated with SDS-PAGE after affinity batch 
purification. Virus samples contain a combination of wild-type PR8 and His tag PR8 viruses 
(obtained from R.G. experiment), and were loaded into 12% polyacrylamide gel and stained 
with Coomassie instant staining. The protein bands marked with red box may represent 
uncleaved HA0 (~ 75 kDa*), and HA1 (~ 42-46 kDA*) and HA2 (27 kDa*) subunits. 
Lane 1: protein marker. Lane 2 & 3:  virus samples from reverse genetics experiment (before 
batch purification). Lane 4:  eluted sample. Lane 5: supernatant sample after virus 
incubation with the resin. Lane 6:  1st washed sample. Lane 7:  2nd washed sample. Lane 8:  
3rd washed sample. 
* Protein band assignments based on literature data (Caton & Browniee, 1982; Yewdell et al, 1988; 
Palamara et al, 2005; Shaw et al, 2008; Hsu et al, 2011; Abdoli et al, 2014). 
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Figure 5.4: Western blot for the batch purified recombinant influenza virus. 
A) Nitrocellulose membrane developed with Western Blue® stabilized substrate for AP 
conjugated Ab. B) X-ray film from ECL-Western blot. There was no band detected for the His 
tagged HA protein on the membrane or the x-ray film. 
Lane 1: protein marker. Lane 2: virus samples from reverse genetics experiment (before 
batch purification). Lane 3: eluted sample. Lane 4: supernatant sample after virus incubation 
with the resin. Lane 5: 1st washed sample. 
 
 
 
 
A) B) 
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5.3.3 Immunodetection of the tagged HA protein using high affinity anti-His 
antibody 
The™‎His-tag mAb was used for detecting the His tagged HA as described in Section 5.2.3. 
Two Western blot membranes were developed, one was developed with a substrate for AP 
conjugated Ab, and the other was developed with ECL assay. The Western blot (Figure 5.5) 
showed that the highly sensitive anti-His Ab also failed to detect the His tagged protein. On 
the x-ray film, an unclear band was observed with the loaded virus sample. However, the 
loaded control sample (the glycosylated +ve) resulted in a large smear, and this may caused 
the faint band observed on the adjacent well. Therefore, the immunodetection was repeated 
without using this control sample and using the wild-type virus as a negative control.  
 
With the second trial, the membrane was exposed to the x-ray film for several exposure 
times (2, 5, 20, and 60 minutes). Increasing the exposure time (Figure 5.6) resulted in x-ray 
films with darker background as well as thicker band for the +ve control sample used. The 
result from the 60 minutes exposure had a very dark background, thus was not shown. With 
all the exposure times tested, there was no His tagged protein detected. 
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Figure 5.5: SDS-PAGE and immunoblotting results for the virus produced from reverse 
genetics experiment. A) 10% SDS gel stained with Coomassie instant staining. B) 
Nitrocellulose membrane developed with Western Blue® stabilized substrate for AP 
conjugated Ab. C) X-ray film from ECL-Western blot. There was no His tagged protein 
detected on the membrane, although a weak band was observed (lane 4) on the x-ray film 
(more investigation required). 
Lane 1: protein marker. Lane 2 & 3: recombinant protein (+ve). Lane 4: Virus sample.   
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Figure 5.6: SDS-PAGE, and ECL-Western blotting detection with different exposure times. 
A) Virus samples loaded into 10% SDS gel and stained with Coomassie instant staining. B) 
X-ray films after exposing the membrane for 2 minutes, C) 5 minutes, and D) 20 minutes. No 
His tagged protein detected on the x-ray films. 
Lane 1: protein marker. Lane 2: recombinant protein (+ve). Lane 3: Virus produced from 
reverse genetics. Lane 4: Wild-type virus. 
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5.3.4 Secondary structure analysis using I-TASSER server 
The secondary structure prediction, solvent accessibility and normalized B-factor for the His 
tagged HA protein were predicted using the I-TASSER server. The results were compared 
with the wild-type HA protein predicted results. 
 
Amino acids S158, and H159-H164 (6 x His) of the recombinant HA, were predicted to form 
a coil secondary structure with a confidence score ranging between 5-7 (Figure 5.7). The 
S158 from the wild-type HA was also predicted as a coil structure with a high confidence 
score as well. However, the serine after the poly-His (S165) was predicted as a helix 
structure, whereas S from the wild-type HA (S159) was predicted to form a coil secondary 
structure, and in both proteins the predicted confidence score was low (=1). 
 
The solvent accessibility (Figure 5.8) of the 6x His was predicted with an exposure range 
between 3 to 4 (H159= 4, H160= 3, H161= 4, H162= 3, H163= 3, H164= 2). Moreover, the 
predicted exposure value of the 158S from the recombinant HA was 4, whereas it was 
predicted to have a lower exposure value (=2) from the wild-type HA. Also, the K157 (lysine) 
from the His tagged HA has an exposure score of 4, while with the wild-type HA, it has a 
score of 3.  
 
From the obtained results (Figure 5.9), the B-factor profile (BFP) for amino acids 158-165 
from the His tagged protein was predicted as follows: 0.86, 1.49, 2.51, 1.77, 1.76, 0.64, 0.10, 
and -0.52, respectively. On the other hand, the BFP scores for the S158 and S159 from the 
wild-type HA, were 0.15 and -0.37, respectively. The acquired BFP scores suggested that  
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Figure 5.7: Predicted secondary structure by I-TASSER server. A) Secondary structure for the His tagged HA protein. B) Secondary structure 
for the wild-type HA protein. The 6x His are marked with green box as well as the two Serine amino acids before and after the His tag. The first 
Serine (S158) and the 6 x His were predicted as a coil structure with high confident score. The second S with the recombinant HA (S165) was 
predicted as a helix structure, but with the wild type-HA (S159) it was predicted as a coil structure. 
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Figure 5.8: Predicted solvent accessibility by I-TASSER server. A) Solvent accessibility for the His tagged HA protein. B) Solvent accessibility 
for the wild-type HA protein. The 6x His are marked with green box, and the two serine amino acids before and after the His tag were marked 
with red arrow. The predicted score for the His tag exposure ranged between 3 to 4.  
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Figure 5.9: Normalized B-factor (NBF) predicted by I-TASSER server. A) NBF for the His tagged HA protein. B) NBF for the wild-type HA 
protein. The 6x His are marked with orange box as well as the two serine amino acids before and after the His tag. 
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the His tag region are slightly more flexible (less stable) when compared to the overall 
predicted normalized B-factor for the HA structure. 
 
5.3.5 Comparing the predicted protein structures obtained in 2011 and 2014 
The HA-His6 protein sequence was submitted to Swiss Model on late 2014 for generating an 
up-to-date tertiary model structure. The template code used for building the model was 
2wr1.1, and it was annotated as a homo-trimer structure. The structure quality and model 
information that was provided by Swiss Model for the current model is discussed in the next 
few sentences (Arnold et al, 2006; Benkert et al, 2011). The QMEAN4 score, which is used 
for the model quality, was -3.65  (refer to Section 3.3.2 for more information), the sequence 
identity was 64.7%, and the oligomeric structure prediction was homo-trimer. 
 
The quaternary structure annotation of the target protein sequence that was submitted in 
2011 and 2014 was predicted as trimer. However, only the recent model was built as a 
homo-trimer (Figure 5.10), whereas the one predicted on 2011 was not able to be built as a 
trimer, and thus was presented as a monomer. The template code used for building the 
2011 model was 2wr0. Therefore, sequence alignment was made using an online tool 
between the 2011 template and the recently made template. The results showed that the 
two templates were 100% identical (see appendix 7). 
 
A comparison between the predicted models (2011 and 2014) for the His tagged HA is 
shown in Figure 5.11 and Figure 5.12. From the figures, the overall HA structure between 
the 2011 and 2014 models was similar, while the His tag folding was different. In the 2011 
model, folding prediction of the His tag resulted in a highly exposed His tag region. However,  
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Figure 5.10: Model structure of His tagged HA homotrimer (2014). 
Model from: A) side view, and B) top view. The region with yellow color represents the His6 
tag. The three HA chains (monomers) are represented in blue, red and grey colors.  
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Figure 5.11: Comparison between His tagged HA structures predicted in 2011 and 2014 
(top view). A) 2011 model. B) 2014 model. The region with yellow color represents the His6 
tag. 
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Figure 5.12: Comparison between His tagged HA structures predicted in 2011 and 2014 
(side view). A) 2011 model. B) 2014 model. The region with yellow color represents the His6 
tag. 
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in the 2014 predicted model, the His tag was folded in a different way, which resulted in only 
a partially exposed region. This may limit the ability of the His tag to bind nickel. 
 
5.3.6 MD simulation and RMSD analysis 
The established simulation box containing water molecules around the HA protein is shown 
in Figure 5.13. With the His tagged HA, the total number of water molecules added was 
50297 and the number of atoms was 166389. For the wild-type HA, the added water 
molecules was 50357 and the atom number was 166317.  
 
After observing the motion for both proteins (see files attached for MD simulation), addition 
of the His tag did not cause a structural change (with respect to the motion seen) on the HA 
domain carrying it. This was compared with the same region on the wild-type HA, which 
does not contain the His tag. 
 
The root-mean-square deviation (RMSD) is a commonly used quantitative measure for the 
conformational similarity and stability between two or more related protein structures 
(Kufareva & Abagyan, 2012; Lee et al, 2015). RMSD plots are calculated during the course 
of MD simulation using the RMSD Tool Plugin available with VMD software. The stability of 
His tagged-HA protein was investigated relative to the wild-type HA. The plots show a 
moving average of 100 ns to allow effective assessment of the overall trends between the 
two systems. 
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Figure 5.13: The established simulation cube around the HA structure.  
The water molecules are represented in the blue color, and the red spheres represent the 
ions. 
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Figure 5.14: RMSD plots of the trajectories of the HA-His6 and the wild-type HA systems. 
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The RMSD plots of the trajectories of the His tagged HA and the wild type HA systems are 
shown in Figure 5.14. RMSD was done on the backbone atoms of the entire HA molecule. 
Within the first few nanoseconds, a quick RMSD jump was observed, due to the initial 
relaxed condition of the starting model. RMSD level for the HA-His was slightly lower than 
the one obtained for the wild-type HA. With both models, a relatively small fluctuation in 
RMSD values was observed, and then trajectories were stabilized over the time course. 
Both systems had reached equilibrium after 80s ns and became stable with RMSD value ~5 
Å.  
 
Overall, there were no significant differences between the HA-his and wild-type HA systems 
in terms of stability and conformational changes.  
 
5.3.7 Reverse genetics 
A final reverse genetics experiment was performed to produce a His tag virus from a 
previously generated recombinant virus (G.PR8). Immunodetection of the newly generated 
His tagged viruses was investigated using a high affinity anti-His Ab.  
 
The percentage of cells successfully transfected with EGFP plasmid was around 40 – 42% 
and as previously discussed, this percentage is within the expected transfection frequency 
with MDCK cells. The virus was successfully purified from all flasks containing infected cells. 
The HA titer obtained for the virus produced from R.G. and using the wild-type PR8 as the 
helper virus was 1600. Also, the HAU for the re-propagated recombinant PR8 virus was 
1600 (the virus was passaged for the third time and the virus sample contains a combination 
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of wild-type and His tag viruses). The HAU obtained with the generated PR8 from R.G. using 
G.PR8 as the helper virus was 12800. 
 
The vRNA was isolated from purified virus samples. The average RNA concentration for the 
virus produced from R.G. with the use of wild-type‎ helper‎ virus‎was‎14‎ ng/μL.‎The‎ same‎
RNA concentration was also obtained for the re-propagated recombinant virus. The average 
RNA concentration for the virus sample that was produced using G.PR8 helper virus was 47 
ng/μL.‎The‎cDNA‎average‎obtained‎after‎performing‎reverse‎transcription‎was‎2.2‎μg/μL‎for‎
all samples. 
 
From the PCR results shown in Figure 5.15, the expected size of the amplified region (269 
bp) that indicates the presence of the recombinant viral mRNA was successfully achieved. 
The correct band size was only visualized on the agarose gel with the three virus samples 
that were expected to contain the generated His tagged virus (virus produced from R.G. with 
wild-type helper virus, virus produced from R.G. with G.PR8 helper virus, and the re-
propagated His tagged virus).  
 
SDS-PAGE and immunoblotting results are shown in Figure 5.16.  Two membranes were 
produced, one was developed using standard substrate for AP conjugated Ab and the other 
was developed using ECL assay. As previously indicated from the HAU, the virus level 
obtained from the R.G with the use of G.PR8, as the helper virus was higher than the other 
two samples containing recombinant viruses. This was also observed with the bands 
intensity, which represents the separated viral proteins on the SDS gel (the same volume 
was loaded into the gel for all the virus samples used). The immunodetection assay
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Figure 5.15: PCR amplification results. The size of the expected amplified His tag region is 
269 bp.  The bands marked with the red box represent the correct amplified size with the 
tested virus samples. 
Lane 1 & 2: Hyperladder™‎ II‎marker.‎Lane 2: virus from R.G. using G.PR8 as the helper 
virus. Lane 3: virus from R.G. using wild-type PR8 as the helper virus. Lane 4: re-
propagated recombinant PR8 virus (3rd generation). Lane 5: wild-type PR8 virus (-ve). Lane 
6: water. Lane 7: HA-His6 pol I plasmid (+ve).  
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Figure 5.16: SDS-PAGE and Western blot results.  
A) 10% SDS gel stained with Coomassie instant staining. B) Western blot membrane. C) X-ray film from ECL-Western blot. Lane 1: marker. 
Lane 2: His tag recombinant protein (+ve). Lane 3: virus from R.G. using G.PR8 as the helper virus. Lane 4: virus from R.G. using wild-type 
PR8 as the helper virus. Lane 5: re-propagated recombinant PR8 virus (3rd generation). Lane 6: wild-type PR8 virus. 
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of the His tag protein again failed to detect the recombinant protein, as there were no bands 
observed on both the membrane and the x-ray with all the virus samples. 
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5.4 Discussion 
 
Affinity batch purification was performed to isolate the generated progeny His-tagged viruses 
from the non-tagged virus. The purpose of doing that was to examine whether having a 
relatively purified tagged viruses could enhance immunorecognition by monoclonal anti-His 
antibodies.  As was observed on the SDS gel, low virus amounts were eluted from the batch 
chromatography, which might only contain the His tagged viruses, or it could be a non- 
specific binding with the Ni-NTA resin. However, affinity purification did not improve the His 
tag immunodetection and recognition by anti-His antibody failed.   
 
A previous study had investigated the immunodetection variability of His tagged recombinant 
proteins using several anti-His antibodies (Debeljak et al, 2006). They have confirmed the 
ability of the His tagged proteins to successfully bind to Ni-NTA resin by performing peptide 
sequence analysis (Debeljak et al, 2006). However, immunodetection of the His tagged 
protein was only successful using anti-tetra-His Ab and was not successful by using anti-
poly-His Ab and anti-penta-His Ab (Debeljak et al, 2006). It could be possible that the His 
tagged virus was able to bind to the resin, but subsequent antibody recognition was not 
successful. 
 
A trial to obtain a successful immunodetection was performed using another anti-His 
antibody that has higher affinity and sensitivity according to the manufacturer. However, the 
detection using this antibody, and also using ECL Western blot detection method was 
unsuccessful. One possible explanation is that the anti-His antibody used was not efficient at 
recognising the His tag, and depending on the recombinant protein, only certain antibodies 
are able to recognise the incorporated tag (Debeljak et al, 2006). It is well known that His 
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tags can be fused at N- or C-termini or within internal sites of the protein of interest, and the 
tag optimal placement is protein-specific (Terpe, 2003; Khan et al, 2006). However, most 
recombinant proteins have the His tag at either the N or C terminus, as the tag frequently 
has to be removed after the purification step (Terpe, 2003; Sadilkova et al, 2008). There is 
no data showing that internal insertion of His tag or any other tag may affect antibody 
recognition of the specific tag. However, N and C terminal tags are more likely to be 
accessible to the antibody (Hosfield & Quinn, 1998), therefore, internal tags have to be well 
exposed to facilitate successful purification and detection of proteins. It can be concluded 
from that the availability of the His tag to the antibody in this study may resulted in the 
unsuccessful recognition.  
 
The solvent accessibility predicted values, which were obtained from I-TASSER or the 
Zhang server (Roy et al, 2010), showed that the His tag accessibility had a moderate/low 
exposure value (3-4). The solvent accessibility represents the exposure level of a single 
amino acid residue to the solvent (water) (Heffernan et al, 2015). Considering that I-TASSER 
provides the most accurate structure and function prediction (Yang & Zhang, 2015b), it can 
be indicated that the anti- 6 x His antibody was unable to bind to the His tag probably 
because it was not fully accessible, and this could be another explanation for the 
unsuccessful immunodetection. Of course, the SDS-PAGE electrophoresis is undertaken 
under denaturing conditions, so theoretically this should negate this possibility.  
 
Moreover, the latest predicted tertiary structure model for the recombinant HA resulted in His 
tag folding completely different to what was predicted in the earlier model. The His tag 
folding in the current model results in a relatively embedded His tag within the interface of 
the HA protein, and this was in agreement to the solvent accessibility value predicted by I-
TASSER server. Swiss Model approach for structure prediction is based on template-base 
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modeling, which identify unknown (target) structure from a related known structure 
(template) (Rother et al, 2011). For the variable regions, they are modelled from a database 
of previously observed loops by finding fragments with compatible sequence (Schwede et al, 
2003; Rother et al, 2011). It has been demonstrated that the loop library increases with time 
(from 2011 to 2014), and that there exists improvements in model prediction and quality 
assessment by Swiss Model, which could explain the changes of the His6 folding prediction 
within the HA structure. An embedded His tag would have lower affinity for the Nickel-NTA 
resin and therefore bind less efficiently. In future, consideration of alternative locations for 
the insertion of the His tag should be made. 
 
From visualizing the MD simulation and RMSD results, addition of the His tag to the HA has 
not affected the protein stability when compared to the wild-type HA protein. In general, it is 
well know that His tags rarely affect the protein function and structure due to their small size 
(Bornhorst & Falke, 2000; Majorek et al, 2014). 
 
Using the first generated viruses from the reverse genetics experiment as the helper virus to 
produce second recombinant virus generation resulted in higher virus titer and possibly 
enhanced production of chimeric viruses among the wild-type viruses. Transfecting the cells 
with the plasmid encoding for recombinant vRNA HA, which was then followed by infecting 
with helper virus contains combination of wild-type and recombinant viruses, may have 
increased the amount of recombinant vRNA present within the cell nucleus, and thus, 
possibly increasing the chance of packaging and assembling more recombinant viruses 
among the non-recombinant one.  
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This experiment aimed to increase the His tagged viruses level among the non-tagged 
viruses, thus, theoretically increases the possibility for recognition by anti-His antibody. 
However, this did not solve the issue with immunodetection.  This could be again due to the 
partial exposure of the His tag, or/and the non- suitablity of the antibody used for this specific 
detection.  
 
Packaging of the His tagged HA vRNA into progeny recombinant virus was sustained among 
the progeny wild-type virus production.  The presence of the recombinant HA mRNA was 
detected within the forth generation viruses (passage 3), which was originated from reverse 
genetics (Figure 5.17). Luytjes et al (1989) constructed a plasmid encoding for the 
CAT(chloramphenicol acetyltransferase) gene flanked by the 3` and 5` noncoding regions of 
the NS gene (Luytjes et al, 1989). The foreign gene was packaged into viral particles with 
the use of helper virus, and passaged successfully several times. However, detection of the 
recombinant gene expression (CAT activity) was then rapidly lost among the helper virus 
after more passages (Luytjes et al, 1989). In another study, recombinant influenza virus 
expressing the HPV16 oncogene was generated using the plasmid reverse genetics system 
(Jindra et al, 2015). The stability of the transgene within the recombinant influenza virus was 
confirmed by passaging the virus for up to 5 rounds (Jindra et al, 2015). It can be 
hypothesized from these two studies that the presence of the wild-type virus (helper virus) 
may lead to a gradual loss of the recombinant gene during virus passaging. This is because 
the presence of the viral wild-type vRNA can compete with the recombinant one for selection 
during viral packaging, possibly due to bundling signals (Goto et al, 2013). However, having 
a pure recombinant virus population will not cause this issue with the virus replication, as the 
only gene type available for packaging is the recombinant one. 
 
In summary, recombinant influenza virus expressing His tag was generated using
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Figure 5.17: His tagged influenza virus persistence from the first generation produced until 
the fourth generation. 
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a recombinant helper virus, which was produced from previous reverse genetics. However, 
enhancing the availability of recombinant virus did not result in positive recognition by the 
anti-His antibody. Moreover increasing the possibility for immunodetection was also not 
successful, after trying several optimisation methods such as affinity batch purification, ECL 
assay and using a monoclonal anti-His antibody with high affinity.  
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Advances in the fields of genetic engineering and molecular biology have enabled the 
development of live vector vaccines (Nascimento & Leite, 2012). Viruses are naturally 
existing vehicles, as they efficiently transfer their genetic material into the host cell (Gale et 
al, 2000; Brave et al, 2006). Using RNA viruses as a vaccine delivery vector started with the 
emergence of the reverse genetics technique (Stukova et al, 2006; Li et al, 2013). Influenza 
viral vectors offer many advantages as a vaccine delivery vehicle, such as the viral ability to 
induce strong immune responses (Stukova et al, 2006). Also, the licensed influenza vaccine 
strains provide a major advantage, as they can serve as a safe vaccine delivery vector 
against a variety of pathogens (Kittel et al, 2004; Stukova et al, 2006). Using influenza virus 
as a vaccine delivery vector is a promising new approach (Stukova et al, 2006; Martinez-
Sobrido & Garcia-Sastre, 2007). However, more research is needed to make it possible to 
utilise the influenza viral vector for vaccination against diseases currently lacking effective 
vaccines.  
 
The reverse genetics method applied in this study was the helper virus-based system. This 
method requires selecting the generated recombinant virus from the majority of helper 
influenza viruses (Neumann & Kawoaka, 2001). Thus, it was essential to develop a strong 
selection system that could be applied for using the LAIV strains as a delivery vector. The 
addition of a poly-histidine affinity tag in order to isolate the desired recombinant protein is a 
frequently used technique, as it offers several advantages (Bornhorst & Falke, 2000). In 
particular, generating influenza viruses containing a His tag within a viral surface protein was 
hypothetically achievable. Therefore, this study focused on investigating the possibility of 
creating a tagged influenza virus that is genetically stable, and more importantly can be 
effectively isolated using the IMAC technique. This virus could then be used in a subsequent 
experiment as a helper virus, replacing the His tag by an antigen segment via negative 
selection. 
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The HA protein was the preferred choice for inserting the His tag for many reasons, such as 
the fact that it is the primary target in vaccination and contains the epitopes for neutralising 
antibodies (Nayak et al, 2009; DuBois et al, 2011). Also, it numbers around 80% of the viral 
membrane-embedded spikes (Harris et al, 2006; Nayak et al, 2009). The His6 sequence was 
inserted next to S158 aa, which is located within the Ca2 antigenic region. This residue was 
one of the 32 identified antigenically unique amino acids, as was the following amino acid 
(S159) (Caton & Browniee, 1982; Deem & Pan, 2009). Also, this residue is located in an 
exposed external loop, as the predicted tertiary structure model demonstrated.  
 
Predicting that the addition of the His tag would not interfere with HA critical functions was 
achieved by mapping the HA sequence features. From this investigation, it was confirmed 
that the selected site for insertion was not likely to cause changes to HA function. Moreover, 
according to several studies on HA modification, addition of foreign epitopes within the HA 
antigenic regions does not affect viral infectivity (Rodrigues et al, 1994; Muster et al, 1995; 
Miyahira et al, 1998; Gilleland Jr. et al, 2000; Thomas et al, 2006). 
 
The exposure of the His tag epitope was confirmed by building a tertiary structure model. 
The‎first‎model’s‎(2011)‎prediction‎resulted‎in‎a‎highly‎accessible‎His‎tag‎folding.‎However,‎
the latest model prediction (2014) showed a different folding of the His6 epitope with limited 
accessibility. Predicting a structure for an inserted region within a particular protein is 
unlikely to find an alignment in the structure template. Building the structural model for this 
modified region will depend on the availability of the previously identified related loops in the 
Swiss Model database library. As this loop library keeps increasing over time (Xiang, 2006), 
this will possibly result in variations in structure prediction. This might explain the variation of 
the predicted His tag folding within the two recombinant HA structures.  
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Recombinant influenza virus carrying a His6 tag was successfully generated using the pol I 
method with the helper virus. The presence of the tagged virus was confirmed by detecting 
the recombinant mRNA HA using the PCR technique. This indicated that the cellular 
(canine) RNA polymerase successfully synthesised the recombinant cDNA of the vRNA into 
viral-like RNA within the cell nucleus. Then, with the presence of the helper viral proteins 
and other vRNAs, it was transcribed, replicated, and packaged into new viral particles. 
 
Immunorecognition of the His tagged protein was unsuccessful. Two types of commercially 
available anti-His-tag antibodies were used for the detection of His tagged HA. The first one 
used was only able to detect His6 tagged protein, while the second antibody used was 
capable of recognising His4, His5, and His6 tagged proteins. However, both antibodies failed 
to recognise the His tag. There are several factors that can lead to unsuccessful His tag 
detection within the recombinant protein. These include the fact that the antibody used could 
be insufficient for detection of the incorporated tag within a particular protein. Debeljak et al 
(2006) showed that immunodetection of their His6 tagged recombinant protein was only 
recognised by the anti-His4 antibody, while recognition by anti-His5 and anti His6 failed. The 
Western blot detection was performed for denatured virus samples in our study, and it was 
expected that the His tag would become more accessible after denaturation by SDS. 
However, this did not result in a positive detection. A possible explanation for that is that 
formation of SDS micelles (detergent binding and folding with the protein) might make the 
His tag or part of it inaccessible to the antibody, and therefore detection was not successful 
(Debeljak et al, 2006; Rath et al, 2009). Other factors that may contribute to failed 
immunodetection are His tag availability to the antibody and the location of the His tag on 
the particular protein (Debeljak et al, 2006). The result obtained by I-TASSER showed a 
low/moderate solvent accessibility value for the His6 tag residues, which was in agreement 
with the latest structural model predicted. This might show that the His epitope was not 
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freely available to the antibody. Moreover, in addition to the fact that the His tag could be 
partially accessible, it was also inserted internally within the HA, and in this case detection 
by antibody could be difficult. It has been suggested that incomplete denaturation of 
antigens during immunodetection could make antibody recognition difficult, mostly when 
detecting internal epitopes (Lykkemark et al, 2014). 
 
Other techniques were performed in order to increase the potential for positive 
immunodetection. Affinity batch purification was done in order to isolate the tagged viruses 
from the non-tagged one. It was suggested that sample purity could affect immunodetection 
(Debeljak et al, 2006). However, performing affinity purification did not improve the antibody 
recognition of the His tag. The eluted sample from the batch purification contained a low 
virus amount, which was indicated by the result observed on the SDS gel. If the His tag was 
partially hidden in the native structure, affinity to the resin would be expected to be poor. As 
the immunodetection failed, it was expected that this eluted sample might be a result of non-
specific binding to the resin. However, as low as two His residues could result in successful 
binding to the Ni-NTA resin (Debeljak et al, 2006), so the His tagged virus could be positively 
isolated. The other technique used was the ECL assay for developing the Western blot 
membrane. However, this highly sensitive method also did not result in a positive detection. 
 
Addition of the foreign epitope (His6 tag) within the HA globular head was not predicted to 
affect the overall HA structure stability. Performing an MD simulation and comparing the 
recombinant HA stability to the wild-type HA has suggested that there are no significant 
differences between them. Expression of a foreign peptide as part of the viral protein is a 
common method used to generate recombinant virus, and generally this did not affect viral 
infectivity, as has been shown by previous studies (Miyahira et al, 1998; Gilleland Jr. et al, 
2000; Thomas et al, 2006; Martinez-Sobrido & Garcia-Sastre, 2007; Li et al, 2013). 
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The recombinant influenza virus was able to persist for several passages. The presence of 
the His tagged mRNA HA within virus population after passage three was confirmed by PCR 
detection. However, with the presence of the wild-type virus, the recombinant HA segment 
would probably become lost after more passages (Luytjes et al, 1989). Isolating the 
recombinant virus and having a relatively pure recombinant virus may prevent loss of the 
modified vRNA among the wild-type one. Generating recombinant virus using the plasmid - 
based reverse genetics system showed that the recombinant virus was stable for more than 
five passages (Jindra et al, 2015). 
 
The final approach tested in this study was performing a second reverse genetics to produce 
His tagged virus, while using a virus produced from previous reverse genetics as the helper 
virus. The aim behind this investigation was to enhance the production of the recombinant 
virus amongst the wild-type one, as this might increase the ability to achieve positive 
immunodetection. The recombinant virus was successfully generated, but detection by anti-
His antibody was again unsuccessful. 
 
It could be possible in the future to investigate the amount of generated His-tagged viruses 
amongst the non-tagged ones using a highly specific technique, such as peptide-mass 
mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS), in which the sequence specific fragment ions are mass analysed within a 
complex peptide mixture (Yergey et al, 2002; Seidler et al, 2010). Using this technique, it 
might be possible to measure the His-tag fragments presented within the virus mixture 
sample, and therefore estimate the amount of recombinant virus generated among the wild-
type virus. Another similar technique is called microcapillary liquid chromatography-tandem 
mass spectrometry (μLC/MS/MS)‎ for‎ peptide‎ sequence‎ analysis‎ (Hoopmann‎ et al, 2009). 
This method has been used in a previous study to confirm the presence of His tagged 
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recombinant protein within the eluted sample after affinity purification (Debeljak et al, 2006). 
In the future, it is preferable to inspect whether purifying the reverse genetics-generated 
virus by IMAC would result in His-tagged virus isolation, regardless of having negative 
immunodetection. Then, confirmation of the presence of the recombinant virus within the 
eluted sample can be achieved by the MALDI-TOF‎or‎the‎μLC/MS/MS‎techniques. 
There are 32 unique antigenic amino acids that have been identified within the different 
antigenic regions in the HA protein (Caton & Browniee, 1982). It is suggested to build 
structural models and obtain solvent accessibility for several of these antigenic amino acids 
with the addition of the His-tag epitope. Comparing between different insertion sites and 
examining multiple predicted models could increase the probability of having the most 
accessible His-tag epitope for antibody. 
 
To improve purification and immunerecognition for the recombinant virus, it might be 
possible to insert the His-tag into two different antigenic domains within the HA protein, or 
possibly use two different tags. A second affinity tag or multi-tagging can be used to 
increase the desired protein purity by performing multiple purification steps (Terpe, 2003). 
Also, having two or multiple tags allows for the use of one or two tags for purification, with 
the other being used for detection (Terpe, 2003). Alternative tags could be used, such as the 
FLAG-tag, which utilises a small hydrophilic peptide (Brizzard & Chubet 2001; Terpe, 2003). 
Another possible way to increase the purification is by the addition of eight or ten histidine 
tag, which might protrude more within the recombinant protein, and thus improve purification 
via affinity chromatography. 
 
In conclusion, recombinant influenza virus incorporating affinity His tag was successfully 
generated using the helper virus-based reverse genetics system. The recombinant influenza 
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virus stability was confirmed via MD simulation. Also, the recombinant virus was able to 
persist for several passages amongst the wild-type one. However, immunorecognition of the 
His tagged protein by the anti-His antibody was unsuccessful. Placing the tag at another site 
or/and using a second affinity tag could solve this issue.  
 
The significance of generating tagged influenza viruses is the potential to use them as the 
helper viruses for the future production of recombinant influenza viruses incorporating 
specific disease proteins. Therefore, isolation of the vaccine designated recombinant virus 
can be effectively achieved from the tagged designated helper virus.  
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Appendix 1 
Protein sequence alignment between HA-His6 (target), and the template (2wr0) Swiss Model 
used building the HA-His6 structural model by. 
s= strand, h=helix. 
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Appendix 1-Cont. 
Protein sequence alignment between HA-His6 (target), and the template (2wr0) Swiss Model 
used building the HA-His6 structural model by. 
s= strand, h=helix. 
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Appendix 2 
Lambda DNA digested with PstI run on a 1.5% agarose gel. 
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Appendix 1 
Lambda DNA digested with PstI run on a 1.5% agarose gel. 
 
 
 
Image obtained from Fermentas Life Science Pty. Ltd., Japan 
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Appendix 3 
Hyperladder™‎50bp‎run‎on‎a‎1.5%‎agarose‎gel. 
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Appendix 4 
Precision‎Plus‎Protein™‎All‎Blue‎Standard‎(#161-0373), BioRad Laboratories, U.S.A. 
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Appendix 5 
Precision‎ Plus‎ Protein™‎ Kaleidoscope™‎ Standard‎ (#161-0374), BioRad Laboratories, 
U.S.A. 
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Appendix 6 
 
Precision‎Plus‎Protein™‎Dual‎Standard‎(#161-0374), BioRad Laboratories, U.S.A. 
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Appendix 5 
Precision Plus Protein TM Dual Color Standards (#161-0374), BioRad Laboratories, USA. 
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Appendix 7 
Protein sequence alignment between 2WR1.1 and 2WR0 templates used for building the 
HA-His6 structural model. 
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Appendix 8 
Recombinant HA protein and wild-type HA protein molecular dynamics simulation files 
(please see files attached). 
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